U.S. patent number 8,062,635 [Application Number 10/575,193] was granted by the patent office on 2011-11-22 for bispecific antibody substituting for functional proteins.
This patent grant is currently assigned to Chugai Seiyaku Kabushiki Kaisha. Invention is credited to Kunihiro Hattori, Tetsuo Kojima, Taro Miyazaki, Tetsuhiro Soeda.
United States Patent |
8,062,635 |
Hattori , et al. |
November 22, 2011 |
Bispecific antibody substituting for functional proteins
Abstract
The present inventors succeeded in constructing bispecific
antibodies, which bind to both the blood coagulation factor
IX/activated blood coagulation factor IX and blood coagulation
factor X, and functionally substitute for blood coagulation factor
VIII/activated blood coagulation factor VIII which enhances the
enzymatic reaction.
Inventors: |
Hattori; Kunihiro (Shizuoka,
JP), Kojima; Tetsuo (Shizuoka, JP),
Miyazaki; Taro (Shizuoka, JP), Soeda; Tetsuhiro
(Shizuoka, JP) |
Assignee: |
Chugai Seiyaku Kabushiki Kaisha
(Tokyo, JP)
|
Family
ID: |
34430861 |
Appl.
No.: |
10/575,193 |
Filed: |
October 8, 2004 |
PCT
Filed: |
October 08, 2004 |
PCT No.: |
PCT/JP2004/014911 |
371(c)(1),(2),(4) Date: |
October 24, 2006 |
PCT
Pub. No.: |
WO2005/035756 |
PCT
Pub. Date: |
April 21, 2005 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20070041978 A1 |
Feb 22, 2007 |
|
Foreign Application Priority Data
|
|
|
|
|
Oct 10, 2003 [WO] |
|
|
PCT/JP03/13062 |
Oct 14, 2003 [WO] |
|
|
PCT/JP03/13123 |
|
Current U.S.
Class: |
424/136.1;
424/94.64; 514/14.4; 514/14.1; 424/133.1; 514/13.7; 514/13.5;
424/146.1; 424/145.1 |
Current CPC
Class: |
C07K
16/36 (20130101); A61P 7/04 (20180101); A61P
7/00 (20180101); C07K 16/2866 (20130101); C07K
2317/24 (20130101); C07K 2317/31 (20130101); C07K
2317/622 (20130101) |
Current International
Class: |
A61K
39/395 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
2009290162 |
|
Apr 2010 |
|
AU |
|
2 019 559 |
|
Dec 1990 |
|
CA |
|
2 603 264 |
|
Oct 2006 |
|
CA |
|
0 369 566 |
|
May 1990 |
|
EP |
|
0 404 097 |
|
Dec 1990 |
|
EP |
|
1 505 148 |
|
Feb 2005 |
|
EP |
|
1510943 |
|
Mar 2005 |
|
EP |
|
0 979 281 |
|
Jul 2005 |
|
EP |
|
1 688 488 |
|
Aug 2006 |
|
EP |
|
1 693 448 |
|
Aug 2006 |
|
EP |
|
1 220 923 |
|
Jun 2007 |
|
EP |
|
1870459 |
|
Dec 2007 |
|
EP |
|
1 876 236 |
|
Jan 2008 |
|
EP |
|
2 275 443 |
|
Jan 2011 |
|
EP |
|
2-145187 |
|
Jun 1990 |
|
JP |
|
5-501543 |
|
Mar 1993 |
|
JP |
|
5-184383 |
|
Jul 1993 |
|
JP |
|
5-199894 |
|
Aug 1993 |
|
JP |
|
5-203652 |
|
Aug 1993 |
|
JP |
|
5-213775 |
|
Aug 1993 |
|
JP |
|
5-304992 |
|
Nov 1993 |
|
JP |
|
09506001 |
|
Jun 1997 |
|
JP |
|
10-165184 |
|
Jun 1998 |
|
JP |
|
10-511085 |
|
Oct 1998 |
|
JP |
|
11-71288 |
|
Mar 1999 |
|
JP |
|
11-506310 |
|
Jun 1999 |
|
JP |
|
2001-523971 |
|
Nov 2001 |
|
JP |
|
2002-518041 |
|
Jun 2002 |
|
JP |
|
2003-055398 |
|
Feb 2003 |
|
JP |
|
2003-509049 |
|
Mar 2003 |
|
JP |
|
WO 91/08770 |
|
Jun 1991 |
|
WO |
|
WO 93/11161 |
|
Jun 1993 |
|
WO |
|
9533844 |
|
Dec 1995 |
|
WO |
|
9601653 |
|
Jan 1996 |
|
WO |
|
WO 96/16673 |
|
Jun 1996 |
|
WO |
|
9627011 |
|
Sep 1996 |
|
WO |
|
WO 96/26964 |
|
Sep 1996 |
|
WO |
|
9803546 |
|
Jan 1998 |
|
WO |
|
WO 98/50431 |
|
Nov 1998 |
|
WO |
|
WO 99/10494 |
|
Mar 1999 |
|
WO |
|
WO 99/67359 |
|
Dec 1999 |
|
WO |
|
WO 01/19992 |
|
Mar 2001 |
|
WO |
|
WO 03/091424 |
|
Jan 2003 |
|
WO |
|
WO 03/035835 |
|
May 2003 |
|
WO |
|
WO 03/042231 |
|
May 2003 |
|
WO |
|
WO 03/087163 |
|
Oct 2003 |
|
WO |
|
WO 2004/065611 |
|
Aug 2004 |
|
WO |
|
WO 2005/035754 |
|
Apr 2005 |
|
WO |
|
WO 2005/035756 |
|
Apr 2005 |
|
WO |
|
2006106905 |
|
Oct 2006 |
|
WO |
|
WO 2006/106903 |
|
Oct 2006 |
|
WO |
|
WO 2006/109592 |
|
Oct 2006 |
|
WO |
|
WO 2007/114325 |
|
Oct 2007 |
|
WO |
|
WO 2007/142325 |
|
Dec 2007 |
|
WO |
|
WO 2009/041621 |
|
Apr 2009 |
|
WO |
|
WO 2009/041643 |
|
Apr 2009 |
|
WO |
|
WO 2009/125825 |
|
Oct 2009 |
|
WO |
|
WO 2009/139822 |
|
Nov 2009 |
|
WO |
|
WO 2010/035769 |
|
Apr 2010 |
|
WO |
|
Other References
Bolton-Maggs et al. The Lancet, 2003, 1801-1809. cited by examiner
.
Hsia et al., Am. J. Hematol. 1008, 83:318-320. cited by examiner
.
Menegatti et al., Semin Thromb Hemost 2009 35:407-415. cited by
examiner .
Bajaj et al., J Biol Chem 1985, 260:11574-11580. cited by examiner
.
Bessos et al., Thrombosis Research, 1985, 40:863-867. cited by
examiner .
Nilsson et al., 1986, Proc. Natl Acad Sci USA, 83:9169-9173. cited
by examiner .
Price et al., Anaesthesia, 2004,59:483-492. cited by examiner .
Rudikoff et al., Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
cited by examiner .
Janeway et al., Immunobiology, 3.sup.rd edition, 1997, Garland
Press, pp. 3:1 to 3:11. cited by examiner .
William E. Paul, M.D. ed., Fundamental Immunology, 3d ed. 1993, p.
242. cited by examiner .
Portolano et al., J Immunol., 1993, 150:880-887. cited by examiner
.
Asselta et al., Semin Thromb Hemost 2009 35:382-389. cited by
examiner .
Association of Hemophilia Clinic Directors of Canada, "Hemophilia
and Von Willebrand's disease: 2. Management Association of
Hemophilia Clinic Directors of Canada", Canadian Medical
Association Journal 153(2):147-157, 1995. cited by other .
Davie et al., "The coagulation cascade: Initiation, maintenance,
and regulation", Biochemistry 30(43):10363-10370, 1991. cited by
other .
Grosse-Hovest et al., "A recombinant bispecific single-chain
antibody induces targeted, supra-agonistic CD28-stimulation and
tumor cell killing", European Journal of Immunology
33(5):1334-1340, 2003. cited by other .
Lenting et al., "The life cycle of coagulation factor VIII in view
of its structure and function", Blood 92(11):3983-3996, 1998. cited
by other .
Piper et al., "Interferon therapy in primary care", Primary Care
Update for Ob/Gyns 8(4):163-169, 2001. cited by other .
Ruef et al., "A bispecific antifibrin-antiplatelet urokinase
conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet
aggregation", Thombosis and Haemostasis 82(1):109-114, 1999. cited
by other .
Shima et al., "Factor VIII Taitei Kotai (2), Ketsuyubyo A Kanja
Katsueki ni okeru in vitro Gyoko Kassei no Kento", Rinsho Ketsueki
46(8):777, 2005 (with English translation). cited by other .
Soeda et al., "Factor VIII Taitei Kotai (1) Ko FIXa/FX bispecific
Kotai no Sakusei oyobi characterization", Rinsho Ketsueki,
46(8):728, 2005 (with English translation). cited by other .
Soeda et al., "Phage library-ho ni yori Sakusei shita Ko-FIXa/Ko-FX
bispecific Kotai no FVIII Taitei Sayo", Japanese Journal of
Thrombosis and Hemstasis, 16(5):526, 2005 (with English
translation). cited by other .
Bebbington et al., "High-Level Expression of a Recombinant Antibody
from Myeloma Cells Using a Glutamine Synthetase Gene as an
Amplifiable Selectable Marker," Biotechnology (N Y), 10:169-175
(1992). cited by other .
Bos et al., "Enhanced Transfection of a Bacterial Plasmid into
Hybridoma Cells by Electroporation: Application for the Selection
of Hybrid Hybridoma (Quadroma) Cell Lines," Hybridoma, 11:41-51
(1992). cited by other .
Brennan et al., "Preparation of Bispecific Antibodies by Chemical
Recombination of Monoclonal Immunoglobulin G1 Fragments," Science,
229:81-83 (1985). cited by other .
Carter, "Bispecific human IgG by design," J. Immunol. Methods,
248:7-15 (2001). cited by other .
Deng et al., "An Agonist Murine Monoclonal Antibody to the Human
c-Mpl Receptor Stimulates Megakaryocytopoiesis," Blood,
92:1981-1988 (1998). cited by other .
Francois et al., "Construction of a Bispecific Antibody Reacting
with the .alpha.-and .beta.-Chains of the Human IL-2 Receptor," J.
Immunol., 150:4610-4619 (1993). cited by other .
GenPept Accession No. AAC26541, "anti BoNT/A Hc scFv antibody
[synthetic construct]," 1 page (Aug. 1, 2001). cited by other .
Hammerling et al., "Use of Hybrid Antibody with Anti-.gamma.G and
Anti-Ferritin Specificities in Locating Cell Surface Antigens by
Electron Microscopy," J. Exp. Med., 128:1461-1473 (1968). cited by
other .
Holliger et al., "`Diabodies`: Small bivalent and bispecific
antibody fragments," Proc. Natl. Acad. Sci. USA, 90:6444-6448
(1993). cited by other .
Huse et al., "Generation of a Large Combinatorial Library of the
Immunoglobulin Repertoire in Phage Lambda," Science, 246:1275-1281
(1989). cited by other .
Kang et al., "Linkage of recognition and replication functions by
assembling combinatorial antibody Fab libraries along phage
surfaces," Proc. Natl. Acad. Sci. USA, 88:4363-4366 (1991). cited
by other .
Karpovsky et al., "Production of Target-Specific Effector Cells
Using Hetero--Cross-Linked Aggregates Containing Anti-Target Cell
and Anti-Fc.gamma. Receptor Antibodies," J. Exp. Med.,
160:1686-1701 (1984). cited by other .
Kim et al., "Mammalian type I interferon receptors consists of two
subunits: IFNaR1 and IFNaR2," Gene, 196:279-286 (1997). cited by
other .
Kroesen et al., "Phase I study of intravenously applied bispecific
antibody in renal cell cancer patients receiving subcutaneous
interleukin 2," Br. J. Cancer, 70:652-661 (1994). cited by other
.
Kurokawa et al., "Enhanced Fibrinolysis by a Bispecific Monoclonal
Antibody Reactive to Fibrin and Tissue Plasminogen Activator,"
Bio/Technology, 7:1163-1167 (1989). cited by other .
Lapan et al., "Interaction of the A1 Subunit of Factor VIIIa and
the Serine Protease Domain of Factor X Identified by Zero-length
Cross-linking," Thromb. Haemost., 80:418-422 (1998). cited by other
.
Le Doussal et al., "Bispecific Monoclonal Antibody-Mediated
Targeting of an Indium-111-Labeled DTPA Dimer to Primary Colorectal
Tumors: Pharmacokinetics, Biodistribution, Scintigraphy and Immune
Response," J. Nucl. Med., 34:1662-1671 (1993). cited by other .
Link et al., "Production and Characterization of a Bispecific IgG
Capable of Inducing T-Cell--Mediated Lysis of Malignant B Cells,"
Blood, 81:3343-3349 (1993). cited by other .
Lofqvist et al., "Haemophilia prophylaxis in young patients--a
long-term follow-up," J. Intern. Med., 241:395-400 (1997). cited by
other .
Lu et al., "Di-diabody: a novel tetravalent bispecific antibody
molecule by design," J. Immunol. Methods, 279:219-232 (2003). cited
by other .
Lu et al., "Fab-scFv fusion protein: an efficient approach to
production of bispecific antibody fragments," J. Immunol. Methods,
267:213-226 (2002). cited by other .
Massino et al., "Quantitative analysis of the products of IgG chain
recombination in hybrid hybridomas based on affinity chromatography
and radioimmunoassay," J. Immunol. Methods, 201:57-66 (1997). cited
by other .
McCafferty et al., "Phage antibodies: filamentous phage displaying
antibody variable domains," Nature, 348:552-554 (1990). cited by
other .
Mertens et al., "Factor VIII-Factor IX Interactions: Molecular
Sites Involved in Enzyme-Cofactor Complex Assembly," Thromb.
Haemost., 82:209-217 (1999). cited by other .
Milstein et al., "Hybrid hybridomas and their use in
immunohistochemistry," Nature, 305:537-540 (1983). cited by other
.
"National Haemophilia Foundation (NHF) Medical and Scientific
Advisory Council (MASAC) Recommendations Concerning Prophylaxis,"
MedicalBulletin, No. 193, 1 page (1994). cited by other .
Nilsson et al., "Twenty-five years' experience of prophylactic
treatment in severe haemophilia A and B," J. Intern. Med.,
232:25-32 (1992). cited by other .
Nitta et al., "Preliminary trial of specific targeting therapy
against malignant glioma," Lancet, 335:368-371 (1990). cited by
other .
Ridgway et al., "`Knobs-into-holes` engineering of antibody
C.sub.H3 domains for heavy chain heterodimerization," Protein Eng.,
9:617-621 (1996). cited by other .
Segal et al., "Introduction: bispecific antibodies," J. Immunol.
Methods, 248:1-6 (2001). cited by other .
Shalaby et al., "Development of Humanized Bispecific Antibodies
Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing
the HER2 Protooncogene," J. Exp. Med., 175:217-225 (1992). cited by
other .
Stickney et al., "Bifunctional Antibody: A Binary
Radiopharmaceutical Delivery System for Imaging Colorectal
Carcinoma," Cancer Res., 51:6650-6655 (1991). cited by other .
Suresh et al., "Advantages of bispecific hybridomas in one-step
immunocytochemistry and immunoassays," Proc. Natl. Acad. Sci. USA,
83:7989-7993 (1986). cited by other .
Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid
Hybridomas," Methods Enzymol., 121:210-228 (1986). cited by other
.
Taki, The Journal of Japanese Society on Thrombosis and Hemostasis,
13:109-113 (2002) (see reference AXX for concise English
explanation). cited by other .
Weiner et al., "A Human Tumor Xenograft Model of Therapy with a
Bispecific Monoclonal Antibody Targeting c-erbB-2 and CD16," Cancer
Res., 53:94-100 (1993). cited by other .
Weiner et al., "The Role of T Cell Activation in Anti-CD3.times.
Antitumor Bispecific Antibody Therapy," J. Immunol., 152:2385-2392
(1994). cited by other .
Xiang et al., "Production of Murine V-Human Cr1 Chimeric Anti-TAG72
Antibody Using V Region cDNA Amplified by PCR," Mol. Immunol.,
27:809-817 (1990). cited by other .
European Search Report for App. Ser. No. 06 73 0769, dated Jun. 18,
2009 (8 pages). cited by other .
Fish & Richardson P.C., Amendment and Response to Restriction
Requirement dated Jun. 25, 2009 in U.S. Appl. No. 10/575,905, filed
Sep. 25, 2009, 14 pages. cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 10/575,905, mailed
Nov. 18, 2009, 14 pages. cited by other .
Schmidt et al., Human Physiology, Moscow, 2:431-436 (1996), and
English translation: Schmidt et al., "Hemostatis and Coagulation,"
Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely
Revised Edition, 418-423 [translated by Marguerite A.
Biederman-Thorson], Springer-Verlag, 1989. cited by other .
Schmidt et al., Human Physiology, Moscow, 3:764 (1996), and English
translation: Schmidt et al., "Enzymes of the pancreatic juice,"
Human Physiology, R.F. Schmidt, G. Thews (Eds.), Second, Completely
Revised Edition, 716 [translated by Marguerite A.
Biederman-Thorson], Springer-Verlag, 1989. cited by other .
Blazar, "Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86)
Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease
Lethality in Part Via Direct Effects on CD4+ and CD8+ T Cells," J.
Immunol., 157:3250-59 (1996). cited by other .
USPTO Non-Final Office Action in U.S. Appl. No. 10/575,905, mailed
Jun. 23, 2010, 10 pages. cited by other .
Adams et al., "Humanization of a recombinant monoclonal antibody to
produce a therapeutic HER dimerization inhibitor, pertuzumab,"
Cancer Immunol. Immunother., 55:717-727 (2006). cited by other
.
Binz et al., "Engineering novel binding proteins from
nonimmunoglobulin domains," Nat. Biotechnol., 23:1257-68 (2005).
cited by other .
Branden and Tooze, "Recognition of Foreign Molecules by the Immune
System," Introduction to Protein Structure, 2d Ed., Garland
Publishing, pp. 299-323 (1999). cited by other .
Comper and Glasgow, "Charge selectivity in kidney ultrafiltration,"
Kidney Int., 47:1242-51 (1995). cited by other .
Couto et al., "Anti-BA46 Monoclonal Antibody Mc3: Humanization
Using a Novel Positional Consensus and in Vivo and in Vitro
Characterization," Cancer Res., 55:1717-22 (1995). cited by other
.
Deen et al., "Structural determinants of glomerular permeability,"
Am. J. Physiol. Renal. Physiol., 281:F579-F596 (2001). cited by
other .
Del Rio et al., "An Engineered Penicillin Acylase with Altered
Surface Charge Is More Stable in Alkaline pH," Ann. NY Acad. Sci.,
799:61-64 (1996). cited by other .
Dillon et al., "Structural and functional characterization of
disulfide isoforms of the human IgG2 subclass," J. Biol. Chem.,
283(23):16206-15 (2008). cited by other .
Ewert et al., "Stability improvement of antibodies for
extracellular and intracellular applications: CDR grafting to
stable frameworks and structure-based framework engineering,"
Methods, 34:184-199 (2004). cited by other .
Ghetie and Ward, "FcRn: the MHC class I-related receptor that is
more than an IgG transporter," Immunol. Today, 18:592-598 (1997).
cited by other .
Ghetie et al., "Increasing the serum persistence of an IgG fragment
by random mutagenesis," Nat. Biotechnol., 15:637-640 (1997). cited
by other .
Ghetie et al., "Multiple roles for the major histocompatibility
complex class I-related receptor FcRn," Annu. Rev. Immunol.,
18:739-766 (2000). cited by other .
Gobburu et al., "Pharmacokinetics/dynamics of 5c8, a monoclonal
antibody to CD154 (CD40 ligand) suppression of an immune response
in monkeys," J. Pharmacol. Exp. Ther., 286:925-930 (1998). cited by
other .
Goode et al., "The glomerular basement membrane charge-selectivity
barrier: an oversimplified concept?," Nephrol. Dial. Transplant.,
11:1714-16 (1996). cited by other .
Graves et al., "Molecular modeling and preclinical evaluation of
the humanized NR-LU-13 antibody," Clin. Cancer Res., 5:899-908
(1999). cited by other .
Gupta et al., "Affinity chromatography and co-chromatography of
bispecific monoclonal antibody immunoconjugates," J. Biochem.
Biophys. Methods, 51:203-216 (2002). cited by other .
Hanson et al., "Catalytic antibodies and their applications," Curr.
Opin. Biotechnol., 16:631-636 (2005). cited by other .
He et al., "Humanization and pharmacokinetics of a monoclonal
antibody with specificity for both E- and P-selectin," J. Immunol.,
160:1029-35 (1998). cited by other .
Hinton et al., "An engineered human IgG1 antibody with longer serum
half-life," J. Immunol., 176:346-356 (2006). cited by other .
Ito et al., "The His-probe method: effects of histidine residues
introduced into the complementarity-determining regions of
antibodies on antigen-antibody interactions at different pH
values," FEBS Lett., 309:85-88 (1992). cited by other .
Kashmiri et al., "Generation, characterization, and in vivo studies
of humanized anticarcinoma antibody CC49," Hybridoma, 14:461-473
(1995). cited by other .
Khawli et al., "Improved tumor localization and radioimaging with
chemically modified monoclonal antibodies," Cancer Biother.
Radiopharm., 11:203-215 (1996). cited by other .
Kim et al., "Antibody Engineering for the Development of
Therapeutic Antibodies," Mol. Cells, 20:17-29 (2005). cited by
other .
Kim et al., "Chemical modification to reduce renal uptake of
disulfide-bonded variable region fragment of anti-tac monoclonal
antibody labeled with 99mTc," Bioconjugate Chem., 10:447-453
(1999). cited by other .
Kim et al., "Lowering of pl by acylation improves the renal uptake
of 99mTc-labeled anti-Tac dsFv: effect of different acylating
reagents," Nucl. Med. Biol., 29:795-801 (2002). cited by other
.
Kobayashi et al., "The pharmacokinetic characteristics of
glycolated humanized anti-Tac Fabs are determined by their
isoelectric points," Cancer Res., 59:422-430 (1999). cited by other
.
Kreutz et al., "Efficient bispecific monoclonal antibody
purification using gradient thiophilic affinity chromatography," J.
Chromatogr. B, 714:161-170 (1998). cited by other .
Lindhofer et al., "Preferential Species-Restricted Heavy/Light
Chain Pairing in Rat/Mouse Quadromas," J. Immunol., 155:219-225
(1995). cited by other .
Lobo et al., "Antibody pharmacokinetics and pharmacodynamics," J.
Pharm. Sci., 93:2645-68 (2004). cited by other .
Manzke et al., "Single-step purification of bispecific monoclonal
antibodies for immunotherapeutic use by hydrophobic interaction
chromatography," J. Immunol. Methods, 208:65-73 (1997). cited by
other .
Martin et al., "Crystal structure at 2.8 A of an FcRn/heterodimeric
Fc complex: mechanism of pH-dependent binding," Mol. Cell,
7:867-877 (2001). cited by other .
Marvin et al., "Recombinant approaches to IgG-like bispecific
antibodies," Acta. Pharmacol. Sin., 26:649-658 (2005). cited by
other .
Marvin et al., "Redesigning an antibody fragment for faster
association with its antigen," Biochemistry, 42:7077-83 (2003).
cited by other .
Merchant et al., "An efficient route to human bispecific IgG," Nat.
Biotechnol., 16:677-681 (1998). cited by other .
Onda et al., "Lowering the Isoelectric Point of the Fv Portion of
Recombinant Immunotoxins Leads to Decreased Nonspecific Animal
Toxicity without Affecting Antitumor Activity," Cancer Res.,
61:5070-77 (2001). cited by other .
Pavlinkova et al., "Charge-modified single chain antibody
constructs of monoclonal antibody CC49: Generation,
characterization, pharmacokinetics, and biodistribution analysis,"
Nucl. Med. Biol., 26:27-34 (1999). cited by other .
Pavlou et al., "The therapeutic antibodies market to 2008," Eur. J.
Pharm. Biopharm., 59:389-396 (2005). cited by other .
Poduslo et al., "Polyamine modification increases the permeability
of proteins at the blood--nerve and blood-brain barriers," J.
Neurochem., 66:1599-1609 (1996). cited by other .
Rajpal et al., a general method for greatly improving the affinity
of antibodies by using combinatorial libraries, Proc. Natl. Acad.
Sci. USA, 102:8466-71 (2005). cited by other .
Rathanaswami et al., "Demonstration of an in vivo generated
sub-picomolar affinity fully human monoclonal antibody to
interleukin-8," Biochem. Biophys. Res. Commun., 334:1004-13 (2005).
cited by other .
Reichert et al., "Monoclonal antibody successes in the clinic,"
Nat. Biotechnol., 23:1073-78 (2005). cited by other .
Sal-Man et al., "Arginine mutations within a transmembrane domain
of Tar, an Escherichia coli aspartate receptor, can drive homodimer
dissociation and heterodimer association in vivo," Biochem. J.,
385:29-36 (2005). cited by other .
Schaeffer et al. "The Rat Glomerular Filtration Barrier Does Not
Show Negative Charge Selectivity," Microcirculation, 9:329-342
(2002). cited by other .
Segal et al., "Bispecific antibodies in cancer therapy," Curr.
Opin. Immunol., 11:558-562 (1999). cited by other .
Shaul, "Exploring the charge space of protein-protein association:
a proteomic study," Proteins, 60:341-352 (2005). cited by other
.
Shields et al., "High resolution mapping of the binding site on
human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn
and design of IgG1 variants with improved binding to the Fc gamma
R," J. Biol. Chem., 276:6591-6604 (2001). cited by other .
Tarditi et al., "Selective high-performance liquid chromatographic
purification of bispecific monoclonal antibodies," J. Chromatogr.,
599:13-20 (1992). cited by other .
Ten Kate et al., "Effect of isoelectric point on biodistribution
and inflammation: imaging with indium-111-labelled IgG," Eur. J.
Nucl. Med., 17:305-309 (1990). cited by other .
Tsurushita et al., "Design of humanized antibodies: From anti-Tac
to Zenapax," Methods, 36:69-83 (2005). cited by other .
Wu et al., "Development of motavizumab, an ultra-potent antibody
for the prevention of respiratory syncytial virus infection in the
upper and lower respiratory tract," J. Mol. Biol., 368:652-65
(2007). cited by other .
Yamasaki et al., "Pharmacokinetic analysis of in vivo disposition
of succinylated proteins targeted to liver nonparenchymal cells via
scavenger receptors: importance of molecular size and negative
charge density for in vivo recognition by receptors," J. Pharmacol.
Exp. Ther., 301:467-477 (2002). cited by other .
Yang et al., "Tailoring structure-function and pharmacokinetic
properties of single-chain Fv proteins by site-specific
PEGylation," Protein Eng., 16:761-770 (2003). cited by other .
Zuckier et al., "Chimeric human-mouse IgG antibodies with shuffled
constant region exons demonstrate that multiple domains contribute
to in vivo half-life," Cancer Res., 58:3905-08 (1998). cited by
other .
International Search Report for App. Ser. No. PCT/JP2009/057309,
mailed Jul. 7, 2009, 8 pages. cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 12/295,039, dated
Oct. 12, 2010, 9 pages. cited by other .
International Preliminary Report on Patentability for App. Ser. No.
PCT/JP2007/057036, dated Oct. 21, 2008, 6 pages. cited by other
.
International Search Report for App. Ser. No. PCT/JP2007/057036,
dated May 1, 2007, 2 pages. cited by other .
European Search Report for App. Ser. No. 07 74 0494, dated Sep. 3,
2009, 3 pages. cited by other .
Brinkman et al. "Phospholipid-binding domain of factor VIII is
involved in endothelial cell-mediated activation of factor X by
factor IXa," Arterioscler. Thromb. Vasc. Biol., 22(3):511-516
(2002). cited by other .
Hoad et al. "Characterization of monoclonal antibodies to human
factor X.Xa: Initial observations with a quantitative ELISA
procedure," J. Immunol. Methods, 136(2):269-278 (1991). cited by
other .
Okubo et al. "The production and characterization of four
monoclonal antibodies to human factor X," Nara Med Assoc.,
38(1):20-28 (1987). cited by other .
Sato et al., "Properties of Two VEGF Receptors, Flt-1 and KDR, in
Signal Transduction," Ann N.Y. Acad. Sci, 902:201-207 (May 2000).
cited by other .
Japanese Patent Office, International Search Report for App. Ser.
No. PCT/JP2003/013123, mailed Nov. 25, 2003, 4 pages. cited by
other .
Japanese Patent Office, International Preliminary Report on
Patentability for App. Ser. No. PCT/JP2003/013123, dated Oct. 20,
2005, 7 pages. cited by other .
European Search Report for App. Ser. No. EP 03 75 1478, dated Jan.
11, 2008, 3 pages. cited by other .
International Preliminary Report on Patentability for App. Ser. No.
JP2006/306821, dated Oct. 9, 2007, 7 pages. cited by other .
Japanese Patent Office, International Search Report for App. Ser.
No. JP2006/306821, mailed Jul. 11, 2006, 6 pages. cited by other
.
Japanese Patent Office, International Search Report for App. Ser.
No. PCT/JP2004/014911, mailed Jan. 25, 2005, 3 pages. cited by
other .
Japanese Patent Office, International Preliminary Report on
Patentability for App. Ser. No. PCT/JP2004/014911, 6 pages
translation, Jan. 25, 2005. cited by other .
European Search Report for App. Ser. No. EP 04 79 2180, dated Jan.
17, 2008, 3 pages. cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 10/575,905, mailed
Jun. 25, 2009, 10 pages. cited by other .
Fish & Richardson P.C., Amendment and Response to Restriction
Requirement dated Nov. 18, 2009 in U.S. Appl. No. 10/575,905, filed
Apr. 16, 2010, 12 pages. cited by other .
Fish & Richardson P.C., Amendment in Reply to Action dated Jun.
23, 2010 in U.S. Appl. No. 10/575,905, filed Dec. 22, 2010, 10
pages. cited by other .
International Preliminary Report on Patentability for App. Ser. No.
PCT/JP2009/057309, dated Nov. 30, 2010, 7 pages. cited by other
.
International Preliminary Report on Patentability for App. Ser. No.
PCT/JP2007/057058, dated Oct. 21, 2008, 11 pages. cited by other
.
International Search Report App. Ser. No. PCT/JP2007/057058, mailed
May 7, 2001, 2 pages. cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 12/295,075, dated
Feb. 22, 2011, 9 pages. cited by other .
USPTO Final Office Action in U.S. Appl. No. 10/575,905, mailed Feb.
24, 2011, 7 pages. cited by other .
Panka et al., "Variable region framework differences result in
decreased or increased affinity of variant anti-digoxin
antibodies," Proc. Natl. Acad. Sci. USA, 85:3080-84 (1988). cited
by other .
Calbiochem.RTM. Buffers, "A guide for the preparation and use of
buffers in biological systems," by Chandra Mohan, Ph.D.,
Copyright.COPYRGT. 2003 EMD Biosciences, Inc., an Affiliate of
Merck KGaA, Darmstadt, Germany, 37 pages. cited by other .
Chamow et al., "A humanized, bispecific immunoadhesin-antibody that
retargets CD3+ effectors to kill HIV-1-infected cells," J.
Immunol., 153:4268-80 (1994). cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 11/910,836, dated
Mar. 18, 2011, 7 pages. cited by other .
Fish & Richardson P.C., Response to Restriction Requirement
dated Oct. 12, 2010 in U.S. Appl. No. 12/295,039, filed on Apr. 11,
2011, 9 pages. cited by other .
USPTO Restriction Requirement in U.S. Appl. No. 11/910,128, dated
Jun. 9, 2011, 10 pages. cited by other.
|
Primary Examiner: Szperka; Michael
Attorney, Agent or Firm: Fish & Richardson P.C.
Claims
The invention claimed is:
1. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein said antibody comprises
complementarity determining regions (CDRs) comprising (A) the amino
acid sequences of anti-blood coagulation factor IX/IXa antibody H
chain CDRs of the following (a1) or (a2) and L chain CDRs of the
following (b1) or (b2); and (B) the amino acid sequences of
anti-blood coagulation factor X antibody H chain CDRs of any one of
the following (c1) to (c9) and L chain CDRs of the following (d1)
or (d2): (a1) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 14, 15, and 16, respectively; (a2) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 18,
19, and 20, respectively; (b1) L chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 206, 207, and 208, respectively;
(b2) L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 214, 215, and 216, respectively; (c1) H chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 22, 23, and 24,
respectively; (c2) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 26, 27, and 28, respectively; (c3) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 30,
31, and 32, respectively; (c4) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 34, 35, and 36, respectively;
(c5) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 38, 39, and 40, respectively; (c6) H chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 42, 43, and 44,
respectively; (c7) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 46, 47, and 48, respectively; (c8) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 50,
51, and 52, respectively; (c9) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 54, 55, and 56, respectively;
(d1) L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 210, 211, and 212, respectively; (d2) L chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 218, 219, and 220,
respectively, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
2. A composition comprising the antibody according to claim 1 and a
pharmaceutically acceptable carrier.
3. A composition comprising the antibody according to claim 1,
wherein said composition is a pharmaceutical composition for
treating bleeding, a disorder accompanied by bleeding, or a
disorder caused by bleeding.
4. The composition according to claim 3, wherein the bleeding,
disorder accompanied by bleeding, or disorder caused by bleeding is
a disorder that arises and/or progresses as a result of an activity
decrease or deficiency of blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
5. The composition according to claim 4, wherein the disorder that
arises and/or progresses as a result of an activity decrease or
deficiency of blood coagulation factor VIII and/or activated blood
coagulation factor VIII is hemophilia A.
6. The composition according to claim 4, wherein the disorder that
arises and/or progresses as a result of an activity decrease or
deficiency of blood coagulation factor VIII and/or activated blood
coagulation factor VIII is a disorder in which an inhibitor against
blood coagulation factor VIII and/or activated blood coagulation
factor VIII is generated.
7. The composition according to claim 4, wherein the disorder that
arises and/or progresses as a result of an activity decrease or
deficiency of blood coagulation factor VIII and/or activated blood
coagulation factor VIII is acquired hemophilia.
8. The composition according to claim 4, wherein the disorder that
arises and/or progresses as a result of an activity decrease of
blood coagulation factor VIII and/or activated blood coagulation
factor VIII is von Willebrand's disease.
9. A method for treating bleeding, a disorder accompanied by
bleeding, or a disorder caused by bleeding, wherein said method
comprises the step of administering the antibody according to claim
1.
10. A kit for treating bleeding, a disorder accompanied by
bleeding, or a disorder caused by bleeding, wherein said kit
comprises at least the antibody according to claim 1.
11. A method of treating bleeding, a disorder accompanied by
bleeding, or a disorder caused by bleeding, wherein said method
comprises the step of administering the antibody according to claim
1 in combination with blood coagulation factor VIII.
12. A kit for treating bleeding, a disorder accompanied by
bleeding, or a disorder caused by bleeding, wherein said kit
comprises at least the antibody according to claim 1 and blood
coagulation factor VIII.
13. A method for treating bleeding, a disorder accompanied by
bleeding, or a disorder caused by bleeding, wherein said method
comprises the step of administering the composition according to
claim 2.
14. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (A) binds the same
epitope of blood coagulation factor IX/IXa as an antibody having
the H chain CDRs of (a1) or (a2) below and the L chain CDRs of (b1
or (b2) below, and (B) binds the same epitope of blood coagulation
factor X as an antibody having the H chain CDRs of any one of (c1)
to (c9) below and the L chain CDRs of (d1) or (d2) below: (a1) H
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
14, 15, and 16, respectively; (a2) H chain CDR 1, 2, and 3 amino
acid sequences described in SEQ ID NOs: 18, 19, and 20,
respectively; (b1) L chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 206, 207, and 208, respectively; (b2) L
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
214, 215, and 216, respectively; (c1) H chain CDR 1, 2, and 3 amino
acid sequences described in SEQ ID NOs: 22, 23, and 24,
respectively; (c2) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 26, 27, and 28, respectively; (c3) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 30,
31, and 32, respectively; (c4) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 34, 35, and 36, respectively;
(c5) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 38, 39, and 40, respectively; (c6) H chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 42, 43, and 44,
respectively; (c7) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 46, 47, and 48, respectively; (c8) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 50,
51, and 52, respectively; (c9) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 54, 55, and 56, respectively;
(d1) L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 210, 211, and 212, respectively; (d2) L chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 218, 219, and 220,
respectively, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
15. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising: (a) an anti-blood
coagulation factor IX/IXa antibody variable region comprising the
amino acid sequence of SEQ ID NO: 13, 17, 85, 205, or 213; and (b)
an anti-blood coagulation factor X antibody variable region
comprising the amino acid sequence of SEQ ID NO: 21, 25, 29, 33,
37, 41, 45, 49, 53, 161, 209, or 217, wherein the antibody
functionally substitutes for blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
16. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising anti-blood
coagulation factor IX/IXa H and L variable domains comprising a set
of six CDR sequences selected from (a1) and (a2) below and
anti-blood coagulation factor X H and L variable domains comprising
a set of six CDR sequences selected from (b1) and (b2) below: (a1)
H chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID
NOs: 14, 15, and 16, respectively, and L chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 214, 215, and 216,
respectively; (a2) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 86, 87, and 88, respectively, and L chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 206,
207, and 208, respectively; (b1) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 22, 23, and 24, respectively,
and L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 218, 219, and 220, respectively; (b2) H chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 162, 163, and 164,
respectively, and L chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 210, 211, and 212, respectively, wherein
the antibody functionally substitutes for blood coagulation factor
VIII and/or activated blood coagulation factor VIII.
17. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising (A) anti-blood
coagulation factor IX/IXa antibody H and L variable domains
comprising a set of six CDR sequences selected from (i) and (ii):
(i) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 14, 15, and 16, respectively, and L chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 214, 215, and 216,
respectively; (ii) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 86, 87, and 88, respectively, and L chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 206,
207, and 208, respectively; and (B) an anti-blood coagulation
factor X antibody variable domain comprising the amino acid
sequence of SEQ ID NO: 21, 25, 29, 33, 37, 41, 45, 49, 53, 161,
209, or 217, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
18. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising (A) an anti-blood
coagulation factor IX/IXa antibody variable domains comprising the
amino acid sequence of SEQ ID NO: 13, 17, 85, 205, or 213; and (B)
anti-blood coagulation factor X antibody H and L variable domains
comprising a set of six CDR sequences selected from (i) and (ii):
(i) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 22, 23, and 24, respectively, and L chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 218, 219, and 220,
respectively; (ii) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 162, 163, and 164, respectively, and L
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
210, 211, and 212, respectively, wherein the antibody functionally
substitutes for blood coagulation factor VIII and/or activated
blood coagulation factor VIII.
19. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising an anti-blood
coagulation factor IX/IXa antibody variable domain comprising the
amino acid sequence of SEQ ID NO: 13, 17, 85, 205, or 213, wherein
the antibody functionally substitutes for blood coagulation factor
VIII and/or activated blood coagulation factor VIII.
20. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising anti-blood
coagulation factor IX/IXa antibody H and L variable domains
comprising a set of six CDR sequences selected from (a) and (b):
(a) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 14, 15, and 16, respectively, and L chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 214, 215, and 216,
respectively; (b) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 86, 87, and 88, respectively, and L chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 206,
207, and 208, respectively, wherein the antibody functionally
substitutes for blood coagulation factor VIII and/or activated
blood coagulation factor VIII.
21. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising an anti-blood
coagulation factor X antibody variable region comprising the amino
acid sequence of SEQ ID NO: 21, 25, 29, 33, 37, 41, 45, 49, 53,
161, 209, or 217, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
22. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, the antibody comprising anti-blood
coagulation factor X antibody H and L variable domains comprising a
set of six CDR sequences selected from (a) and (b): (a) H chain CDR
1, 2, and 3 amino acid sequences described in SEQ ID NOs: 22, 23,
and 24, respectively, and L chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 218, 219, and 220, respectively;
(b) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 162, 163, and 164, respectively, and L chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 210, 211, and 212,
respectively, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
23. A method of promoting blood coagulation factor X activation by
blood coagulation factor IXa, the method comprising contacting a
blood coagulation factor X and a blood coagulation factor IXa with
the antibody according to claim 1.
24. A method of promoting coagulation of blood or plasma, the
method comprising contacting blood or plasma with the antibody
according to claim 1.
25. The method of claim 24, wherein the blood or plasma is
deficient in blood coagulation factor VIII or has a functional
reduction in blood coagulation factor VIII activity.
26. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (a) binds the same
epitope of blood coagulation factor IX/IXa as an antibody having a
variable region comprising the amino acid sequence of SEQ ID NO:
13, 17, 85, 205, or 213, and (b) binds the same epitope of blood
coagulation factor X as an antibody having variable region
comprising the amino acid sequence of SEQ ID NO: 21, 25, 29, 33,
37, 41, 45, 49, 53, 161, 209, or 217, wherein the antibody
functionally substitutes for blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
27. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (A) binds the same
epitope of blood coagulation factor IX/IXa as an antibody having H
and L variable domains comprising a set of six CDR sequences
selected from (a1) and (a2) below, and (B) binds the same epitope
of blood coagulation factor X as an antibody having H and L
variable domains comprising a set of six CDR sequences selected
from (b1) and (b2) below, (a1) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 14, 15, and 16, respectively,
and L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 214, 215, and 216, respectively; (a2) H chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 86, 87, and 88,
respectively, and L chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 206, 207, and 208, respectively; (b1) H
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
22, 23, and 24, respectively, and L chain CDR 1, 2, and 3 amino
acid sequences described in SEQ ID NOs: 218, 219, and 220,
respectively; (b2) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 162, 163, and 164, respectively, and L
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
210, 211, and 212, respectively; wherein the antibody functionally
substitutes for blood coagulation factor VIII and/or activated
blood coagulation factor VIII.
28. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (A) binds the same
epitope of blood coagulation factor IX/IXa as an antibody having H
and L variable domains comprising a set of six CDR sequences
selected from (i) and (ii): (i) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 14, 15, and 16, respectively,
and L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 214, 215, and 216, respectively; (ii) H chain CDR 1, 2, and
3 amino acid sequences described in SEQ ID NOs: 86, 87, and 88,
respectively, and L chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 206, 207, and 208, respectively; and (B)
binds the same epitope of blood coagulation factor X as an antibody
having variable domain comprising the amino acid sequence of SEQ ID
NO: 21, 25, 29, 33, 37, 41, 45, 49, 53, 161, 209, or 217, wherein
the antibody functionally substitutes for blood coagulation factor
VIII and/or activated blood coagulation factor VIII.
29. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (A) binds the same
epitope of blood coagulation factor IX/IXa as an antibody having
variable domains comprising the amino acid sequence of SEQ ID NO:
13, 17, 85, 205, or 213; and (B) binds the same epitope of blood
coagulation factor X as an antibody having H and L variable domains
comprising a set of six CDR sequences selected from (i) and (ii):
(i) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 22, 23, and 24, respectively, and L chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs:218,219, and 220,
respectively; (ii) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 162, 163, and 164, respectively, and L
chain CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs:
210, 211, and 212, respectively, wherein the antibody functionally
substitutes for blood coagulation factor VIII and/or activated
blood coagulation factor VIII.
30. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody binds the same epitope
of blood coagulation factor IX/IXa as an antibody having variable
domain comprising the amino acid sequence of SEQ ID NO: 13, 17, 85,
205, or 213, wherein the antibody functionally substitutes for
blood coagulation factor VIII and/or activated blood coagulation
factor VIII.
31. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody binds the same epitope
of blood coagulation factor IX/IXa as an antibody having H and L
variable domains comprising a set of six CDR sequences selected
from (a) and (b): (a) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 14, 15, and 16, respectively, and L chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 214,
215, and 216, respectively; (b) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 86, 87, and 88, respectively,
and L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 206, 207, and 208, respectively, wherein the antibody
functionally substitutes for blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
32. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody binds the same epitope
of blood coagulation factor X as an antibody having variable region
comprising the amino acid sequence of SEQ ID NO: 21, 25, 29, 33,
37, 41, 45, 49, 53, 161, 209, or 217, wherein the antibody
functionally substitutes for blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
33. A bispecific antibody that recognizes blood coagulation factor
IX and/or activated blood coagulation factor IX and blood
coagulation factor X, wherein the antibody (A) binds the same
epitope of blood coagulation factor X as an antibody having H and L
variable domains comprising a set of six CDR sequences selected
from (a) and (b): (a) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 22, 23, and 24, respectively, and L chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 218,
219, and 220, respectively; (b) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 162, 163, and 164, respectively,
and L chain CDR 1, 2, and 3 amino acid sequences described in SEQ
1D NOs: 210, 211, and 212, respectively, wherein the antibody
functionally substitutes for blood coagulation factor VIII and/or
activated blood coagulation factor VIII.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the National Stage of International Application
No. PCT/JP2004/014911, filed on Oct. 8, 2004, which claims the
benefit of International Applications No. PCT/JP2003/13062, filed
on Oct. 10, 2003, and PCT/JP2003/13123, filed on Oct. 14, 2003. The
contents of all of the foregoing applications are hereby
incorporated by reference in their entireties.
TECHNICAL FIELD
The present invention relates to bispecific antibodies that
functionally substitute for the cofactors which enhance enzymatic
reaction, and pharmaceutical compositions comprising the antibody
as an active ingredient.
BACKGROUND ART
Antibodies have received much attention as a medicine because of
their high stability in blood and low antigenicity. Of these are
bispecific antibodies that can simultaneously recognize two types
of antigens. Bispecific antibodies have been proposed for some
time; however, only antibodies that simply connect two types of
antigens, such as those for retargeting NK cells, macrophages, and
T cells (see Non-Patent Document 7), have been reported. For
example, MDX-210, which is currently under clinical study, is a
bispecific antibody that merely retargets Fc.gamma.RI-expressing
monocytes and such to HER-2/neu-expressing cancer cells. Thus,
there is no example so far that utilizes a bispecific antibody as
an alternative means to functionally substitute for the cofactor
which enhances enzymatic reaction.
Examples of cofactors are tissue factor (TF), blood coagulation
factor V (F.V), activated blood coagulation factor V (F.Va), blood
coagulation factor VIII (F.VIII), activated blood coagulation
factor VIII (F.VIIIa), thrombomodulin (TM), protein S (PS), protein
Z (PZ), heparin, complement C4b, complement regulatory factor H,
membrane cofactor protein (MCP), and complement receptor 1
(CR1).
Of these, F.VIIIIF.VIIIa is a cofactor required for sufficient
activity expression of activated blood coagulation factor IX
(F.IXa). Scheiflinger F. et al. discovered that a certain
anti-F.IXDF.IXa antibody acts to promote the activation of blood
coagulation factor X (F.X) by F.IXa in a chromogenic assay (Patent
Document 1). However, in an assay that examines the ability for
coagulation recovery in F.VIII-deficient plasma, the coagulation
recovery ability was observed only when F.IXa was added
exogenously, but not if this antibody was used alone.
F.VIIIa has been known to interact with not only F.IXa but also
with F.X (see Non-Patent Documents 5 and 6). In this respect, the
antibody of Scheiflinger F. et al. cannot be said to sufficiently
substitute for the function of F.VIII/F.VIIIa, and its activity
also seems to be insufficient.
Through dedicated research, the present inventors succeeded in
producing bispecific antibodies that functionally substitute for
the cofactors which enhance enzymatic activity, and thereby
completed this invention. [Patent Document 1] WO 01/19992 [Patent
Document 2] U.S. Pat. No. 4,474,893 [Patent Document 3] EP 404,097
[Patent Document 4] WO 93/11161 [Patent Document 5] Japanese Patent
Application No: 2002-112369 [Patent Document 6] Japanese Patent
Application No: 2003-012648 [Patent Document 7] Japanese Patent
Application Kokai Publication No. (JP-A) H5-304992 (unexamined,
published Japanese patent application) [Patent Document 8] JP-A
H2-145187 [Patent Document 9] JP-A H5-213775 [Patent Document 10]
JP-A H110-165184 [Patent Document 11] JP-A H111-71288 [Patent
Document 12] JP-A 2002-518041 [Patent Document 13] JP-A H 11-506310
[Patent Document 14] JP-A H5-199894 [Patent Document 15] JP-A
H110-511085 [Patent Document 16] JP-A H5-184383 [Non-Patent
Document 1] Nilsson I M et al., "J. Intern. Med." 1992, Vol.235,
p.25-32 [Non-Patent Document 2] Lofqvist T et al,. "J. Intern. Med"
1997, Vol.241, p.395-400 (the "o" of Lofqvist is written with an
umlaut) [Non-Patent Document 3] 24.sup.th Meeting of The Japanese
Society on Thrombosis and Hematosis, Special Committee on Examining
Hemophilia Standardization, Mini-symposium, 2001,
http://wwwjsth.org [Non-Patent Document 4] Medical Bulletin #193
1994 [Non-Patent Document 5] Mertens K et al., "Thromb. Haemost."
1999, Vol.82, p.209-217 [Non-Patent Document 6] Lapan K A et al.,
"Thromb. Haemost." 1998, Vol.80, p.418-422 [Non-Patent Document 7]
Segal D M et al., "Journal of Immunological Methods" 2001, Vol.248,
p.1-6 [Non-Patent Document 8] Bos R and Nieuwenhuitzen W,
"Hybridoma" 1992, Vol.11, No. 1, p.41-51 [Non-Patent Document 9]
Brennan M et al., "Science" 1985, Vol.229, No.1708, p.81-3
[Non-Patent Document 10] Karpovsky B et al., "J. Exp. Med." 1984,
Vol.160, No.6, p.1686-701 [Non-Patent Document 11] Suresh M R et
al., "Methods Enzymol." 1986, Vol.121, p. 210-28 [Non-Patent
Document 12] Massimo Y S et al., "J. Immunol. Methods" 1997,
Vol.201, p.57-66 [Non-Patent Document 13] Brennan M et al.,
"Science" 1985, Vol.229, p.81 [Non-Patent Document 14] Shalaby M R
et al., "J. Exp. Med." 1992, Vol.175, p.217-25 [Non-Patent Document
15] Holliner P et al., "Proc. Natl. Acad. Sci. USA" 1993, Vol.90,
p. 6444-8 [Non-Patent Document 16] Ridgway J B et al., "Protein
Eng." 1996, Vol.9, p. 617-21 [Non-Patent Document 17] Hammerling U
et al., "J. Exp. Med." 1968, Vol.128, p.1461-73 [Non-Patent
Document 18] Kurokawa T et al., "Bio/Technology" 1989, Vol.7,
p.1163 [Non-Patent Document 19] Link B K et al., "Blood" 1993,
Vol.81, p.3343 [Non-Patent Document 20] Nitta T et al., "Lancet"
1990, Vol.335, p.368-71 [Non-Patent Document 21 ] deLeij L et al.,
"Foundation Nationale de Transfusion Sanguine, Les Ulis France"
1990, p.249-53 [Non-Patent Document 22] Le Doussal J M et al., "J.
Nucl. Med." 1993, Vol.34, p.1662-71 [Non-Patent Document 23]
Stickney D R et al., "Cancer Res." 1991, Vol.51, p.6650-5
[Non-Patent Document 24] Weiner L M et al., "Cancer Res." 1993,
Vol.53, p.94-100 [Non-Patent Document 25] Kroesen B J et al., "Br.
J. Cancer" 1994, Vol.70, p.652-61 [Non-Patent Document 26] Weiner G
J et al., "J. Immunol." 1994, Vol.152, p.2385 [Non-Patent Document
27] Suresh M R et al., "Proc. Natl. Acad. Sci. USA" 1986, Vol.83,
p.7989-93 [Non-Patent Document 28] Milstein C and Cuello A C,
"Nature" 1983, Vol.305, p.537 [Non-Patent Document 29] Xiang J et
al., "Mol. Immunol." 1990, Vol.27, p.809 [Non-Patent Document 30]
Bebbington C R et al., "Bio/Technology" 1992, Vol.10, p.169
[Non-Patent Document 31] Huse W D et al., "Science" 1989, Vol. 246,
p.1275 [Non-Patent Document 32] McCafferty J et al., "Nature" 1990,
Vol.348, p.552 [Non-Patent Document 33] Kang A S et al., "Proc.
Natl. Acad. Sci. USA" 1991, Vol.88, p.4363
DISCLOSURE OF THE INVENTION
An objective of the present invention is to provide bispecific
antibodies that functionally substitute for the cofactors which
enhance enzymatic reaction.
Through dedicated research, the present inventors succeeded in
discovering bispecific antibodies that specifically bind to both
F.DUF.IXa and F.X and substitute for the function of cofactor
F.VIIIa (i.e., a function to promote F.X activation by F.IXa). That
is, the present inventors succeeded in producing bispecific
antibodies that recognize both an enzyme and its substrate and
functionally substitute for cofactors of the enzyme.
The present invention relates to bispecific antibodies that
functionally substitute for the cofactors which enhance enzymatic
reaction, and more specifically to: [1] An antibody recognizing
both an enzyme and a substrate thereof, wherein said antibody is a
bispecific antibody which functionally substitutes for a cofactor
that enhances the enzymatic reaction. [2] The antibody according to
[1], wherein said enzyme is a proteolytic enzyme. [3] The antibody
according to [2], wherein said proteolytic enzyme, substrate, and
cofactor are blood coagulation/fibrinolysis-associated factors. [4]
The antibody according to [3], wherein the enzyme of a blood
coagulation/fibrinolysis-associated factor is blood coagulation
factor IX and/or activated blood coagulation factor IX; the
substrate is blood coagulation factor X; and the cofactor is blood
coagulation factor VIII and/or activated blood coagulation factor
VIII. [5] The antibody according to any one of [1] to [4], wherein
said antibody comprises a complementarity determining region
comprising the amino acid sequence of anti-blood coagulation factor
Ix/IXa antibody CDR3 of the following (a1) or (a2) or a
complementarity determining region functionally equivalent thereto,
and a complementarity determining region comprising the amino acid
sequence of anti-blood coagulation factor X antibody CDR3 described
in any one of the following (b1) to (b9) or a complementarity
determining region functionally equivalent thereto: (a1) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 16; (a2) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 20; (b1) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 24; (b2) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 28; (b3) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 32; (b4) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 36; (b5) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 40; (b6) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 44; (b7) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 48; (b8) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 52; (b9) H chain
CDR 3 amino acid sequence described in SEQ ID NO: 56. [6] The
antibody according to any one of [1] to [4], wherein said antibody
comprises a complementarity determining region comprising the amino
acid sequence of anti-blood coagulation factor Ix/Ixa antibody CDR
of the following (a1) or (a2) or a complementarity determining
region functionally equivalent thereto, and a complementarity
determining region comprising the amino acid sequence of anti-blood
coagulation factor X antibody CDR described in any one of the
following (b1) to (b9) or a complementarity determining region
functionally equivalent thereto: (a1) H chain CDR 1, 2, and 3 amino
acid sequences described in SEQ ID NOs: 14, 15, and 16,
respectively; (a2) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 18, 19, and 20, respectively; (b1) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 22,
23, and 24, respectively; (b2) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 26, 27, and 28, respectively;
(b3) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 30, 31, and 32, respectively; (b4) H chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 34, 35, and 36,
respectively; (b5) H chain CDR 1, 2, and 3 amino acid sequences
described in SEQ ID NOs: 38, 39, and 40, respectively; (b6) H chain
CDR 1, 2, and 3 amino acid sequences described in SEQ ID NOs: 42,
43, and 44, respectively; (b7) H chain CDR 1, 2, and 3 amino acid
sequences described in SEQ ID NOs: 46, 47, and 48, respectively;
(b8) H chain CDR 1, 2, and 3 amino acid sequences described in SEQ
ID NOs: 50, 51, and 52, respectively; (b9) H chain CDR 1, 2, and 3
amino acid sequences described in SEQ ID NOs: 54, 55, and 56,
respectively. [7] A composition comprising the antibody according
to any one of [1] to [6] and a pharmaceutically acceptable carrier.
[8] The composition according to [7], wherein said composition is a
pharmaceutical composition used for preventing and/or treating
bleeding, disorder accompanied by bleeding, or disorder caused by
bleeding. [9] The composition according to [8], wherein the
bleeding, disorder accompanied by bleeding, or disorder caused by
bleeding is a disorder that arises and/or progresses as a result of
an activity decrease or deficiency of blood coagulation factor VIII
and/or activated blood coagulation factor VIII. [10] The
composition according to [9], wherein the disorder that arises
and/or progresses as a result of an activity decrease or deficiency
of blood coagulation factor VIII and/or activated blood coagulation
factor VIII is hemophilia A. [11] The composition according to [9],
wherein the disorder that arises and/or progresses as a result of
an activity decrease or deficiency of blood coagulation factor VIII
and/or activated blood coagulation factor VIII is a disorder in
which an inhibitor against blood coagulation factor VIII and/or
activated blood coagulation factor VIII is generated. [12] The
composition according to [9], wherein the disorder that arises
and/or progresses as a result of an activity decrease or deficiency
of blood coagulation factor VIII and/or activated blood coagulation
factor VIII is acquired hemophilia. [13] The composition according
to [9], wherein the disorder that arises and/or progresses as a
result of an activity decrease of blood coagulation factor VIII
and/or activated blood coagulation factor VIII is von Willebrand's
disease. [14] A method for preventing and/or treating bleeding,
disorder accompanied by bleeding, or disorder caused by bleeding,
wherein said method comprises the step of administering the
antibody according to any one of [1] to [6], or the composition
according to any one of [7] to [13]. [15] Use of the antibody
according to any one of [1] to [6] for preparing the composition
according to any one of [7] to [13]. [16] A kit used in the method
of preventing and/or treating disorders according to [14], wherein
said kit comprises at least the antibody according to any one of
[1] to [6] or the composition according to [7]. [17] A method of
preventing and/or treating bleeding, disorder accompanied by
bleeding, or disorder caused by bleeding, wherein said method
comprises the step of administering the antibody according to any
one of [4] to [6] or the composition according to any one of [7] to
[13] in combination with blood coagulation factor VIII. [18] A kit
used in the method of preventing and/or treating bleeding, disorder
accompanied by bleeding, or disorder caused by bleeding according
to [17], wherein said kit comprises at least the antibody according
to any one of [4] to [6], or the composition according to [7], and
blood coagulation factor VIII.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts the insertion region of pcDNA4-g4H.
FIG. 2 depicts the insertion regions of pcDNA4-g4L and
pIND-g4L.
FIG. 3 depicts the insertion region of pIND-g4H.
FIG. 4 depicts results of measuring the F.VIIIa-mimetic activity of
an anti-F.IXa/anti-F.X bispecific antibody, generated from
anti-F.IXa antibody XB12 and anti-F.X antibody SB04, SB21, SB42,
SB38, SB30, SB07, SB05, SB06, or SB34. The concentration of the
antibody solutions was 10 .mu.g/mL (final concentration 1
.mu.g/mL). The result is nine types of bispecific antibodies that
showed an increase in the F.VIIIa-mimetic activity: XB12/SB04,
XB12/SB21, XB12/SB42, XB12/SB38, XB12/SB30, XB12/SB07, XB12/SB05,
XB12/SB06, and XB12/SB34, in the order of activity strength.
FIG. 5 depicts results of measuring the F.VIIIa-mimetic activity of
an anti-F.IXa/anti-F.X bispecific antibody generated from
anti-F.IXa antibody XT04 and anti-F.X antibody SB04, SB21, SB42,
SB38, SB30, SB07, SB05, SB06, or SB34. The concentration of the
antibody solutions was 10 .mu.g/mL (final concentration 1
.mu.g/mL). As a result, XT04/SB04, XT04/SB21, XT04/SB42, XT04/SB38,
XT04/SB30, XT04/SB07, XT04/SB05, XT04/SB06, and XT04/SB34 showed an
increase in the F.VIIIa-mimetic activity.
FIG. 6 depicts results of measuring the F.VIIIa-mimetic activity of
various concentrations of XB12/SB04, which showed the highest
activity in FIG. 4. As a result, XB12/SB04 showed a
concentration-dependent increase of F.VIIIa-mimetic activity.
FIG. 7 depicts results of measuring the plasma coagulation time
(APTT) in the presence of XB12/SB04, XB12/SB21, XB12/SB42,
XB12/SB38, XB12/SB30, XB12/SB07, XB12/SB05, XB12/SB06, or
XB12/SB34. The concentration of the antibody solutions mixed with
F.VIII-deficient plasma was 1.7 .mu.g/mL for XB12/SB06 and 10
.mu.g/mL for the rest. As a result, XB12/SB04, XB12/SB21,
XB12/SB42, XB12/SB38, XB12/SB30, XB12/SB07, XB12/SB05, XB12/SB06,
and XB12/SB34 showed a coagulation time shortening effect compared
with in the absence of the antibodies.
FIG. 8 depicts results of measuring the plasma coagulation time
(APTT) in the presence of XT04/SB04, XT04/SB21, XT04/SB42,
XT04/SB38, XT04/SB30, XT04/SB07, XT04/SB05, XT04/SB06, and
XT04/SB34. The concentration of the antibody solutions mixed with
F.VIII-deficient plasma was 5 .mu.g/mL for XT04/SB06 and 10
.mu.g/mL for the rest. As a result, XT04/SB04, XT04/SB21,
XT04/SB42, XT04/SB38, XT04/SB30, XT04/SB07, XT04/SB05, and
XT04/SB06 showed a coagulation time shortening effect compared with
in the absence of the antibodies. XT04/SB34 showed no coagulation
time shortening effect.
FIG. 9 depicts results of measuring the coagulation time with
various concentrations of XB12/SB04, which showed the highest
coagulation time (APTT) shortening effect in FIGS. 7 and 8. As a
result, XB12/SB04 showed a concentration-dependent effect of
shortening the coagulation time. The antibody concentration in the
figure shows values of the antibody solution mixed with
F.VIII-deficient plasma.
FIG. 10 depicts results of the GST-AP Western blotting of SB04 or
SB06, where 1), 2) and 3) are results of reacting transcribed
GST-AP with SB04, SB06, and a sample containing no antibody,
respectively. The results show detection of only the binding
reaction of SB04 with GST-AP.
FIG. 11 depicts a pELBGlacI vector. ColE1ori: the replication
origin region of ColE1 plasmid series; f1ori: replication origin
region of f1 phage; lacI: coding region of lactose repressor
protein; P.sub.lac: lactose promoter; pelBss: signal sequence of E.
coli PelB protein; scFv: single-strand antibody molecule coding
region; gene III (gene3): f1 phage Gene III protein coding region;
Amp.sup.r: ampicillin-resistant gene; and Sfi I: restriction enzyme
Sfi I cleavage site.
FIG. 12 depicts results of measuring the F.VIIIa-mimetic activity
using culture supernatants of the expressed bispecific antibodies,
which are combinations of an anti-F.IXa antibody (A19, A25, A31,
A38, A39, A40, A41, A44, A50, A69, or XB12) and an anti-F.X
antibody (B2, B5, B9, B10, B11, B12, B13, B14, B15, B16, B18, B19,
B20, B21, B23, B25, B26, B27, B31, B34-1, B34-2, B35, B36, B38,
B42, SB04, SB15, or SB27). "+" represents cases where the
F.VIIIa-mimetic activity is 0.1 or more.
FIG. 13 depicts results of a plasma coagulation assay performed
using purified preparations of expressed bispecific antibodies,
which are combined from an anti-F.IXa antibody (A19, A25, A31, A38,
A39, A40, A41, A44, A50, A69, or XB12) and an anti-F.Xantibody (B2,
B5, B9, B10, B11, B12, B13, B14, B15, B16, B18, B19, B20, B21, B23,
B25, B26, B27, B31, B34-1, B34-2, B35, B36, B38, B42, SB04, SB15,
or SB27). The coagulation time was shortened by 10 to 20 seconds
("+"), 20 to 40 seconds ("++"), 40 to 50 seconds ("+++") or 50
seconds ("++++") or more with the antibody addition compared with
when the antibodies were not added.
FIG. 14 depicts results of measuring the coagulation time at
various concentrations of A44/B26, which had a high coagulation
time (APTT) shortening effect in FIG. 13. The coagulation time was
113 seconds when the antibody was not added. As a result, A44/B26
showed a concentration-dependent effect of shortening the
coagulation time. The antibody concentration in the figure shows
values of the antibody solution mixed with F.VIII-deficient
plasma.
FIG. 15 depicts results of measuring the coagulation time at
various concentrations of A69/B26, which had a high coagulation
time (APTT) shortening effect in FIG. 13. The coagulation time was
109.6 seconds when the antibody was not added. As a result, A69/B26
showed a concentration-dependent effect of shortening the
coagulation time. The antibody concentration in the figure shows
values of the antibody solution mixed with F.VIII-deficient
plasma.
FIG. 16 depicts results of measuring the coagulation time (APTT) in
the coexistence of A44/B26 or XB12/SB04 with F.VIII. As a result,
when compared to F.VIII alone, a mixed solution of A44/B26 or XB
12/SB04 with F.VIII showed a coagulation time shortening
effect.
FIG. 17 depicts results of measuring the coagulation time (APTT) in
inhibitor plasma under the presence of A44/B26 or XB12/SB04. As a
result, A44/B26 or XB12/SB04 showed a coagulation time shortening
effect compared with in the absence of the antibodies.
FIG. 18 depicts results of measuring the coagulation time at
various concentrations of XB12/SB04 and humanized XB12/humanized
SB04. The coagulation time was 111.3 seconds when no antibody was
added. As a result of the measurement, humanized XB12/humanized
SB04 showed a coagulation time shortening effect similar to that of
XB12/SB04. The antibody concentration in the figure shows values of
the antibody solutions mixed with F.VIII-deficient plasma.
DETAILED DESCRIPTION
A bispecific antibody according to the present invention is a
molecule comprising two types of antibodies or antibody fragments
having specificities for different antigens. The bispecific
antibody is, not particularly limited, but preferably
monoclonal.
The bispecific antibodies of the present invention are preferably
recombinant antibodies, generated using gene recombination
techniques (see, e.g., Borrebaeck C A K and Larrick J W,
THERAPEUTIC MONOCLONAL ANTIBODIES, Published in the United Kingdom
by MACMILLAN PUBLISHERS LTD, 1990). A recombinant antibody can be
obtained by cloning an antibody-encoding DNA from
antibody-producing cells, such as hybridomas or sensitized
lymphocytes, incorporating the DNA into an appropriate vector, and
introducing the vector into a host for antibody production.
Further, antibodies of the present invention may be antibody
fragments or modified antibodies. Antibody fragments include
diabody (Db), linear antibody, single-strand antibody (hereinafter
also referred to as scFv) molecules, etc. Herein, "Fv" fragment
represents the smallest antibody fragment, comprising a complete
antigen recognition site and binding site. An "Fv" fragment is a
dimer (V.sub.H-V.sub.L dimer) in which one heavy (H) chain variable
region (V.sub.H) and one light (L) chain variable region (V.sub.L)
are strongly connected by a non-covalent bond. Three
complementarity determining regions (CDRs) of each variable region
interact to form an antigen-binding site on the surface of a
V.sub.H-V.sub.L dimer. Six CDRs confer an antigen-binding site on
an antibody. However, even one variable region (or half of an Fv
which contains only three antigen-specific CDRs) is capable of
recognizing an antigen and binding thereto, although its affinity
is lower than that of the entire binding site.
In addition, Fab fragment (also referred to as (F(ab)) further
contains an L chain constant region and an H chain constant region
(CH1). A Fab' fragment differs from a Fab fragment in that the
former contains several additional residues derived from the
carboxyl terminal of an H chain CH1 region, which comprises one or
more cysteines from the hinge region of an antibody. Fab'-SH refers
to Fab' having a free thiol group in one or more cysteine residues
of the constant region. F(ab') fragments are generated by cleaving
the disulfide bond in the cysteines of the hinge portion of a
F(ab').sub.2 pepsin digest. Other chemically bound antibody
fragments are also known to those skilled in the art.
Diabody refers to a bivalent antibody fragment constructed by gene
fusion (Holliger P et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448
(1993); EP 404,097; WO 93/11161; etc.). Diabody is a dimer
comprising two peptide chains; in each polypeptide chain, an L
chain variable region (V.sub.L) is connected to an H chain variable
region (V.sub.H) on the same chain via a linker that is too short
to allow paring between the two regions (for example, about 5
residues). V.sub.L and V.sub.H encoded on the same polypeptide
chain form a dimer because they cannot form a single-stranded
variable region fragment due to the short linker between them.
Thus, a diabody ends up with two antigen binding sites.
A single-strand antibody or scFv fragment contains the V.sub.H and
V.sub.L regions of an antibody, and these regions exist in a single
polypeptide chain. In general, an Fv polypeptide further contains a
polypeptide linker between V.sub.H and V.sub.L regions, such that
scFv is able to form a structure that is necessary for antigen
binding (see Pluckthun "The Pharmacology of Monoclonal Antibodies"
Vol. 113 (Rosenburg and Moore ed (Springer Verlag, New York) pp.
269-315, 1994 for general remarks on scFv). The linkers of the
present invention are not particularly limited, as long as they do
not inhibit expression of the antibody variable regions connected
to both ends of a linker.
An IgG type bispecific antibody can be secreted by a hybrid
hybridoma (quadroma) formed by fusing two types of hybridomas that
produce IgG antibodies (Milstein C et al., Nature 1983, 305:
537-540). It can also be secreted by introducing into cells genes
of the L chains and H chains that constitute the two IgGs of
interest (a total of four types of genes) for co-expression.
However, theoretically, there are as many as ten combinations of H
chains and L chains in the IgGs produced by these methods. It is
difficult to purify an IgG comprising the desired combination of H
and L chains from ten different types of IgGs. Furthermore, in
theory, the amount of the combination of interest is dramatically
decreased, and thus large-scale cell culture is required, leading
to a further increase in manufacturing cost.
In this case, by appropriately substituting amino acid(s) in the
CH3 region of an H chain, it is possible to preferentially secrete
IgGs that have a heterologous combination of H chains (Ridgway, JB
et al. Protein Engineering 1996, 9: 617-621, Merchant, AM et al.
Nature Biotechnology 1998, 16: 677-681).
As for L chains, an L chain variable region is less diverse
compared to an H chain variable region; therefore, acquisition of a
common L chain that provides binding activities with two H chains
can be expected. Efficient expression of a bispecific IgG becomes
possible by introducing genes of this common L chain and both of
the H chains into a cell for IgG expression (Nature Biotechnology.
1998, 16, 677-681). However, the possibility of two randomly
selected types of antibodies containing the same L chain is low;
thus, it is difficult to put the aforementioned idea into practice.
In this respect, a method has been proposed for selection of a
common L chain adapting arbitrary different H chains to show high
binding ability (WO 2004/065611). An H chain having the
above-described CH3 variant (Nature Biotechnology. 1998, 16,
677-681) is rarely secreted in the absence of the other H chain. By
making use of this characteristic to first induce expression of the
right-arm L chain and H chain and stop the expression, and then
induce expression of the left-arm L chain and H chain, the
proportion of IgGs expressed in the combination of interest may be
increased (PCT/JP2004/008585).
A bispecific antibody can also be prepared by chemically
cross-linking Fab's. A bispecific F(ab').sub.2 can be produced, for
example, by maleimidating a Fab' prepared from one antibody with
o-PDM (ortho-phenylenedi-maleimide) and reacting the product with a
Fab' prepared from another antibody, so as to cross-link Fab's
derived from different antibodies (Keler T et al. Cancer Research
1997, 57: 4008-4014). Further, a method for chemically connecting
antibody fragments such as a Fab'-thionitrobenzoic acid (TNB)
derivative and Fab'-thiol (SH) is also known (Brennan M et al.
Science 1985, 229: 81-83).
Instead of cross linkage, a leucine zipper derived from Fos and Jun
or the like can be used. Although Fos and Jun also form a
homodimer, their preferential heterodimer formation is utilized. A
Fab' added with a Fos leucine zipper and a second Fab' added with a
Jun leucine zipper are expressed for preparation. By mixing and
reacting monomeric Fab'-Fos and Fab'-Jun, which have been reduced
under mild conditions, a bispecific F(ab').sub.2 can be formed
(Kostelny S A et al. J. of Immunology, 1992, 148: 1547-53). This
method is not limited to Fab' and can also be applied to scFv, Fv,
etc.
A bispecific antibody can also be prepared in a form of diabody. A
bispecific diabody is a heterodimer comprising two cross-over scFv
fragments. That is, a bispecific diabody can be prepared by
constructing a heterodimer using V.sub.H(A)-V.sub.L(B) and
V.sub.H(B)-V.sub.L(A), which have been formed by connecting V.sub.H
and V.sub.L derived from two types of antibodies: A and B, with a
relatively short linker of about 5 amino acid residues (Holliger P
et al. Proc. of the National Academy of Sciences of the USA 1993,
90: 6444-6448).
In this case, construction of a bispecific diabody of interest can
be promoted by performing appropriate amino acid substitutions
(knobs-into-holes: Zhu Z et al. Protein Science. 1997, 6: 781-788)
so as to link two types of scFv's with a flexible and relatively
long linker of about 15 amino acid residues (a single-chain
diabody: Kipriyanov S M et al. J. of Molecular Biology. 1999, 293:
41-56).
sc(Fv).sub.2 which can be prepared by linking two types of scFv's
with a flexible and relatively long linker of about 15 amino acid
residues can also become a bispecific antibody (Mallender W D et
al. J. of Biological Chemistry, 1994, 269: 199-206).
A modified antibody may be, for example, an antibody that binds to
various molecules such as polyethylene glycol (PEG). In the
modified antibodies of the present invention, substances to be
bound are not limited. Such modified antibodies can be obtained by
chemically modifying the antibodies obtained. These methods have
already been established in this field.
The antibodies of the present invention include human antibody,
mouse antibody, rat antibody and such, without any limitation on
their origins, and may be genetically modified antibodies such as
chimera antibody and humanized antibody.
Methods for obtaining human antibodies are known, and a human
antibody of interest can be obtained, for example, by immunizing a
transgenic animal having all repertoires of human antibody genes
with an antigen of interest (see WO 93/12227, WO 92/03918, WO
94/02602, WO 94/25585, WO 96/34096, WO 96/33735).
Genetically modified antibodies can be produced by known methods.
Specifically, for example, a chimera antibody comprises variable
regions from the H and L chains of an antibody from immunized
animals, and constant regions from the H and L chains of a human
antibody. A chimera antibody can be obtained by linking a DNA
encoding the variable region of an antibody derived from immunized
animals with a DNA encoding the constant region of a human
antibody, inserting the resulting DNA into an expression vector,
and introducing the recombinant vector into a host for
production.
A humanized antibody is a modified antibody also referred to as
reshaped human antibody. A humanized antibody is constructed by
grafting the complementarity determining region (CDR) of an
antibody derived from immunized animals into the CDR of a human
antibody. General genetic engineering technologies are also
known.
Specifically, a DNA sequence designed to link the CDR of a mouse
antibody to the framework region (FR) of a human antibody is
synthesized by PCR, using several oligonucleotides that have been
prepared to contain overlapping portions at their terminal regions.
After linking the obtained DNA to a DNA encoding the constant
region of a human antibody, the resulting DNA is incorporated into
an expression vector and introduced into a host to produce a
humanized antibody (see EP 239400 and WO 96/02576). As a human
antibody FR to be linked via CDR, one that is capable of forming an
antigen-binding site with a good complementarity determining region
is selected. Amino acids of the framework region in an antibody
variable region may be substituted as necessary, so that the
complementarity determining region of a reshaped human antibody
forms an appropriate antigen-binding site (Sato K et al, Cancer
Research 1993, 53: 851-856). The framework region may be
substituted with framework regions derived from various human
antibodies (see WO 99/51743).
The present invention provides bispecific antibodies which
functionally substitute for cofactors that recognize both an enzyme
and its substrate.
Cofactors of the present invention are not particularly limited, as
long as they are capable of acting on an enzyme to enhance the
enzymatic reaction. A cofactor of the present invention is, for
example, a cofactor of a proteolytic enzyme. Specific examples of a
cofactor of a proteolytic enzyme are cofactors for blood
coagulation and fibrinolysis associated factors (F.VIIIHF.VIIIa,
F.V/F.Va, PZ, TM, TM/PS system), cofactors for complement reactions
(C4b, MCP, CR1, H factor), and such.
The following combinations can be listed as specific examples of
enzyme and enzyme substrate, as well as enzyme cofactors. (a)
Cofactor for Blood Coagulation and Fibrinolysis Associated Factor
(Example 1) Enzyme: F.IXa Substrate: F.X Cofactor:
F.VIIIIF.VIIIa
Cofactor F.VIIIa binds to both F.IXa and F.X and enhances F.X
activation by F.IXa. Among bispecific antibodies that recognize
both the above-described enzyme F.IXa and substrate F.X, some have
an enhancing effect on F.X activation. Some of these antibodies are
thought to have an effect of substituting for the function of
cofactor F.VIII/F.VIIIa. (b) Cofactor for Blood Coagulation and
Fibrinolysis Associated Factor (Example 2) Enzyme: ZPI Substrate:
F.X/F.Xa Cofactor: PZ
Cofactor PZ binds to ZPI of the serpin family and activated blood
coagulation factor X (F.Xa) to enhance the F.Xa-inhibiting activity
of ZPI. Specifically, some bispecific antibodies that recognize
both ZPI and F.X/F.Xa are thought to have an effect of substituting
for the PZ function. (c) Cofactor for Blood Coagulation and
Fibrinolysis Associated Factor (Example 3) Enzyme: thrombin
Substrate: TAFI Cofactor: TM
Cofactor TM enhances TAFI activation by thrombin. Specifically,
some bispecific antibodies that recognize both thrombin and TAFI
are thought to have an effect of substituting for the TM function.
(d) Cofactors for Blood Coagulation and Fibrinolysis Associated
Factor (Example 4) Enzyme: thrombin Substrate: PC Cofactors:
TM/PS
The TM/PS system enhances PC activation by thrombin. Specifically,
some bispecific antibodies that recognize both thrombin and PC are
thought to functionally substitute for the TM/PS system. (e)
Cofactor for Blood Coagulation and Fibrinolysis Associated Factor
(Example 5) Enzyme: F.Xa Substrate: Prothrombin Cofactor:
F.V/F.Va
Cofactor F.Va binds to both F.Xa and prothrombin to enhance
prothrombin activation by F.Xa. Among bispecific antibodies that
recognize both the above-described enzyme F.Xa and its substrate
prothrombin, some have enhancing effects on prothrombin activation.
Some of these antibodies are thought to have a function that
substitutes for the function of cofactor F.V/F.Va. (f) Cofactor for
Complement Reaction (Example 1) Enzyme: C1s Substrate: C2 Cofactor:
C4b
C4b has C1s' promoting effect on C2 decomposition. Specifically,
some bispecific antibodies that recognize both C1s and C2 are
thought to functionally substitute for C4b. (g) Cofactors for
Complement Reaction (Example 2) Enzyme: Complement Regulatory
Factor I Substrate: C3b Cofactors: Complement Regulatory Factor H,
Membrane Cofactor Protein (MCP), and Complement Receptor 1
(CR1)
Complement Regulatory Factors H, MCP, and CR1 have the promoting
effect of Complement Regulatory Factor 1 on C3b degradation.
Specifically, among bispecific antibodies that recognize both
Complement Regulatory Factor 1 and C3b, some are thought to
functionally substitute for Complement Regulatory Factors H, MCP,
and CR1.
Among the above-described cofactors, F.VIII/F.VIIIa is particularly
preferable. Although F.VIIV/F.VIIIa undergoes limited proteolysis
by proteolytic enzymes such as thrombin, as long as it has
F.VIII/F.VIIIa activity, its form does not matter. Further,
F.VIIIVF.VIIIa variants and F.VIII/F.VIIIa that have been
artificially modified by gene recombination techniques are also
included in F.VIII/F.VIIIa, as long as they retain F.VIII/F.VIIIa
cofactor activity.
Methods for obtaining bispecific antibodies which functionally
substitute for cofactors of the present invention are not
particularly limited, and may be obtained by any methods. For
example, when obtaining a bispecific antibody that functionally
substitutes for enzyme A and substrate B, enzyme A and substrate B
are each immunized to an animal to obtain anti-enzyme A antibody
and anti-substrate B antibody. Subsequently, a bispecific antibody
comprising the anti-enzyme A antibody H and L chains and the
anti-substrate B antibody H and L chains is produced. Herein, it is
desirable to obtain several types of each of the anti-enzyme A
antibody and the anti-substrate B antibody, such that these
antibodies can be preferably used to produce as many combinations
of bispecific antibodies as possible. After bispecific antibodies
are produced, antibodies with an activity that substitutes for
cofactor function are selected.
Antibodies against an enzyme or a substrate can be obtained by
methods known to those skilled in the art. For example, antibodies
can be prepared by immunizing animals with antigens. Antigens for
immunizing animals are, for example, complete antigens having
immunogenicity and incomplete antigens (including hapten) without
immunogenicity. In the present invention, an enzyme whose cofactor
can be functionally substituted by an antibody of the present
invention which acts as the cofactor, or a substrate of the enzyme,
is used as the above-described antigen (immunogen). As animals to
be immunized, for example, mouse, rat, hamster, guinea pig, rabbit,
chicken, rhesus monkey and such can be used. Immunization of these
animals with antigens can be performed by methods known to those
skilled in the art. In the present invention, antibody L chain and
H chain variable regions are preferably collected from immunized
animals or cells thereof. This procedure can be performed by one
skilled in the art by using generally known methods.
Antigen-immunized animals express antibodies against the antigen,
especially in the spleen cells. Therefore, for example, mRNA can be
prepared from spleen cells of an immunized animal, and variable
regions of the L chain and H chain can be recovered by RT-PCR using
primers to the animal's variable regions.
Specifically, animals are immunized with an enzyme or a substrate.
The enzyme and substrate used as immunogens may be whole proteins
or partial peptides thereof. Further, depending on the
circumstances, a candidate antigen bound to another molecule to
form a soluble antigen, or fragments of which, may be used as an
immunogen for immunizing animals.
Spleen cells are isolated from the spleens of immunized mice, and
fused with mouse myeloma cells to produce hybridomas. After
selecting hybridomas that bind to the respective antigens, variable
regions of the L chain and H chain are recovered by RT-PCR, using
for example, primers corresponding to the variable regions. Primers
to CDR, primers to framework regions which are less diversified
than CDR, or primers to signal sequences and CH1 or L chain
constant region (C.sub.L) may also be used.
Alternatively, mRNA is extracted from the spleen cells of immunized
animals, and cDNAs of the L chain and H chain variable regions are
recovered by RT-PCR, using primers to vicinity of the variable
regions. Further, lymphocytes can also be immunized in vitro, and
used to construct scFv or Fab presenting libraries. The variable
regions may be obtained by concentrating and cloning an
antigen-binding antibody clone by panning. In this case, screening
can also be performed using similar libraries constructed from
mRNAs derived from the peripheral blood monocytes, spleen, tonsil
and such of human and non-immunized animals as materials.
The variable regions are then used to prepare antibody expression
vectors. By introducing an anti-enzyme antibody expression vector
and an anti-substrate antibody expression vector into a same cell
and expressing the antibodies, a bispecific antibody can be
obtained.
Antibodies that have a cofactor function-substituting activity can
be selected, for example, by the methods described below. (1) In a
reaction system comprising the enzyme and the substrate, the
selection is performed using elevation of enzyme activity
(substrate degradation ability) as an index, wherein the elevation
of enzyme activity is a result of antibody addition. (2) In a
system for measuring or simulating the biological functions which
the enzyme, substrate, and cofactor are involved in (for example, a
system for measuring plasma coagulation), the selection is
performed using activity of functional recovery as an index,
wherein the activity of functional recovery is a result of antibody
addition in the absence of the cofactor.
The antibody thus obtained can be purified to homogeneity.
Separation and purification of the antibody may be performed by
separation and purification methods used for general proteins. For
example, antibodies can be separated and purified by appropriately
selecting and combining chromatography columns such as affinity
chromatography, filter, ultrafiltration, salting out, dialysis, SDS
polyacrylamide gel electrophoresis, isoelectric electrophoresis and
so on (Antibodies: A Laboratory Manual. Ed Harlow and David Lane,
Cold Spring Harbor Laboratory, 1988), but the methods are not
limited thereto. A column used in affinity chromatography is, for
example, protein A column, protein G column and such.
For example, when F.VIII/F.VIIIa is the substitute cofactor, that
is, when the enzyme and substrate combination is plasma coagulation
and fibrinolysis associated factors F.IXa and F.X, the bispecific
antibody of the present invention preferably has a structure
comprising the variable region of an anti-F.IXa antibody and the
variable region of an anti-F.X antibody.
Bispecific antibodies of the present invention which functionally
substitute for F.VIII/F.VIIIa were generated by the following
method. Mice were subcutaneously immunized with commercial F.IXa or
F.X. Spleen cells were isolated from spleens of the immunized mice
with an elevated antibody titer, and fused with mouse myeloma cells
to form hybridomas. Hybridomas that bind to antigen F.IXa or F.X
were selected, and the L chain and H chain variable regions were
recovered by RT-PCR, using primers to the variable regions. The L
chain variable region was incorporated into a C.sub.L-containing L
chain expression vector, and the H chain variable region was
inserted into an H chain expression vector containing an H chain
constant region. In addition, mRNA was extracted from the spleens
of these immunized mice, and each cDNA of the L chain and H chain
variable regions was recovered by RT-PCR, using primers to the
respective variable region. Using these variable regions, an
scFv-presenting phage library was constructed. Antigen-binding
antibody clones were concentrated and cloned by panning and the
antibody expression vectors were formed using the variable region
thereof. The anti-F.IXa antibody (H chain, L chain) expression
vectors and anti-F.X antibody (H chain, L chain) expression vectors
were introduced into same cells for antibody expression and
bispecific antibodies were obtained.
Bispecific antibodies thus obtained were assessed for their effects
to functionally substitute for F.VIII/F.VIIIa (cofactors for F.X
activation by F.IXa) in an assay system comprising F.XIa (F.IX
activating enzyme), F.IX, F.X, a synthetic substrate (S-2222) for
F.Xa, and phospholipid. In principle, as a bispecific antibody
having activity to functionally substitute for F.VIII/F.VIIIa,
bispecific antibodies showing F.VIIIa-mimetic activity of 0.1 or
more in this assay system were selected based on the assay results.
The F.VIIIa-mimetic activity referred to herein is a value obtained
during 30 or 60 minutes by subtracting the value of absorbance
change of a solvent or culture supernatant that does not express
the antibody from the value of absorbance change of an antibody
solution or a culture supernatant that expresses the antibody.
Bispecific antibodies selected above or bispecific antibodies
closely related to them were measured for their ability to restore
coagulation in a coagulation time assay system that uses human
F.VIII-deficient plasma. As a result, bispecific antibodies which
are capable of shortening coagulation time as compared to when not
added were obtained. The coagulation time referred to herein is, as
shown in Example 7, the activated partial thromboplastin time
measured using human F.VIII-deficient plasma. Among these
bispecific antibodies, preferable bispecific antibodies have the
ability to shorten coagulation time by 10 seconds or more, more
preferably by 20 seconds or more, even more preferably by 40
seconds or more, and most preferably by 50 seconds or more.
The H chain CDR3s of the present invention's antibodies are not
particularly limited, but specifically have a complementarity
determining region comprising an amino acid sequence described in
any one of the H chain CDR3 sequences (SEQ ID NO: 16, 20, 60, 64,
68, 72, 76, 80, 84, 88,92, and 96) of XB12, XT04, A19, A25, A31,
A38, A39, A40, A41, A44, A50, and A69 described in the examples
described below or those functionally equivalent thereto, and the
complementarity determining region comprising an amino acid
sequence described in any one of the H chain CDR3 sequences (SEQ ID
NO: 24, 28, 32, 36, 40, 44, 48, 52, 56, 100, 104, 108, 112, 116,
120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168,
172, 176, 180, 184, 188, 192, 196, 200, and 204) in SB04, SB05,
SB06, SB07, SB21, SB30, SB34, SB38, SB42, B2, B5, B9, B10, B11,
B12, B13, B14, B15, B16, B18, B19, B20, B21, B23, B25, B26, B27,
B31, B34-1, B34-2, B35, B36, B38, B42, SB15, and SB27,
respectively, or those functionally equivalent thereto.
Further, a specific example of the above-described antibodies is
preferably combined from an antibody having a complementarity
determining region comprising any one of the H chain CDR amino acid
sequences of XB12, XT04, A19, A25, A31, A38, A39, A40, A41, A44,
A50, and A69 (SEQ ID NO: 14-16, 18-20, 58-60, 62-64, 66-68, 70-72,
74-76, 78-80, 82-84, 86-88, 90-92, and 94-96) or a complementarity
determining region functionally equivalent thereto, and an antibody
having a complementarity determining region comprising any one of
the H chain CDR amino acid sequences (SEQ ID NO: 22-24, 26-28,
30-32, 34-36, 38-40, 42-44, 46-48, 50-52, 54-56, 98-100, 102-104,
106-108, 110-112, 114-116, 118-120, 122-124, 126-128, 130-132,
134-136, 138-140, 142-144, 146-148, 150-152, 154-156, 158-160,
162-164, 166-168, 170-172, 174-176, 178-180, 182-184, 186-188,
190-192, 194-196, 198-200, and 202-204) in SB04, SB05, SB06, SB07,
SB21, SB30, SB34, SB38, SB42, B2, B5, B9, B10, B11, B12, B13, B14,
B15, B16, B18, B19, B20, B21, B23, B25, B26, B27, B31, B34-1,
B34-2, B35, B36, B38, B42, SB15, and SB27), or a complementarity
determining region functionally equivalent thereto
Amino acid sequences of the H chain variable regions of XB12, XT04,
A19, A25, A31, A38, A39, A40, A41, A44, A50, A69, SB04, SB05, SB06,
SB07, SB21, SB30, SB34, SB38, SB42, B2, B5, B9, B10, B11, B12, B13,
B14, B15, B16, B18, B19, B20, B21, B23, B25, B26, B27, B31, B34-1,
B34-2, B35, B36, B38, B42, SB15, and SB27 disclosed in the present
invention are shown as SEQ ID NOs: 13, 17, 57, 61, 65, 69, 73, 77,
81, 85, 89, 93, 21, 25, 29, 33, 37, 41, 45, 49, 53, 97, 101, 105,
109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153, 157,
161, 165, 169, 173, 177, 181, 185, 189, 193, 197, and 201.
Amino acid sequences of the L chain variable regions of A44, B26,
XB12, and SB04 disclosed in the present invention are shown as SEQ
ID NOs: 205, 209, 213, and 217. The L chain CDR sequences of A44,
B26, XB12, and SB04 are shown as SEQ ID NOs: 206-208, 210-212,
214-216, and 218-220. The H chain CDR nucleotide sequences of XB12,
SB04, A44, and B26 are shown as SEQ ID NOs: 221 (222), 223 (224),
225 (226), 233 (234), 235 (236), 237 (238), 245 (246), 247 (248),
249 (250), 257 (258), 259 (260), and 261 (262) (sequences within
brackets are amino acid sequences encoded by the respective nucleic
acids), and their L chain CDR nucleotide sequences are shown as SEQ
ID NOs: 227 (228), 229(230),231 (232), 239 (240), 241 (242), 243
(244), 251 (252), 253 (254), 255 (256), 263 (264), 265 (266), and
267 (268).
SEQ ID NOs: 58, 62, 66, 70, 74, 78, 82, 86, 90, 94, 98, 102, 106,
110, 114, 118, 122, 126, 130, 134, 138, 142, 146, 150, 154, 158,
162, 166, 170, 174, 178, 182, 186, 190, 194, 198, 202, 206, 210,
214, 218, 222, 228, 234, 240, 246, 252, 258, and 264 represent
CDR1.
SEQ ID NOs: 59, 63, 67, 71, 75, 79, 83, 87, 91, 95, 99, 103, 107,
111, 115, 119, 123, 127, 131, 135, 139, 143, 147, 151, 155, 159,
163, 167, 171, 175, 179, 183, 187, 191, 195, 199, 203, 207, 211,
215, 219, 224, 230, 236, 242, 248, 254, 260, and 266 represent
CDR2.
SEQ ID NOs: 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108,
112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160,
164, 168, 172, 176, 180, 184, 188, 192, 196, 200, 204, 208, 212,
216, 220, 226, 232, 238, 244, 250, 256, 262, and 268 represent
CDR3.
Antibodies of the present invention are, not particularly limited,
but preferably the bispecific antibodies combined from an
anti-factor IXa antibody and an anti-factor X antibody, which have
the same epitopes as the aforementioned antibodies or epitopes
closely related thereto. Antibodies having a same or closely
related epitope herein refer to, for example, those that compete
with one another on antigen binding in competitive ELISA, etc.
Without being limited thereto, in this competitive ELISA method,
factor Ix/IXa or factor X is immobilized onto a 96-well MicroWell
plate, an appropriately labeled antibody and an antibody to be
assessed are simultaneously added, and bound antibody is detected
by using the label. This label is not particularly limited and
includes alkaline phosphatase label, peroxidase label, biotin
labelled-streptavidin binding enzyme (alkaline phosphatase,
peroxidase and so on), FITC and such. There is an epitope overlap
if at least 50% competition is observed when the antibody is
present in a concentration of up to 100,000-fold excess of an
antibody to be assessed.
When preparing a full-length antibody using the variable regions
disclosed in the present invention, constant regions of the
antibody are not particularly limited, and those known to one
skilled in the art, for example, ones-described in "Sequences of
proteins of immunological interest, (1991), U.S. Department of
Health and Human Services. Public Health Service National
Institutes of Health" and "An efficient route to human bispecific
IgG, (1998). Nature Biotechnology vol.16, 677-681", and such can be
used.
In one embodiment of the antibodies of the present invention, the
antibodies have an effect to functionally substitute for cofactors,
and are thus expected to become effective drugs for diseases caused
by decrease in the activity (function) of these cofactors. In cases
where the cofactor functionally substituted by an antibody of the
present invention is a blood coagulation and
fibrinolysis-associated factor, the above-described diseases are,
for example, bleeding, diseases accompanied by bleeding, diseases
caused by bleeding, and such. In particular, functional reduction
and deficiency in F.VIII/F.VIIIa, F.IX/F.IXa, and F.XI/F.XIa have
been known to cause abnormal hemorrhage referred to as
hemophilia.
Of the hemophilias, abnormal hemorrhage due to congenital
hypofunction of F.VIII/F.VIIIa or deficiency in F.VIII/F.VIIIa is
referred to as hemophilia A. When a hemophilia A patient bleeds,
replacement therapy with a F.VIII formulation is performed. In
addition, preventive administration of a F.VIII formulation may be
performed (see Non-Patent Documents 1 and 2) on the day of vigorous
exercise or on field trip, when frequent intra-articular bleeding
occurs, or when the patient is classified as severe hemophilia.
Since this preventive administration of F.VIII formulation
remarkably reduces hemorrhage episodes of patients with hemophilia
A, it has recently become widely popular. Reduction of bleeding
episodes not only reduces lethal and nonlethal bleeding risks and
the accompanying agony, but also prevents hemophilic arthropathy
caused by frequent intra-articular hemorrhage. As a result, it
greatly contributes to the improvement of hemophilia A patients'
QOL.
The half life of a F.VIII formulation in blood stream is as short
as about 12 to 16 hours. Therefore, for continuous prevention, it
is necessary to administer a F.VIII formulation about three times a
week. This is equivalent to maintaining approximately 1% F.VIII
activity or more (see Non-Patent Documents 3 and 4). Also, in
replacement therapies for bleeding event, it is necessary to
periodically administer booster F.VIII formulations for a certain
period of time, except when the bleeding is mild, in order to
prevent rebleeding and establish complete hemostasis.
Further, F.VIII formulations are intravenously administered. There
are technical difficulties in performing intravenous
administration, and it becomes even more difficult particularly
when performing administration on young patients whose veins are
thin.
In the above-described preventive administration of F.VIII
formulation and emergency administration thereof in cases of
bleeding event, home treatment and self-injection are used in most
cases. The need for frequent administration and the technical
difficulties involved not only inflict pain on patients, but also
become a reason that hinders home treatment and self-injection from
becoming popular.
Accordingly, there have been strong demands for, as compared to
current blood coagulation factor VIII formulations, drugs that have
longer administration intervals and drugs that can be easily
administered.
Further, anti-F.VIII antibodies which are referred to as inhibitors
may be generated in hemophilia A patients, particularly in severe
hemophilia A patients. If an inhibitor is generated, effects of
F.VIII formulation become hindered by the inhibitor. As a result,
hemostasis control becomes very difficult for patients.
When such a hemophilia A inhibitor patient bleeds, neutralization
therapy using a mass dose of F.VIII formulation, or bypass therapy
using a complex concentrate or F.VIIa formulation is usually
performed. However, in neutralization therapy, administration of a
mass dose of F.VIII formulation may adversely enhance the inhibitor
(anti-F.VIII antibody) titer. Additionally, in bypass therapy, the
relatively short half-lives (about 2 to 8 hours) of complex
concentrates and the F.VIIa formulation are becoming problematic.
Furthermore, since their action mechanisms are independent of the
F.VIII/F.VIIIa function, that is, a function to catalyze the
activation of F.X by F.IXa, hemostatic mechanism may not function
well and become nonresponsive. Therefore, in many cases of
hemophilia A inhibitor patients, sufficient hemostatic effects are
not obtained, when compared to hemophilia A non-inhibitor
patients.
Therefore, there have been strong demands for drugs that are
unaffected by the presence of inhibitors and which can functionally
substitute for F.VIII/F.VIIIa.
In addition to hemophilia and acquired hemophilia caused by
anti-F.VIII autoantibody, von Willebrand's disease which is caused
by functional abnormality or deficiency of vWF has been known as an
abnormal bleeding disorder associated with F.VIII/F.VIIIa. vWF is
necessary not only for the normal adhesion of platelets to
subendothelial tissues at sites of vessel wall damage, but also for
the formation of complexes with F.VIII to maintain a normal plasma
F.VIII level. In patients with von Willebrand's disease, these
functions decline and functional abnormality of hemostasis
occurs.
In the above-described respects, methods that utilize antibodies
may be considered for creation of drugs that (i) have long
administration intervals, (ii) are easily administered and (iii)
are unaffected by the presence of inhibitors, and (iv) can
functionally substitute for F.VIII/F.VIIIa in a
F.VIII/F.VIIIa-independent manner. Generally, the half-lives of
antibodies in blood stream are relatively long--from several days
to several weeks. Further, antibodies are known to migrate into the
blood stream after subcutaneous administration. That is, antibody
drugs in general meet the above-described requirements of (i) and
(ii).
The present invention provides pharmaceutical compositions
comprising an antibody of the present invention as an active
ingredient. For example, when an antibody of the present invention
is one of the antibodies that recognize both F.IX/F.IXa and F.X,
and can functionally substitute for F.VIIIa, the antibody is
expected to become a pharmaceutical (pharmaceutical composition) or
drug for preventing or treating bleeding, disorders accompanied by
bleeding, or disorders caused by bleeding. Furthermore, when an
antibody of the present invention is one of the antibodies that
recognize both F.X/F.Xa and prothrombin, and can functionally
substitute for F.Va, the antibody is expected to become a
pharmaceutical (pharmaceutical composition) or drug for preventing
or treating bleeding, disorders accompanied by bleeding, or
disorders caused by bleeding.
At the same time, it is expected that an antibody that binds to ZPI
and F.X and functionally substitutes for PZ becomes a
pharmaceutical (pharmaceutical composition) or drug with
anti-thrombotic action, an antibody that binds to thrombin and TAFI
and functionally substitutes for TM becomes a pharmaceutical
(pharmaceutical composition) or drug with an hemostasis-promoting
effect, and an antibody that binds to thrombin and PC and
functionally substitutes for PS/TM system becomes a pharmaceutical
(pharmaceutical composition) or drug with an coagulation-modulating
effect.
In addition, since complement C4 deficiency causes systemic lupus
erythematosus (SLE), an antibody that functionally substitutes for
C4b is expected to become a pharmaceutical (pharmaceutical
composition) or drug with an effect that suppresses SLE occurrence.
Since H factor deficiency causes suppurative infection and
autoimmune glomerulonephritis, an antibody that functionally
substitutes for H factor is expected to become a pharmaceutical
(pharmaceutical composition) or drug with an effect of suppressing
the onset of these diseases.
For formulation of pharmaceuticals, pharmaceutical compositions
comprising an antibody of the present invention used for treatment
or prevention as an active ingredient may be mixed with an
appropriate pharmaceutically acceptable carrier, medium and such
that are inert thereto, if needed. For example, sterile water or
physiological saline, stabilizer, excipient, antioxidant (ascorbic
acid etc.), buffer (phosphoric acid, citric acid, other organic
acids, etc.), antiseptic, surfactant (PEG, Tween, etc.), chelating
agent (EDTA, etc.), binding agent and such can be cited.
Pharmaceutical compositions may also contain other low molecular
weight polypeptides, proteins such as serum albumin, gelatin, and
immunoglobulin, amino acids such as glycine, glutamine, asparagine,
arginine, and lysine, sugars such as polysaccharide and
monosaccharide and carbohydrates, and sugar alcohols such as
mannitol and sorbitol. When preparing aqueous solutions for
injection, for example, solubilizing agents include physiological
saline, isotonic solutions containing glucose and other adjunctive
agents such as D-sorbitol, D-mannose, D-mannitol, and sodium
chloride, and may be used in combination with appropriate
solubilizing agents such as alcohol (ethanol etc.), polyalcohol
(propylene glycol, PEG etc.), and non-ionic surfactant (polysorbate
80, HCO-50 etc.).
Further, if necessary, antibodies of the present invention may be
encapsulated into microcapsuls (microcapsuls made of hydroxymethyl
cellulose, gelatin, poly(methyl methacrylate), etc.), or included
in a colloidal drug delivery system (liposome, albumin microsphere,
microemulsion, nanoparticle, and nanocapsule, etc.) (see
"Remington's Pharmaceutical Science 16th edition", Oslo Ed. (1980)
etc.). Methods for formulating sustained-release drugs are also
known, and can be applied to antibodies of the present invention
(Langer et al., J.Biomed.Mater.Res. 15: 267-277 (1981); Langer,
Chemtech. 12: 98-105 (1982); U.S. Pat. No. 3,773,919; European
Patent Application No (EP): 58,481; Sidman et al., Biopolymers 22:
547-556 (1983); EP133,988).
Antibodies or pharmaceutical compositions of the present invention
can be used in combination with blood coagulation factor VIII.
Antibodies or pharmaceutical compositions of the present invention
may be administered with blood coagulation factor VIII
simultaneously or with some interval between them. Administration
may be performed in a kit that combines an antibody or
pharmaceutical composition of the present invention with blood
coagulation factor VIII. When an antibody or pharmaceutical
composition of the present invention is used in combination with
blood coagulation factor VIII, if desired, it is also possible to
use dosages lower than when they are used alone.
Although the dosage of the pharmaceutical compositions of the
present invention is appropriately determined considering the type
of formulation, method of administration, age and body weight of
patients, symptoms of patients, type and progress of disease, etc,
and ultimately by doctors, generally, doses of 0.1 to 2000 mg/day
can be divided into one to several administrations for adults. The
dosage is preferably 1 to 1000 mg/day, more preferably 5 to 500
mg/day, and most preferably 100 to 300 mg/day. Although the dosage
varies according to the body weight and age of patients,
administration methods and such, one skilled in the art can
suitably select an appropriate dosage. Preferably, the dosing
period is also appropriately determined according to, for example,
the healing process of patients.
Further, it is also possible to perform gene therapy by inserting a
gene encoding an antibody of the present invention into gene
therapy vectors. As an administration method apart from direct
administration of naked plasmids, the genes may be administered by
packaging into liposome and such, or insertion into various virus
vectors such as retrovirus vector, adenovirus vectors, vaccinia
virus vectors, pox virus vectors, adeno-associated virus vectors,
and HVJ vectors (see Adolph "Virus Genome Method" C RC Press,
Florid (1996)), or by coating onto carrier beads such as colloidal
gold particle (WO93/17706 etc.). However, the gene may be
administered by any methods, as long as the antibody can be
expressed in vivo to exert its action. Preferably, a sufficient
dose is administered through an appropriate parenteral route, such
as intravenous, intraperitoneal, subcutaneous, intracutaneous,
intra-adipose tissue, intramammary, and intramuscular injection and
infusion, inhalation, gas-inducible particle bombardment method
(with an electron gun and such), or mucosal route using nasal drop.
Genes encoding an antibody of the present invention may be
administered by introducing the gene into blood cells, cells
derived from bone marrow and such, using ex vivo liposome
transfection, particle bombardment method (U.S. Pat. No. 4,945,050)
or virus infection, and re-introducing these cells into animals. In
gene therapy, any gene encoding an antibody of the present
invention, for example, genes comprising nucleotide sequences of
CDRs of the above-described XB12, SB04, A44, and B26 may be
used.
The present invention also provides methods for preventing and/or
treating bleeding, disorders accompanied by bleeding, or disorders
caused by bleeding, comprising the steps of administering an
antibody or composition of this invention. Antibodies or
compositions can be administered, for example, by the
aforementioned methods.
The present invention also relates to use of the antibodies of this
invention for manufacturing (pharmaceutical) compositions of this
invention.
Further, the present invention provides kits comprising at least an
antibody or composition of this invention to be used in the
above-described methods. Glass syringe, injection needle,
pharmaceutically acceptable medium, alcohol cotton, bandage,
instruction manual that describes the usage, or such may also be
optionally packaged into the kits.
All documents of prior arts cited in the present specification have
been incorporated herein by reference.
Herein below, the present invention will be specifically described
with reference to Examples, but it is not to be construed as being
limited thereto.
EXAMPLE 1
Preparation of Non-neutralizing Antibody Against Factor IXa
(F.IXa)
1-1. Immunization and Preparation of Hybridomas
Eight BALB/c mice (male, 6 weeks old when immunization was
initiated (Charles River, Japan)) and five MRL/lpr mice (male, 6
weeks old when immunization was initiated (Charles River, Japan))
were immunized with human factor IXa.beta. (Enzyme Research
Laboratories, Inc.) as described below. As an initial immunization,
factor IXa.beta. (40 .mu.g/head) emulsified with FCA (Freund's
complete adjuvant H37 Ra (Difco laboratories)) was subcutaneously
administered. Two weeks later, factor IXa.beta. (40 .mu.g/head)
emulsified with FIA (Freund's incomplete adjuvant (Difco
laboratories)) was subcutaneously administered. Afterward, three to
seven booster immunizations were performed at one week intervals.
After the titer of a plasma antibody against factor IXa.beta. was
confirmed to be elevated by ELISA (Enzyme linked immunosorbent
assay) described in 1-2, factor IXa.beta. (40 .mu.g/head) diluted
in PBS(-) (phosphate buffered saline free of calcium ion and
magnesium ion) was intravenously administered as a final
immunization. Three days after the final immunization, spleens were
excised from mice. While a portion thereof was used in Example
10-2, the remaining spleen cells were fused with mouse myeloma
cells P3X63Ag8U.1 (referred to as P3U1, ATCC CRL-1597) by a
standard method using PEG1500 (Roche Diagnosticks). Fused cells
suspended in RPMI1640 medium (Invitrogen) containing 10% FBS
(Invitrogen) (hereinafter referred to as 10% FBS/RPMI1640) were
seeded in a 96-well culture plate, and 1, 2, 3, and 5 days after
the fusion, the medium was replaced with a HAT selection medium
(10% FBS/RPMI1640/2% HAT 50.times. concentrate (Dainippon
Pharmaceutical Co. Ltd)/5% BM-Condimed H1 (Roche Diagnostics) to
selectively culture hybridomas. Using the supernatants collected on
the 8.sup.th or 9.sup.th day after fusion, factor IXa-binding
activity was measured by ELISA described in 1-2 to select
hybridomas having factor IXa-binding activity. Subsequently, the
activity of neutralizing factor IXa enzymatic activity was measured
by the method described in 1-3 to select hybridomas that do not
have factor IXa-neutralizing activity. Hybridomas were cloned twice
by performing limiting dilutions in which one cell is seeded in
each well of a 96-well culture plate. Single colony cells confirmed
by microscopic observation were subjected to ELISA and
neutralization activity assay as described in 1-2 and 1-3 was
performed for clone selection. Ascites containing the cloned
antibody was prepared by the method described in 1-4, and the
antibody was purified from the ascites. The purified antibody was
unable to extend APTT (activated partial thromboplastin time) and
this was confirmed by the method described in 1-5.
1-2. Factor IXa ELISA
Factor IXa.beta. was diluted to 1 .mu.g/mL with a coating buffer
(100 mM sodium bicarbonate, pH 9.6, 0.02% sodium azide) and
distributed in Nunc-Immuno plate (Nunc-Immuno.TM. 96 MicroWell.TM.
plates MaxiSorp.TM. (Nalge Nunc International)) at 100 .mu.L/well.
Then, the plate was incubated at 4.degree. C. overnight. After
washing the plate with PBS(-) containing Tween.RTM. 20 thrice, it
was blocked with a diluent buffer (50 mM Tris-HCl, pH 8.1, 1%
bovine serum albumin, 1 mM MgCl.sub.2, 0.15 M NaCl, 0.05%
Tween.RTM. 20, 0.02% sodium azide) at room temperature for 2 hours.
After removal of the buffer, a diluent buffer-diluted mouse
antiserum or hybridoma. culture supernatant was added at 100
.mu.L/well, and incubated at room temperature for 1 hour. After
washing the plate thrice, alkaline phosphatase-labeled goat
anti-mouse IgG (H+L) (Zymed Laboratories) which had been diluted to
1/2000 with the diluent buffer was added at 100 .mu.L/well, and
incubated at room temperature for 1 hour. After washing the plate
six times, a colorimetric substrate Blue-Phos.TM. Phosphate
Substrate (Kirkegaad & Perry Laboratories) was added at 100
.mu.L/well, and incubated at room temperature for 20 minutes. After
adding the Blue-Phos.TM. Stop Solution (Kirkegaad & Perry
Laboratories) (100 .mu.L/well), absorbance at 595 nm was measured
with a Model 3550 Microplate Reader(Bio-Rad Laboratories).
1-3. Measurement of Factor IXa Neutralizing Activity
Phospholipid (Sigma-Aldrich) was dissolved in distilled water for
injection, and ultrasonicated to prepare a phospholipid solution
(400 .mu.g/mL). Tris buffered saline containing 0.1% bovine serum
albumin (hereinafter abbreviated as TBSB) (40 .mu.L), 30 ng/mL
factor IXa.beta. (Enzyme Research Laboratories) (10 .mu.L), 400
.mu.g/mL phospholipid solution (5 .mu.L), TBSB containing 100 mM
CaCl.sub.2 and 20 mM MgCl.sub.2 (5 .mu.L), and hybridoma culture
supernatant (10 .mu.L) were mixed in a 96-well plate, and incubated
at room temperature for 1 hour. To this mixed solution, 50 .mu.g/mL
factor X (Enzyme Research Laboratories) (20 .mu.L) and 3 U/mL
factor VIIIa (American diagnostica) (10 .mu.L) were added and
reacted at room temperature for 30 minutes. The reaction was
stopped by adding 0.5 M EDTA (10 .mu.L). After addition of an
S-2222 solution (50 .mu.L; Chromogenix) and incubation at room
temperature for 30 minutes, the absorbance was measured at
measurement wavelength 405 nm and reference wavelength 655 nm on a
Model 3550 Microplate Reader (Bio-Rad Laboratories, Inc.).
1-4. Ascites Preparation and Antibody Purification
Ascites of the established hybridomas was produced according to
standard procedures. That is, the hybridoma was cultured in vitro
(2.times.10.sup.6) and transplanted into the peritoneal cavity of a
BALB/c mouse (male, 5 to 7 weeks old at the time experiment was
started, Japan Charles River) or BALB/c nude mouse (female, 5 to 6
weeks old at the time experiment was started, Japan Charles River
and Japan CLEA), which was intraperitoneally administered twice
with pristane (2,6,10,14-tetramethylpentadecane, WAKO Pure Chemical
Industries) in advance. One to four weeks after the
transplantation, ascites was collected from the mouse with an
inflated abdomen.
The antibody was purified from the ascites using a Protein G
Sepharose.TM. 4 Fast Flow column (Amersham Biosciences). The
ascites was diluted 2-fold with a binding buffer (20 mM sodium
acetate, pH 5.0) and applied to the column, which had been washed
with 10 column volumes of the binding buffer. The antibody was
eluted with 5 column volumes of an elution buffer (0.1 M
glycine-HCl, pH 2.5), and neutralized with a neutralizing buffer (1
M Tris-HCl, pH 9.0). The resulting solution was concentrated using
a Centriprep.TM. 10 (Millipore), and the solvent was replaced with
TBS (50 mM Tris-buffered saline). The antibody concentration was
calculated from the absorbance at 280 nm with A (1%, 1 cm)=13.5.
Absorbance was measured with DU-650 (Beckman Coulter).
1-5. Measurement of APTT (Activated Partial Thromboplastin
Time)
APTT was measured with a CR-A (Amelung)-connected KC10A (Amelung).
A mixture of the TBSB-diluted antibody solution (50 .mu.L),
standard human plasma (Dade Behring) (50 .mu.L), and APTT reagent
(Dade Behring) (50 .mu.L) was warmed at 37.degree. C. for 3
minutes. To this mixture, 20 mM CaCl.sub.2 (Dade Behring) (50
.mu.L) was added to start a coagulation reaction, and the
coagulation time was measured.
EXAMPLE 2
Preparation of Non-factor X (F.X)-neutralizing Antibody
2-1. Immunization and Hybridoma Preparation
Eight BALB/c mice (male, 6 weeks old when immunization was
initiated, Japan Charles River) and five MRL/lpr mice (male, 6
weeks old when immunization was initiated, Japan Charles River)
were immunized with human factor X (Enzyme Research Laboratories)
as described below. As an initial immunization, factor X (40
.mu.g/head) emulsified with FCA was subcutaneously administered.
Two weeks later, factor X (20 or 40 .mu.g/head) emulsified with FIA
was subcutaneously administered. Subsequently, three to six booster
immunizations were given at one week intervals. After the titer of
a plasma antibody against factor X was confirmed to be elevated by
ELISA as described in 2-2, factor X (20 or 40 .mu.g/head) diluted
in PBS (-) was administered intravenously as a final immunization.
Three days after the final immunization, mouse spleens were
excised. While a portion thereof was used in Example 10-2, the
remaining spleen cells were fused with mouse myeloma P3U1 cells,
according to a standard method using PEG1500. Fused cells suspended
in 10% FBS/RPMI1640 medium were seeded in a 96-well culture plate,
and hybridomas were selectively cultured by replacing the medium
with a HAT selection medium 1, 2, 3 and 5 days after the fusion.
Binding activity toward factor X was measured by ELISA described in
2-2, using the culture supernatant collected on the 8.sup.th day
after fusion. Hybridomas having factor X-binding activity were
selected, and their activities to neutralize factor Xa enzymatic
activity were measured by the method described in 2-3. Hybridomas
that do not have a neutralizing activity toward factor Xa were
cloned by performing limiting dilution twice. Ascites containing
the cloned antibody was prepared by the method described in 1-4,
and the antibody was purified from the ascites. The purified
antibody was unable to extend APTT and this was confirmed by the
method described in 1-5.
2-2. Factor X ELISA
Factor X was diluted to 1 .mu.g/mL with a coating buffer, and
dispersed into Nunc-Immuno plate at 100 .mu.L/well. Then the plate
was incubated at 4.degree. C. overnight. After washing the plate
with PBS (-) containing Tween.RTM. 20 thrice, it was blocked with a
diluent buffer at room temperature for 2 hours. After removal of
the buffer, a diluent buffer-diluted mouse antiserum or hybridoma
culture supernatant was added to the plate, and incubated at room
temperature for 1 hour. After washing the plate thrice, alkaline
phosphatase-labeled goat anti-mouse IgG (H+L) which had been
diluted to 1/2000 with the diluent buffer was added, and incubated
at room temperature for 1 hour. After washing the plate six times,
a colorimetric substrate Blue-Phosr.TM. Phosphate Substrate
(Kirkegaad & Perry Laboratories) was added at 100 .mu.L/well,
and incubated at room temperature for 20 minutes. After adding
Blue-Phos.TM. Stop Solution (Kirkegaad & Perry Laboratories)
(100 .mu.L/well), absorbance ate 595 nm was measured with a Model
3550 Microplate Reader (Bio-Rad Laboratories).
2-3. Measurement of Factor Xa-neutralizing Activity
Hybridoma culture supernatant diluted to 1/5 with TBSB (10 .mu.L)
was mixed with 40 .mu.L of TBCP (TBSB containing 2.78 mM CaCl.sub.2
and 22.2 .mu.M phospholipids (phosphatidyl choline:phosphatidyl
serine=75:25, Sigma-Aldrich) containing 250 .mu.g/mL factor Xa
(Enzyme Research Laboratories), and incubated at room temperature
for 1 hour. To this mixed solution, TBCP (50 .mu.L) containing
prothrombin (Enzyme Research Laboratories) (20 .mu.g/mL) and 100
ng/mL activated coagulation factor V (factor Va (Haematologic
Technologies)) were added, and reacted at room temperature for 10
minutes. The reaction was stopped by adding 0.5 M EDTA (10 .mu.L).
To this reaction solution, 1 mM S-2238 solution (Chromogenix) (50
.mu.L) was added, and after incubation at room temperature for 30
minutes, absorbance at 405 nm was measured with a Model 3550
Microplate Reader (Bio-Rad Laboratories).
EXAMPLE 3
Construction of Chimera Bispecific Antibody Expression Vector
3-1. Preparation of Antibody Variable Region-encoding DNA Fragments
from Hybridomas
From the hybridomas that produce anti-F.IXa antibody or anti-F.X
antibody, total RNA was extracted using the QIAGEN.RTM. RNeasy.RTM.
Mini Kit (QIAGEN) according to the method described in the
instruction manual. The total RNA was dissolved in sterile water
(40 .mu.L). Single-stranded cDNA was synthesized by RT-PCR using
the SuperScript cDNA synthesis system (Invitrogen) with the
purified RNA (1 to 2 .mu.g) as template, according to the method
described in the instruction manual.
3-2. PCR Amplification of Antibody H Chain Variable Region and
Sequence Analysis
As primers for amplifying the mouse antibody H chain variable
region (VH) cDNA, an HB primer mixture and HF primer mixture
described in the report by Krebber et al. (J. Immunol. Methods
1997; 201: 35-55) were prepared. Using 0.5 .mu.L each of the 100
.mu.M HB primer mixture and 100 .mu.M HF primer mixture, a reaction
solution (25 .mu.L) (cDNA solution prepared in 3-1 (2.5 .mu.L), KOD
plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl.sub.2, 0.75 units
DNA polymerase KOD plus (TOYOBO)) was prepared. Using a thermal
cycler Gen-eAmp PCR system 9700 (Parkin Elmer), PCR was performed
according to amplification efficiency of the cDNA fragments, either
under conditions A (3 min heating at 98.degree. C. followed by 32
cycles of reaction (98.degree. C., 20 sec, 58.degree. C., 20 sec,
and 72.degree. C., 30 sec in one cycle)) or conditions B (3 min
heating at 94.degree. C. followed by 5 cycles of reaction
(94.degree. C., 20 sec, 46.degree. C., 20 sec, and 68.degree. C.,
30 sec in one cycle) and 30 cycles of reaction (94.degree. C., 20
sec, 58.degree. C., 20 sec, and 72.degree. C., 30 sec in one
cycle)). After PCR, the reaction solution was subjected to 1%
agarose gel electrophoresis. Amplified fragments of the desired
size (about 400 bp) were purified using a QIAquick Gel Extraction
Kit (QIAGEN) according to the methods described in the attached
instruction manual, and eluted with sterile water (30 .mu.L).
Nucleotide sequences of the DNA fragments were determined using a
BigDye Terminator Cycle Sequencing Kit (Applied Biosystems) on a
DNA sequencer ABI PRISM 3100 Genetic Analyzer (Applied Biosystems),
according to the method described in the attached instruction
manual. Sequence groups determined by this method were
comparatively analyzed using an analytical software, GENETYX-SV/RC
Version 6.1 (Genetyx), and DNAs with different sequences were
selected.
3-3. Preparation of Antibody Variable Region DNA Fragments for
Cloning
The following procedure was performed to add restriction enzyme Sfi
I cleavage sites for cloning to both termini of the antibody
variable region amplification fragments.
To amplify the VH fragments added with an Sfi I cleavage site (Sfi
I-VH), a primer (primer VH-5' end) in which the primer HB
(Gly4Ser)2-linker sequence was replaced with a sequence containing
Sfi I cleavage site (SEQ ID NO: 5) was prepared. Using 0.5 .mu.L
each of the 10 .mu.M sequence-specific primer VH-5' end and 10
.mu.M primer scfor (J. Immunol. Methods 1997; 201: 35-55), a
reaction solution (20 .mu.L) (purified solution of VH cDNA
amplification fragment prepared in 3-2 (1 .mu.L), KOD plus buffer
(TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl.sub.2, 0.5 units DNA polymerase
KOD plus (TOYOBO)) was prepared. Using a thermal cycler GeneAmp PCR
system 9700 (Parkin Elmer), PCR was performed according to
amplification efficiency of the cDNA fragments, either under
conditions A (3 min heating at 98.degree. C. followed by 32 cycles
of reaction (98.degree. C., 20 sec, 58.degree. C., 20 sec, and
72.degree. C., 30 sec in one cycle)) or conditions B (3 min heating
at 94.degree. C. followed by 5 cycles of reaction (94.degree. C.,
20 sec, 46.degree. C., 20 sec, and 68.degree. C., 30 sec in one
cycle) and 30 cycles of reaction (94.degree. C., 20 sec, 58.degree.
C., 20 sec, and 72.degree. C., 30 sec in one cycle)). After PCR,
the reaction solution was subjected to 1% agarose gel
electrophoresis. Amplified fragments of the desired size (about 400
bp) were purified using a QIAquick Gel Extraction Kit (QIAGEN) by
the method described in the attached instruction manual, and eluted
with sterile water (30 .mu.L).
To amplify the mouse antibody L chain variable region (VL) cDNA
fragments, 0.5 .mu.L each of the 100 .mu.M LB primer mixture and
100 .mu.M LF primer mixture described in the report by Krebber et
al. (J. Immunol. Methods 1997; 201: 35-55) was first used, and a
reaction solution (25 .mu.L) (cDNA solution prepared in 3-1 (2.5
.mu.L), KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM MgCl.sub.2,
0.75 units DNA polymerase KOD plus (TOYOBO)) was prepared. Using a
thermal cycler GeneAmp PCR system 9700 (Parkin Elmer), PCR was
performed according to amplification efficiency of the fragments,
under conditions of 3 minutes heating at 94.degree. C. followed by
5 cycles of reaction (94.degree. C., 20 sec, 46.degree. C., 20 sec,
and 68.degree. C., 30 sec in one cycle) and 30 cycles of reaction
(94.degree. C., 20 sec, 58.degree. C., 20 sec, and 72.degree. C.,
30 sec in one cycle). After PCR, the reaction solution was
subjected to 1% agarose gel electrophoresis. Amplified fragments of
the desired size (about 400 bp) were purified using the QIAquick
Gel Extraction Kit (QIAGEN) by the method described in the attached
instruction manual, and eluted with sterile water (30 .mu.L). The
fragments are in a state in which the primer LF-derived
(Gly4Ser)3-linker sequence is added to their C termini. In order to
add an Sfi I cleavage site to the C termini of the fragments, a
primer (primer VL-3' end) in which the primer LF (Gly4Ser)3-linker
sequence was replaced with a sequence having Sfi I cleavage site
(SEQ ID NO: 6) was prepared. To amplify the VL fragments added with
an Sfi I cleavage site (Sfi I-VL), 0.5 .mu.L each of the 10 .mu.M
VL-3' end primer mixture and 10 .mu.M scback primer was used, and a
reaction mixture (20 .mu.L) (purified solution of VL cDNA
amplification fragment (1 .mu.L), KOD plus buffer (TOYOBO), 0.2 mM
dNTPs, 1.5 mM MgCl.sub.2, 0.5 units DNA polymerase KOD plus
(TOYOBO)) was prepared. PCR was performed using a thermal cycler
GeneAmp PCR system 9700 (Parkin Elmer) under conditions of
3-minutes heating at 94.degree. C. followed by 5 cycles of reaction
(94.degree. C., 20 sec, 46.degree. C., 20 sec, and 68.degree. C.,
30 sec in one cycle) and 30 cycles of reaction (94.degree. C., 20
sec, 58.degree. C., 20 sec, and 72.degree. C., 30 sec in one
cycle). After PCR, the reaction solution was subjected to 1%
agarose gel electrophoresis. Amplified fragments of the desired
size (about 400 bp) were purified using the QIAquick Gel Extraction
Kit (QIAGEN) by the method described in the attached instruction
manual, and eluted with sterile water (30 .mu.L).
The purified Sfi I-VH and Sfi I-VL fragments were digested with Sfi
I (Takara Bio) at 50.degree. C. overnight in a reaction solution
prepared according to the method described in the attached
instruction manual. Subsequently, the reaction solution was
purified using a QIAquick PCR Purification Kit (QIAGEN) by the
method described in the attached instruction manual, and eluted
with Buffer EB (30 .mu.L) included in the kit.
3-4. Bispecific IgG Antibody Expression Plasmid
When producing the bispecific IgG antibody of interest, the
knobs-into-holes technique of IgG1 (Ridgway et al., Protein Eng.
1996; 9: 617-621) was referred to when preparing IgG4 with an amino
acid-substituted CH3 portion to form heteromolecules for each H
chain. Type a (IgG4.gamma.a) is substituted with Y349C and T366W,
and type b (IgG4.gamma.b) is substituted with E356C, T366S, L368A,
and Y407V. Further, a substitution (-ppcpScp-.fwdarw.-ppcpPcp-) was
also introduced at the hinge regions of both types. Almost all the
H chains become heteromolecules by this technique; however, this
does not necessarily apply to L chains, and the formation of
unnecessary antibody molecules may affect subsequent activity
measurements. Therefore, to separately express the arms of each
antibody molecule (called HL molecule), which have different
specificities, and efficiently form the type of bispecific IgG
antibody of interest within cells, those that are inducible by
different drugs were used as the expression vectors for each HL
molecule.
As an expression vector for an arm of the antibody molecule (called
right arm HL molecule for convenience), pcDNA4-g4H or pcDNA4-g4L
(FIG. 1 or FIG. 2) was prepared, in which the respective H chain or
L chain region, that is, an appropriate mouse antibody variable
region (VH or VL) and a human IgG4.gamma.a constant region (SEQ ID
NO: 7) or K constant region (SEQ ID NO: 8), were incorporated into
the tetracycline-inducible type vector pcDNA4 (Invitrogen)
downstream of the signal sequence (IL3ss) for animal cells (Proc.
Natl. Acad. Sci. USA. 1984; 81: 1075). First, Eco RV and Not I
(Takara Bio) were used to digest pcDNA4 at the restriction enzyme
cleavage sites that are present in its multi-cloning site. The
right arm H chain- or L chain-expression unit (about 1.6 kb or
about 1.0 kb respectively) of a chimera bispecific antibody having
appropriate antibody variable regions was digested with XhoI
(Takara Bio). Then, it was purified with the QIAquick PCR
Purification Kit (QIAGEN) by the method described in the attached
instruction manual, and reacted with DNA polymerase KOD (TOYOBO) at
72.degree. C. for 10 minutes in a reaction solution composition
described in the attached instruction manual to blunt the ends. The
blunt-end fragments were purified with the QIAquick PCR
Purification Kit(QIAGEN) by the method described in the attached
instruction manual, and digested with Not I (Takara Bio). The Not
I/blunt end fragments (about 1.6 kb or 1.0 kb respectively) and the
Eco RV/Not I-digested pcDNA4 were subjected to a ligation reaction
using Ligation High (TOYOBO), according to the method described in
the attached instruction manual. An E. coli DH5.alpha. strain
(Competent high DH5.alpha. (TOYOBO)) was transformed with the
above-described reaction solution. From the ampicillin-resistant
clones thus obtained, respective plasmid DNAs were isolated using
the QIAprep Spin Miniprep Kit (QIAGEN).
As an expression vector for the antibody molecule's other arm
(called left arm HL molecule for convenience), pIND-g4H or pIND-g4L
(FIG. 2 or FIG. 3) was prepared according to the above-described
method, in which the H chain or L chain respective region, that is,
an appropriate mouse antibody variable region (VH or VL) and a
human IgG4.gamma.b constant region (SEQ ID NO: 9) or .kappa.
constant region (SEQ ID NO: 8), were incorporated into the ecdysone
analogue inducible type vector pIND (Invitrogen) downstream of the
signal sequence (IL3ss) for animal cells (EMBO. J. 1987; 6: 2939),
and the respective plasmid DNAs were isolated.
3-5. Construction of Bispecific Antibody Expression Vector
The tetracycline-inducible type expression plasmid prepared in 3-4
(pcDNA4-g4H or pcDNA4-g4L) was digested with Sfi I, and was
subjected to 1% agarose gel electrophoresis. Fragments (about 5 kb)
lacking the intrinsic antibody variable region part (VH or VL (see
FIG. 1 or FIG. 2)) were purified using the QIAquick Gel Extraction
Kit (QIAGEN) by the method described in the attached instruction
manual, and eluted with sterile water (30 .mu.L). The fragments,
and the corresponding Sfi I-VH or Sfi-VL fragment derived from the
Sfi I-digested anti-F.IXa antibody prepared in 3-3, were subjected
to a ligation reaction using the Quick Ligation Kit (New England
Biolabs) according to the method described in the attached
instruction manual. An E. coli DH5.alpha. strain (Competent high
DH5.alpha. (TOYOBO)) was transformed with the above-described
reaction solution. Further, fragments obtained by removing the
antibody variable region part by a similar technique as described
above (VH or VL (see FIG. 2 or FIG. 3)) from the Sfi I-digested
ecdysone analogue-inducible type expression plasmid (pIND-g4H or
pIND-4GL) prepared in 3-4 and the corresponding Sfi I-digested
anti-F.X antibody-derived Sfi I-VH or Sfi I-VL fragment were
incorporated by a similar method.
In each of the ampicillin-resistant transformants thus obtained,
insertion of the fragment of interest was confirmed by colony PCR
method using primers that sandwich the inserted fragment. First,
for the anti-F.IXa antibody chimeric H chain or L chain expression
vector, a 21-mer CMVF primer (SEQ ID NO: 10) which anneals to the
CMV forward priming site upstream of the insertion site, and an
18-mer BGHR primer (SEQ ID NO: 11) which anneals to the BGH reverse
priming site downstream of the insertion site were synthesized
(Sigma Genosys). For the anti-F.X antibody chimeric H chain or L
chain expression vector, a 24-mer EcdF primer (SEQ ID NO: 12) which
anneals to the upstream of the insertion site and an 18-mer BGHR
primer (SEQ ID NO: 11) which anneals to the BGH reverse priming
site downstream of the insertion site were synthesized (Sigma
Genosys). For colony PCR, a reaction solution (20 .mu.L) (0.2 .mu.L
primer (10 .mu.M), KOD dash buffer (TOYOBO), 0.2 mM dNTPs, and 0.75
units DNA polymerase KOD dash) (TOYOBO)) was prepared. To this
reaction solution, cells of the transformant strain were added in
appropriate amounts and PCR was performed. PCR was performed using
a thermal cycler GeneAmp PCR system 9700 (Parkin Elmer) under
conditions of 1 minute heating at 96.degree. C. followed by 30
cycles of reaction (96.degree. C., 10 sec, 55.degree. C., 10 sec,
and 72.degree. C., 30 sec in one cycle). After PCR, the reaction
solution was subjected to 1% agarose gel electrophoresis, and
clones from which amplification fragments of the desired size were
obtained, were selected. The PCR product was treated with an
ExoSAP-IT (Amersham Biosciences) to inactivate excess primers and
dNTPs according to the attached instruction manual. Nucleotide
sequences of the DNA fragments were determined using a BigDye
Terminator Cycle Sequencing Kit (Applied Biosystems) on a DNA
sequencer ABI PRISM 3100 Genetic Analyzer (Applied Biosystems),
according to the method described in the attached instruction
manual. Sequence groups determined by the present method were
analyzed with an analytical software, GENETYX-SV/RC Version 6.1
(Genetyx). For VH, clones of interest having no insertion,
deletion, or mutation were selected. For VL, different from the
P3U1-derived pseudo VL gene used in hybridomas, clones of interest
having no insertion, deletion, or mutation were selected.
From the clones of interest, the respective plasmid DNAs were
isolated by using a QIAprep Spin Miniprep Kit (QIAGEN), and then
dissolved in sterile water (100 .mu.L). Anti-F.IXa antibody
chimeric H chain expression vector, anti-F.IXa antibody chimeric L
chain expression vector, anti-F.X antibody chimeric H chain
expression vector, and anti-F.X antibody chimeric L chain
expression vector were named pcDNA4-g4D RaHn, pcDNA4-g4IXaLn,
pIND-g4XHn, and pIND-g4XLn, respectively. Each plasmid solution was
stored at 4.degree. C. till use.
EXAMPLE 4
Expression of Chimera Bispecific Antibodies in Animal Cells
4-1. Preparation of DNA Solutions
Expression of the antibody's right arm HL molecule expression
vectors (pcDNA4-g4IXaHn and pcDNA4-g4IXaLn) is induced by
tetracycline. In the absence of tetracycline, Tet
repressor-encoding plasmid pcDNA6/TR (Invitrogen) is required to
completely suppress their expressions. Further, expression of the
left arm antibody HL molecule expression vectors (pINE-g4XHn and
pIND-g4XLn) was induced by an insect hormone ecdysone analogue
(ponasterone A). This requires plasmid pVgRXR (Invitrogen) which
encodes the ecdysone receptor and retinoid X receptor that react
with ponasterone A and induce expression. Therefore, for the
transfection of animal cells, a mixture of six types of plasmid
DNAs in total was prepared. For 1 mL of cell culture,
pcDNA4-g4IXaHn, pcDNA4-g4IXaLn, pIND-g4XHn and pIND-g4XLn (218.8 ng
each), as well as pcDNA6/TR and pVgRXR (1312.5 ng each) were
used.
4-2. Transfection of Animal Cells
Human fetal renal carcinoma cell-derived HEK293H strain
(Invitrogen) was suspended in a DMEM culture medium (Invitrogen)
containing 10% FCS (MOREGATE), and 1 mL of which was seeded at a
cell density of 5.times.10.sup.5 cells/mL in each well of a 12-well
plate for adhesive cells (CORNING) and cultured in a CO.sub.2
incubator (37.degree. C., 5% CO.sub.2). The plasmid DNA mixture
prepared in 4-1 was added to a mixture of transfection reagents,
Lipofectaine 2000 (Invitrogen) (7 .mu.L) and Opti-MEM I medium
(Invitrogen) (250 .mu.L), and left to stand at room temperature for
20 minutes. The resulting mixture was added to the cells in each
well and incubated for 4 to 5 hours in a CO.sub.2 incubator
(37.degree. C., 5% CO.sub.2).
4-3. Induction of Bispecific IgG Antibody Expression
Culture medium was removed by suction from the transfected cell
culture described above, and then 1 mL of a CHO-S-SFM-II
(Invitrogen) medium containing 1 .mu.g/mL tetracycline (Wako Pure
Chemical Industries) was added. The resulting mixture was incubated
for one day in a CO.sub.2 incubator (37.degree. C., 5% CO.sub.2) to
induce primary expression of the antibody's right arm HL molecule.
Subsequently, after removing the medium by suction, washing with 1
mL of CHO-S-SFM-II medium, and adding 1 mL of a CHO-S-SFM-II medium
containing 5 .mu.M ponasterone A (Invitrogen), the mixture was
incubated in a CO.sub.2 incubator (37.degree. C., 5% CO.sub.2) for
2 to 3 days, and secondary expression of the antibody's left arm HL
molecule was induced so that the bispecific IgG antibody was
secreted into the medium. The culture supernatant was recovered and
centrifuged (about 2000 g, 5 min, room temperature) to remove the
cells, and concentrated using Microcon.RTM. YM-50 (Millipore), if
necessary. The sample was stored at 4.degree. C. till use.
EXAMPLE 5
Quantification of Human IgG Concentration
Goat affinity purified antibody to human IgG Fc (Cappel) was
adjusted to 1 .mu.g/mL with a coating buffer, and immobilized to a
Nunc-Immuno plate. After blocking with a diluent buffer (D.B.), a
sample of the culture supernatant suitably diluted with D.B. was
added. Further, as a standard for calculating the antibody
concentration, human IgG4 (humanized anti-TF antibody, see WO
99/51743) diluted with D.B. in a two-fold dilution series up to 11
stages beginning at 1000 ng/mL was similarly added. After three
washes, goat anti-human IgG alkaline phosphatase (Biosource
International) was reacted. After five washes, the plate was color
developed using the Sigma 104.RTM. phosphatase substrate
(Sigma-Aldrich) as a substrate, and the absorbance at 405 nm was
measured on an absorbance reader Model 3550 (Bio-Rad Laboratories)
with a reference wavelength of 655 nm. Using the Microplate Manager
III (Bio-Rad Laboratories) software, human IgG concentration in the
culture supernatant was calculated from the standard curve.
EXAMPLE 6
F.VIIIa (Activated Coagulation Factor VIII)-mimetic Activity
Assay
The F.VIIIa-mimetic activity of a bispecific antibody was assessed
by the following enzymatic assay. The following reactions were all
performed at room temperature. A mixture of 40 .mu.L factor IX
(3.75 .mu.g/mL; Enzyme Research Laboratories) and 10 .mu.L of the
antibody solution was incubated in a 96-well plate for 1 hour.
Then,10 .mu.L factor XIa (10 ng/mL; Enzyme Research Laboratories),
20 .mu.L factor X (50 .mu.g/mL; Enzyme Research Laboratories), 5
.mu.L phospholipid (400 .mu.g/mL; see Examples 1-3), and 15 .mu.L
TBSB containing 5 mM CaCl.sub.2 and 1 mM MgCl.sub.2 (hereinafter
abbreviated as TBSB-S) were added to initiate enzymatic reaction.
After 30 minutes, the reaction was stopped by adding 10 .mu.L of
0.5 M EDTA.
After adding a colorimetric substrate solution (50 .mu.L) to each
well, absorbance at 405 nm (reference wavelength 655 nm) at 0 and
30 minutes was measured with a Model 3550 Microplate Reader (Bio
Rad Laboratories). The F.VIIIa-rnimetic activity was presented as a
value obtained by subtracting the value of absorbance change in 30
minutes without antibody addition from that with the antibody
addition (see FIG. 4 and FIG. 5).
TBSB was used as a solvent for phospholipids, while TBSB-S was used
as a solvent for factor XIa, factor IX, and factor X. The
calorimetric substrate solution was a 1:1 mixture of "Tesutochiinu"
colorimetric substrate S-2222 (Chromogenix) dissolved according to
the attached instruction manual and a polybrene solution (0.6 mg/L
hexadimethrine bromide (Sigma)).
Further, the concentration dependency of XB12/SB04's
F.VIIIa-mimetic activity, which was the highest among all, was
measured (FIG. 6).
EXAMPLE 7
Plasma Coagulation Assay
To elucidate whether a bispecific antibody corrects the coagulation
ability of hemophilia A blood, effects of the bispecific antibody
on activated partial thromboplastin time (APTT) were examined using
F.VIII-deficient plasma. A mixed solution comprising an antibody
solution at various concentrations (50 .mu.L), F.VIII-deficient
plasma (50 .mu.L; Biomerieux), and APTT reagent (50 .mu.L; Dade
Behring) was warmed at 37.degree. C. for 3 minutes. Coagulation
reaction was initiated by adding 20 mM CaCl.sub.2 (50 .mu.L; Dade
Behring) to the above-described mixture. The time required for
coagulation was measured with CR-A (Amelung)-connected KC10A
(Amelung) (FIG. 7 and FIG. 8).
Further, XB12/SB04, which showed the highest coagulation
time-shortening activity, was measured for its concentration
dependency (FIG. 9).
EXAMPLE 8
Antibody Purification
The culture supernatant (10 mL) obtained by the method described in
Example 4 was concentrated to 1 mL with Centricon.RTM. YM-50
(Millipore). To this concentrate, 10% BSA (10 .mu.L), 1% Tween.RTM.
20 (10 .mu.L), and rProtein A Sepharose.TM. Fast Flow (Amersham
Biosciences) (100 .mu.L) were added, and the solution was mixed by
overturning at 4.degree. C. overnight. The solution was transferred
to an Ultrafree.RTM.-MC 0.22 .mu.m filter cup (Millipore), and
after washing with TBS containing 0.01% Tween.RTM. 20 (500 .mu.L)
thrice, the rProtein A Sepharosem resin was suspended in 100 .mu.L
of 10 mM HCl/0.01% Tween.RTM. 20 (pH 2.0) and left to stand for 3
minutes. Then, the antibody was eluted, and the eluate was
immediately neutralized with the addition of 5 .mu.L 1 M Tris-HCl,
pH 8.0. Using the Microplate Manager III (Bio-Rad Laboratories)
software, the human IgG concentration was calculated from the
standard curve. The antibody concentration was quantified according
to Example 5.
EXAMPLE 9
GST-AP Western Blotting of Anti-F.X Antibody
A recombinant E. coli expressing fusion protein of F.X activated
peptide (AP) with glutathione S transferase (GST) was constructed.
The cDNA covering the full-length translation region of human F.X
was PCR amplified from the human liver Marathon-Ready cDNA
(Clontech). This cDNA was then used as a template to amplify the
region encoding AP region by PCR (Leytus et al., Biochemistry 1986;
25: 5098), which was subcloned into a pGEM-T vector (Promega) to
obtain GST-AP-encoding pGEX-F10AP. E. coli transformed with this
plasmid was cultured, and at OD=0.8, 1 mM IPTG was added to induce
GST-AP expression. After centrifuging the culture solution
(3,000.times.g, 30 min, 4.degree. C.), the cells were collected and
stored at -20.degree. C. till use.
After resuspending the cell pellet in 1/20 culture volume of PBS,
2.4 mL of SDS-PAGE sample buffer (IWAKI) was added for every 0.1 mL
of the suspension, and the resulting mixture was boiled at
95.degree. C. for 5 minutes. This reaction solution (10 .mu.L) was
added to each well of a 14% SDS-PAGE mini gel (Asahi Technoglass),
and subjected to electrophoresis. The gel after electrophoresis was
transferred onto an Immobilon-P.TM. Transfer Membrane (MILLIPORE)
using a semi-dry blotter (BIO-RAD), and blocked with BT-PBS (PBS
containing 2% BSA and 0.05% Tween.RTM. 20). After the blocking was
completed, it was reacted for 1 hour with anti-F.X mouse antibody
SB04 or SB06 purified in Example 1-4 and diluted with BT-PBS to 2
.mu.g/mL. After washing with PBS containing 0.05% Tween.RTM. 20,
the membrane was reacted for 1 hour with an alkaline
phosphatase-labeled goat anti-mouse IgG (H+L) (Zymed Laboratories)
diluted 2000-fold with BT-PBS. After washing with PBS containing
0.05% Tween.RTM. 20, the membrane was color-developed with a
colorimetric substrate, BCIP/NBT Phosphatase Substrate (Kirkegaad
& Perry Laboratories) (see FIG. 10).
EXAMPLE 10
Obtaining Bispecific Antibody from Immunized Mouse Spleen-derived
scFv Library
10-1. Antigen and Immunization
Three BALB/c mice (male, 6 weeks old when immunization was
initiated (Japan Charles River)), 3 MRL/lpr mice (male, 6 weeks old
when immunization was initiated (Japan Charles River)), and 3
C57BL/6N mice (male, 6 weeks old when immunization was initiated
(Japan Charles River)) were immunized with antigen factor IXa.beta.
(Enzyme Research Laboratories, Inc.) or factor X (Enzyme Research
Laboratories, Inc.) as described below. As an initial immunization,
the antigen (40 .mu.g/head) emulsified with FCA (Freund's complete
adjuvant H37 Ra; Difco laboratories)) was subcutaneously
administered. Two weeks later, the antigen (40 .mu.g/head)
emulsified with FIA (Freund's incomplete adjuvant; Difco
laboratories) was subcutaneously administered. Afterward, three
booster immunizations were given at one week intervals, and 8 days
after the final immunization, spleens were excised from the
mice.
10-2. Construction of Phage Library
A portion of the spleens excised from the immunized mice prepared
in Example 1-1 and 2-1, and the spleens excised from the immunized
mice prepared in Example 10-1 were placed in Trizol Reagent
(Invitrogen) (50 mg spleen/ml of the reagent), and homogenized
using a glass homogenizer. Subsequently, total RNA was extracted
according to the method described in the attached instruction
manual. From the extract solution, polyA(+)RNA was extracted using
a PolyATract System 1000 kit (Promega) according to the method
described in the attached instruction manual. cDNA was synthesized
by RT-PCR (SuperScript III First-Strand Synthesis System for
RT-PCR, Invitrogen) and stored at -20.degree. C. till use.
As primers for amplification of mouse antibody heavy chain variable
region (VH) and light chain variable region (VL) cDNAs, HB primer
mixture, HF primer mixture, LB primer mixture, and LF primer
mixture used in Examples 3-2 and 3-3 were prepared. For VH
amplification, a 50 .mu.L reaction solution (2.5 .mu.L cDNA
solution, KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1.5 mM
MgCl.sub.2, 3.75 units DNA polymerase KOD plus (TOYOBO)) was
prepared using 1 .mu.L of 100 .mu.M HB primer mixture and 100 .mu.M
HF primer mixture each. Further, for VL amplification, a 50 .mu.L
reaction solution of the same composition as described above was
prepared using 1 .mu.L of 100 .mu.M LB primer mixture and 100 .mu.M
LF primer mixture each. PCR was performed using a thermal cycler
GeneAmp PCR system 9700 (Parkin Elmer) by a 3-minutes heating at
98.degree. C. followed by 32 cycles of reaction (98.degree. C., 20
sec, 58.degree. C., 20 sec, and 72.degree. C., 30 sec in one
cycle). After PCR, the reaction solution was subjected to 2%
agarose gel electrophoresis. Amplified fragments of the size of
interest (about 400 bp) were purified using the QIAquick Gel
Extraction Kit(QIAGEN) by the method described in the attached
instruction manual, and eluted with sterile water (50 .mu.L). Next,
for scFv fragment amplification, ten tubes of a 100 .mu.L reaction
solution (3 .mu.L VH fragment solution, 3 .mu.L VL fragment
solution, KOD plus buffer (TOYOBO), 0.2 mM dNTPs, 1 mM MgCl.sub.2,
5 units DNA polymerase KOD plus (TOYOBO)) were prepared. After the
1.sup.st PCR (3-min heating at 94.degree. C. followed by 7 cycles
of reaction (94.degree. C., 1 min and 63.degree. C., 4 min in one
cycle)), 10 .mu.M scfor primer and 10 .mu.M scback primer (2.5
.mu.L each) were added to each tube kept warm at 63.degree. C., and
then the 2.sup.nd PCR (a 35-sec heating at 94.degree. C. followed
by 30 cycles of reaction (94.degree. C., 2 min and 63.degree. C., 2
min in one cycle)) was performed. After PCR, the reaction solution
was purified using the QIAquick PCR purification kit (QIAGEN), and
the purified products were digested with restriction enzyme Sfi I
(Takara Bio) at 50.degree. C. overnight. After subjecting the
digests to 2% agarose gel electrophoresis, amplified fragments of
the size of interest (about 800 bp) were purified using the
QIAquick Gel Extraction Kit (QIAGEN) by the method described in the
attached instruction manual, and eluted with an appropriate amount
of sterile water. For presenting scFv on phage gene III protein,
pELBGlacI (see FIG. 11) was used as a phagemid vector. After
digesting the vector (10 .mu.g) with restriction enzyme Sfi I
(Takara Bio) at 50.degree. C. overnight, cleavage fragments of the
size of interest (about 5 kb) were purified using the QIAquick Gel
Extraction Kit (QIAGEN) by the method described in the attached
instruction manual, and eluted with an appropriate amount of
sterile water. The purified PCR product and the purified vector
fragment were subjected to a ligation reaction at 16.degree. C.
overnight, using Ligation High (TOYOBO) according to the method
described in the attached instruction manual. Electrocompetent E.
coli XL1 Blue cells (Stratagene) or electromax DH12s (Invitrogen)
were transformed using the reaction solution, by an electroporation
method according to the method described in the attached
instruction manual. All of the ampicillin-resistant transformants
thus obtained were collected and stored as the recombinant library
at -20.degree. C. until use.
The E. coli library (2.times.10.sup.9 cfu) was inoculated into 50
mL of 2.times. YTAG (2.times. TY containing 100 .mu.g/mL ampicillin
and 2% glucose), and cultured at 37.degree. C. till OD 600 reached
0.4 to 0.5.4.times.10.sup.11 of helper phage VCS M13 (Stratagene)
was added to the culture, which was left to stand at 37.degree. C.
for 15 minutes for cell infection. The infected cells were cultured
at 30.degree. C. for 10 hours, following addition of 450 mL of
2.times. YTAK (2.times. TY containing 100 .mu.g/mL ampicillin and
25 .mu.g/mL kanamycin) and 25 .mu.L of 1 mol/L IPTG. The culture
supernatant was collected by centrifugation, mixed with 100 mL of
PEG-NaCl solution (10% polyethylene glycol 8000, 2.5 mol/L NaCl),
and left to stand at 4.degree. C. for 60 minutes. Phage was
precipitated by centrifugation at 10,800.times. g for 30 minutes,
and the precipitate was suspended in 40 mL of water, mixed with 8
mL of PEG-NaCl solution, and left to stand at 4.degree. C. for 1
hour. Phage was precipitated by centrifugation at 10,800.times. g
for 30 minutes, and suspended in 5 mL of PBS to obtain the phage
library. The phage was stored at 4.degree. C. till use.
10-3. Concentration of Bound Phage by Panning
Factor IXa.beta. or factor X was labeled with biotin using No-Weigh
Premeasured NHS-PEO.sub.4-Biotin Microtubes (Pierce). The
biotin-labeled factor IXa.beta. or factor X (100 pmol) was added to
the phage library solution prepared in 10-2 (600 .mu.L), and
contacted with the antigen for 60 minutes. Dynabeads M-280
Streptavidin (600 .mu.L; DYNAL) washed with 5% M-PBS (PBS
containing 5% w/v skim milk) was added for binding for 15 minutes.
The bead-bound phage was washed several times with PBST (PBS
containing 0.1% Tween-20; 1 mL) and then with PBS. The beads were
suspended in 0.8 mL of 0.1 mol/L glycine/HCl (pH 2.2) for 5 minutes
to elute the phage.
Alternatively, the phage library (80 .mu.L/well.times.5) which had
been incubated with 2.5% w/v skim milk for 15 minutes was added to
factor IXa.beta. or factor X (10 .mu.g/well.times.5) immobilized
onto an immunoplate (MaxiSorp, Nunc), and was contacted with the
antigen for 60 minutes. The antigen-bound phage was washed several
times with PBST (PBS containing 0.1% Tween-20; 1 mL) and then with
PBS. The bound phage was incubated with 0.8 mL of 0.1 mL
glycine/HCl (pH 2.2) for 5 minutes to elute the phage.
The phage solution thus collected was neutralized by adding 2 mol/L
Tris (45 .mu.L), added to 10 mL of XL1-Blue cells in logarithmic
growth phase (OD 600=0.4 to 0.5), and left to stand for 30 minutes
at 37.degree. C. for cell infection. The mixture was spread on a
2.times. YTAG plate and cultured at 30.degree. C. Colonies were
collected, inoculated into 2.times. YTAG, and cultured at
37.degree. C. until OD 600=0.4 to 0.5. IPTG (1 mol/L; 5 .mu.L) and
helper phage VCS M13 (10.sup.11 pfu) were added to the culture
solution (10 mL), and the mixture was left to stand at 37.degree.
C. for 30 minutes. The cells were collected by centrifugation,
resuspended in 2.times. YTAK (100 mL), and cultured at 30.degree.
C. for 10 hours. The culture supematant was recovered by
centrifugation, mixed with 10% PEG-5 mol/L NaCl solution (20 mL),
and left to stand at 4.degree. C. for 20 minutes. Phage was
precipitated by centrifugation at 10,800.times.g for 30 minutes and
suspended in PBS (2 mL), and provided for the subsequent
panning.
10-4. Phage ELISA
The above-described single colony was inoculated into 2.times. YTAG
(100 .mu.L) and cultured at 30.degree. C. overnight. After 5 .mu.L
of this culture was inoculated into 2.times. YTAG (500 .mu.L) and
cultured at 37.degree. C. for 5 hours, helper phage
(2.times.10.sup.8 pfu) was added, and the culture was then left to
stand at 37.degree. C. for 30 minutes. Further, after 30
minutes-cultivation with shaking at 37.degree. C., 2.times. YTAK
containing 0.5 mM IPTG (120 .mu.L) was added. After an overnight
culture at 30.degree. C., the centrifuged supernatant was subjected
to ELISA. For ELISA of clones obtained by panning biotin-labeled
antigens, a StreptaWell 96 microtiter plate (Roche) coated with 1.0
.mu.g/mL of biotin-labeled antigen was used. Further, for ELISA of
clones obtained by panning native antigens, an immunoplate
(MaxiSorp, Nunc) immobilized with 1.0 .mu.g/mL of native antigen
was used. After washing with PBST to remove the antigen, the
reaction was blocked with 200 .mu.L of 2% M-PBS or 2% BSA-PBS (PBS
containing 2% w/v BSA) as a blocking buffer for 1 hour at room
temperature. After removing the buffer, the culture supernatant was
added to the plate, and left to stand for 60 minutes for phage
binding. After washing, the bound phage was detected with an
HRP-bound anti-M13 antibody (Amersham Pharmacia Biotech) and TMB
substrate (Zymed). The reaction was stopped by adding 1 mol/L
H.sub.2SO.sub.4, and A450 value was measured with a plate
reader.
10-5. Sequence Determination and Clone Selection
Using the 2.times. YTAG culture medium of the ELISA-positive
recombinant E. coli clone, nucleotide sequence of the scFv region
was determined by PCR amplification with the primers PBG3-F1
(5'-CAGCTATGAAATACCTATTGCC-3'/SEQ ID NO: 1) and PBG3-R1
(5'-CTTTTCATAATCAAAATCACCGG-3'/SEQ ID NO: 2). A 15 .mu.L PCR
solution comprising 1 .mu.L culture medium, 1.5 .mu.L 10.times. KOD
Dash buffer, 0.2 .mu.L each of 10 pmol/L primers, and 0.3 .mu.l KOD
Dash polymerase (TOYOBO, 2.5 U/.mu.L) was subjected to 30 cycles of
amplification (96.degree. C., 10 sec, 55.degree. C., 10 sec, and
72.degree. C., 30 sec) using the GeneAmp PCR system 9700 thermal
cycler (Perkin Elmer). After PCR, 3 .mu.L ExoSAP-IT (Amersham) was
added to 5 .mu.L of the reaction solution, and the mixture was kept
warm at 37.degree. C. for 15 minutes and subsequently at 80.degree.
C. for 15 minutes. The reaction of this sample was performed using
the BigDye Terminator Cycle Sequencing kit (Applied Biosystems)
with PBG3-F2 (5'-ATTGCCTACGGCAGCCGCT-3'/SEQ ID NO: 3) or PBG3-R2
(5'-AAATCACCGGAACCAGAGCC-3'/SEQ ID NO: 4) as primer, and the
products were electrophoresed with an Applied Biosystems PRISM 3700
DNA Sequencer. As a result, clones which have different CDR3 amino
acid sequences predicted from the nucleotide sequences were
selected for 52 clones as anti-factor IXa and 33 clones as
anti-factor X.
10-6. Construction of Bispecific IgG Antibody Expression Vector
To express scfv antibody as an IgG type, antibody variable regions
(VH, VL) were cloned into inducible type expression vectors, by
means similar to those shown in Examples 3-3, 3-4, and 3-5.
Anti-F.IXa antibody variable regions (VH and VL) were individually
incorporated into a tetracycline inducible type vector (pcDNA4-g4H
and pcDNA4-g4L, respectively). Anti-F.X antibody variable regions
(VH and VL) were individually incorporated into an ecdysone
analogue inducible type vector (pIND-g4H and pcDNA4-g4L,
respectively). From the clones of interest, the respective plasmid
DNAs were isolated using the QIAprep Spin Mimiprep Kit (QIAGEN) and
dissolved in sterile water (100 .mu.L).
10-7. Expression of Chimera Bispecific Antibody in Animal Cells
Using the DNA solution prepared by means similar to that shown in
Example 4-1, DNA was expressed in animal cells by means similar to
those shown in Examples 4-2 and 4-3, and the culture supernatant
was collected. The sample was stored at 4.degree. C. till use.
EXAMPLE 11
Antibody Purification
To 10 mL of the culture supernnatant obtained by the method
described in Example 10-7, 100 .mu.L of rProtein A Sepharose.TM.
Fast Flow (Amersham Biosciences) was added and mixed by overturning
at 4.degree. C. overnight. The solution was transferred to an
Ultrafree.RTM.-MC 0.22 .mu.m filter cup (Millipore), and after
three washes with 500 .mu.L of TBS containing 0.01% Tween.RTM. 20,
rprotein A Sepharose T resin was suspended in 100 .mu.L of 10 mM
HCl/0.01% Tween.RTM. 20 (pH 2.0), and left to stand for 3 minutes.
The antibody was then eluted and the eluate was immediately
neutralized by adding 5 .mu.L of 1 M Tris-HCl, pH 8.0. Using the
Microplate Manager III (Bio-Rad Laboratories) software, the human
IgG concentration in the culture supernnatant was calculated from
the standard curve of human IgG4 (humanized anti-TF antibody, see
WO 99/51743). The antibody concentration was quantitated according
to Example 5.
EXAMPLE 12
F.VIIIa (Activated Coagulation Factor VIII)-mimetic Activity
Assay
The F.VIIIa-rniimetic activity of a bispecific antibody was
assessed by the following enzymatic assay. The following reactions
were all performed at room temperature. A mixed solution of 10
.mu.L factor IX (15 .mu.g/mL; Enzyme Research Laboratories), 5
.mu.L TBSB containing 100 mM CaCl.sub.2 and 20 mM MgCl.sub.2 and 50
.mu.L of the culture supernatant obtained by the method described
in Example 10-7 was incubated in a 96-well plate for 1 hour. Then,
10 .mu.L factor XIa (10 ng/mL; Enzyme Research Laboratories), 20
.mu.L factor X (50 .mu.g/mL; Enzyme Research Laboratories), and 5
.mu.L phospholipids (400 .mu.g/mL) were added to initiate the
enzymatic reaction. After 30 minutes, the reaction was stopped by
adding 10 .mu.L of 0.5 M EDTA.
After adding 50 .mu.L of a calorimetric substrate solution to each
well, the absorbance at 405 nm (reference wavelength 655 nm) was
measured at 0 and 60 minutes with a Model 3550 Microplate Reader
(Bio Rad Laboratories). F.VIIIa-mimetic activity was expressed as a
value obtained by subtracting the value of absorbance change in the
culture supernatant expressing no antibody from that of the culture
supernatant expressing the antibody.(see FIG. 12).
TBSB was used as a solvent for phospholipid, factor XIa, factor IX,
and factor X. The calorimetric substrate solution was a 1:1 mixture
of "Tesutochimu" colorimetric substrate S-2222 (Chromogenix)
dissolved according to the attached instruction manual and
polybrene solution (0.6 mg/L hexadimethnine bromide; Sigma).
EXAMPLE 13
Plasma Coagulation Assay
To elucidate whether a bispecific antibody prepared according to
the method of Example 11 recovers the coagulation capability of
hemophilia A blood, effects of the antibody on activated partial
thromboplastin time (APTT) using F.VIII-deficient plasma were
assessed by a method similar to that shown in Example 7 (see FIG.
13). Further, A44/B26 and A69/B26, which are highly effective in
shortening coagulation time, were measured for their concentration
dependency (see FIGS. 14 and 15).
EXAMPLE 14
Evaluation of the Concominant Use of a Bispecific Antibody and
F.VIII
Concominant use of a bispecific antibody and F.VIII was evaluated
under the following plasma coagulation assay conditions. A mixture
of 40 .mu.L antibody solution (25 .mu.g/mL) and 50 .mu.L
F.VIII-deficient plasma (Biomerieux) was incubated at room
temperature for 30 minutes. To this mixture, 10 .mu.L of the
recombinant blood coagulation factor VIII formulation Kogenate.RTM.
FS (BAYER) and 50 .mu.L APTT reagents (Dade Behring) were added,
and warmed at 37.degree. C. for 3 minutes. Coagulation reaction was
initiated by adding 50 .mu.L of 20 mM of CaCl.sub.2 (Dade Behring).
The time required for coagulation was measured using CR-A
(Amelung)-connected KC10A (Amelung) (see FIG. 16).
EXAMPLE 15
Effects of Bispecific IgG Antibody in Inhibitor Plasma
Effects of a bispecific IgG antibody in the inhibitor plasma were
assessed under the following plasma coagulation assay conditions. A
mixture of 50 .mu.L F.VIII-deficient plasma (Biomerieux) and 10
.mu.L anti-human F.VIII neutralizing antibody (100 .mu.g/mL;
Catalog Number: MAB3440, CHEMICON) was incubated at room
temperature for 30 minutes. This plasma was used as inhibitor
plasma. To this inhibitor plasma, 40 .mu.L of the antibody solution
(25 .mu.g/mL) and 50 .mu.L APTT reagent (Dade Behring) were added,
and warmed at 37.degree. C. for 3 minutes. Coagulation reaction was
initiated by adding 50 .mu.L of 20 mM CaCl.sub.2 (Dade Behring) to
the mixture. The time required for coagulation was measured using
CR-A (Amelung)-connected KC10A (Amelung) (see FIG. 17).
EXAMPLE 16
Humanization of Bispecific Antibody
Among the bispecific antibodies obtained in Examples 1 to 7, XB12
(mouse anti-factor IXa antibody)/SB04 (mouse anti-factor X
antibody), which was the most effective in shortening blood
coagulation time, was subjected to humanization as follows.
16-1. Homology Search of Human Antibodies
The database was constructed based on amino acid sequence data of
human antibodies obtained from Kabat Database
(ftp://ftp.ebi.ac.uk/pub/databases/kabat/) and IMGT Database
(http://imgt.cines.fr/) available publicly, and homology search was
carried out separately for the mouse XB12-H chain variable region,
mouse XB132-L chain variable region, mouse SB04-H chain variable
region, and mouse SB04-L chain variable region. The results
confirmed that they have high homologies to the human antibody
sequences shown below, and it was thus decided that they would be
used as the framework region (hereinafter abbreviated as FR) of
humanized antibodies. (1) XB12-H chain variable region:
KABATID-020619 (Kabat Database) (Mariette et al., Arthritis Rheum.
1993; 36: 1315-1324) (2) XB12-L chain variable region: EMBL
Accession No. X61642 (IMGT Database) (Mark et al., J Mol Biol.
1991; 222: 581-597.) (3) SB04-H chain variable region:
KABATID-025255 (Kabat Database) (Demaison et al., Immunogetetics
1995; 42: 342-352) (4) SB04-L chain variable region: EMBL Accession
No. AB0641 11 (IMGT Database) (Unpublished data)
For preparation of humanized antibodies, complementarity
determining regions (hereinafter abbreviated as CDR) of each mouse
antibody were grafted into the FRs of human antibodies (1)-(4).
Also, the web site on the NCBI available publicly
(http://www.ncbi.nhn.nih.gov/BLAST/) was used to search secretory
signal sequences of human antibody that are highly homologous to
human antibodies (1)-(4). The following secretory signal sequences
obtained by the homology search were used. (1) XB12-H chain
variable region: GenBank Accession No. AF062120 (2) XB12-L chain
variable region: GenBank Accession No. M74019 (3) SB04-H chain
variable region: GenBank Accession No. BC019337 (4) SB04-L chain
variable region: GenBank Accession No. AY204756 16-2. Construction
of Humanized Antibody Gene Expression Vector
Twelve synthetic oligonucleotides of about 50 bases were prepared
from a nucleotide sequence encoding the amino acid sequence from
the secretory signal sequence to the antibody variable region, such
that about 20 bases of their 3'-terminal hybridize with each other.
Further, a primer hybridizing to the 5'-terminal of an antibody
variable region gene and having the XhoI cleavage sequence, and a
primer hybridizing to the 3'-terminal of an antibody variable
region gene and having the SfiI cleavage sequence were
prepared.
The synthetic oligonucleotides prepared (2.5 .mu.M, 1 .mu.L each)
were mixed, and 1.times. TaKaRa Ex Taq Buffer, 0.4 mM dNTPs, and
0.5 units TaKaRa Ex Taq (all from Takara Shuzo) were added to make
up a 48 .mu.L reaction solution. After warming the mixture at
94.degree. C. for 5 minutes, 2 cycles of reaction (94.degree. C., 2
min, 55.degree. C., 2 min, and 72.degree. C., 2 min) were performed
to assemble and elongate each of the synthetic oligo DNAs. Next, a
primer hybridizing to the 5'-terminal and a primer hybridizing to
the 3'-terminal of the antibody gene were added (10 .mu.M, 1 .mu.L
each), and the antibody variable region genes were amplified by 35
cycles of reaction (94.degree. C., 30 sec, 55.degree. C., 30sec,
and 72.degree. C., 1 min) and a 5 minutes reaction at 75.degree. C.
After PCR, the reaction solution as a whole was subjected to 1%
agarose gel electrophoresis. Amplified fragments of the expected
size (about 400 bp) were purified with the QIAquick Gel Extraction
Kit (QIAGEN) by the method described in the attached instruction
manual, and eluted with sterile water (30 .mu.L). Fragments were
cloned using the pGEM-T Easy Vector System (Promega) by the method
described in the attached instruction manual. Nucleotide sequences
of the DNA fragments were determined using the BigDye.Terminator
Cycle Sequencing Kit (Applied Biosystems) on ABI PRISM 3700 DNA
Sequencer (Applied Biosystems) according to the method described in
the attached instruction manual.
After digesting a plasmid confirmed to comprise the correct
humanized antibody variable region gene sequence with XhoI and
SfiI, the reaction solution was subjected to 1% agarose gel
electrophoresis. DNA fragments of the expected size (about 400 bp)
were purified using the QIAquick Gel Extraction Kit (QIAGEN) by the
method described in the attached instruction manual, and eluted
with sterile water (30 .mu.L). Further, after digesting the
tetracycline-inducible type expression plasmids (pcDNA4-g4H,
pcDNA4-g4L) and the ecdysone analogue inducible type expression
plasmids (pIND-g4H, pIND-g4L) prepared in Example 3-4 with XhoI and
SfiI, fragments comprising the antibody constant region (about 5
kb) were purified using the QIAquick Gel Extraction Kit (QIAGEN) by
the method described in the attached instruction manual, and eluted
with sterile water (30 .mu.L). The humanized XB12 antibody gene
fragment (H chain variable region (hereinafter VH) or L chain
variable region (hereinafter VL)) digested with XhoI and SfiI, and
the tetracycline-inducible type expression plasmid (pcDNA4-g4H,
pcDNA4-g4L) digested with XhoI and SfiI were subjected to a
ligation reaction using the Rapid DNA Ligation Kit (Roche
Diagnostics) by the method described in the attached instruction
manual. In addition, the humanized SB04 antibody gene fragment
digested with XhoI and SfiI (H chain variable region or L chain
variable region), and the ecdysone analogue inducible type
expression plasmid digested with XhoI and SfiI (pIND-g4H, pIND-g4L)
were subjected to a ligation reaction using the Rapid DNA Ligation
Kit (Roche Diagnostics) by the method described in the attached
instruction manual. A portion of each of the reaction mixture was
used to transform DH5.alpha. strain E. coli (TOYOBO).
16-3. Preparation of Humanized Bispecific Antibody
The genes were transfected and expressed in HEK293H by the methods
described in Examples 4-2 and 4-3, using four types of humanized
antibody expression vectors as well as pcDNA6/TR and pVgRXR.
Further, antibody purification and quantification of antibody
concentration were conducted by the methods shown in Examples 8 and
5.
16-4. Activity Assessment of Humanized Bispecific Antibody and
Modification of Antibody Sequence
To assess the plasma coagulation ability of the thus-prepared
humanized bispecific antibodies and chimera bispecific antibody
XB12/SB04, effects of the antibodies on APTT were examined using
F.VIII-deficient plasma. Amino acids of the human antibody FR were
modified to increase activities of humanized bispecific antibodies
whose blood coagulation capability has been reduced. In addition,
the cysteine residues in the CDR3 of XB12 antibody VH were modified
to alanine in concern of the possible drop in its thermostability.
Specifically, mutations were introduced into the humanized antibody
expression vector using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene) by the method described in the attached
instruction manual. By repeating amino acid modification of the FR
sequence and assessment of blood coagulation ability, a humanized
bispecific antibody (humanized XB12 antibody (VH:hXB12f-A,
VL:hXBVL)/humanized SB04 antibody (VH:hSB04e, VL:hSBVL-F3f)) was
obtained (FIG. 18).
INDUSTRIAL APPLICABILITY
The present invention provides bispecific antibodies that recognize
both an enzyme and its substrate, and which functionally substitute
for a cofactor which enhances the enzymatic activity.
The bispecific antibodies according to the present invention are
thought to have high stability in blood and low antigenicity. Thus,
it is greatly expected that they will become pharmaceuticals.
SEQUENCE LISTINGS
1
268122DNAArtificialan artificially synthesized primer sequence
1cagctatgaa atacctattg cc 22223DNAArtificialan artificially
synthesized primer sequence 2cttttcataa tcaaaatcac cgg
23319DNAArtificialan artificially synthesized primer sequence
3attgcctacg gcagccgct 19420DNAArtificialan artificially synthesized
primer sequence 4aaatcaccgg aaccagagcc 20524DNAArtificialan
artificially synthesized primer sequence 5ttactcgcgg cccagccggc
catg 24628DNAArtificialan artificially synthesized primer sequence
6ggaattcggc ccccgaggcc cactcacg 2871215DNAHomo sapiens 7ggcctcgggg
gccagctttc tggggcaggc caggcctgac cttggctttg gggcagggag 60ggggctaagg
tgaggcaggt ggcgccagcc aggtgcacac ccaatgccca tgagcccaga
120cactggacgc tgaacctcgc ggacagttaa gaacccaggg gcctctgcgc
cctgggccca 180gctctgtccc acaccgcggt cacatggcac cacctctctt
gcagcttcca ccaagggccc 240atccgtcttc cccctggcgc cctgctccag
gagcacctcc gagagcacag ccgccctggg 300ctgcctggtc aaggactact
tccccgaacc ggtgacggtg tcgtggaact caggcgccct 360gaccagcggc
gtgcacacct tcccggctgt cctacagtcc tcaggactct actccctcag
420cagcgtggtg accgtgccct ccagcagctt gggcacgaag acctacacct
gcaacgtaga 480tcacaagccc agcaacacca aggtggacaa gagagttgag
tccaaatatg gtcccccatg 540cccaccatgc ccagcacctg agttcctggg
gggaccatca gtcttcctgt tccccccaaa 600acccaaggac actctcatga
tctcccggac ccctgaggtc acgtgcgtgg tggtggacgt 660gagccaggaa
gaccccgagg tccagttcaa ctggtacgtg gatggcgtgg aggtgcataa
720tgccaagaca aagccgcggg aggagcagtt caacagcacg taccgtgtgg
tcagcgtcct 780caccgtcctg caccaggact ggctgaacgg caaggagtac
aagtgcaagg tctccaacaa 840aggcctcccg tcctccatcg agaaaaccat
ctccaaagcc aaagggcagc cccgagagcc 900acaggtgtgc accctgcccc
catcccagga ggagatgacc aagaaccagg tcagcctgtg 960gtgcctggtc
aaaggcttct accccagcga catcgccgtg gagtgggaga gcaatgggca
1020gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct
ccttcttcct 1080ctacagcagg ctaaccgtgg acaagagcag gtggcaggag
gggaatgtct tctcatgctc 1140cgtgatgcat gaggctctgc acaaccacta
cacacagaag agcctctccc tgtctctggg 1200taaatgagcg gccgc
12158684DNAHomo sapiens 8ggcctcgggg gccgaattcc taaactctga
gggggtcgga tgacgtggcc attctttgcc 60taaagcattg agtttactgc aaggtcagaa
aagcatgcaa agccctcaga atggctgcaa 120agagctccaa caaaacaatt
tagaacttta ttaaggaata gggggaagct aggaagaaac 180tcaaaacatc
aagattttaa atacgcttct tggtctcctt gctataatta tctgggataa
240gcatgctgtt ttctgtctgt ccctaacatg ccctgtgatt atccgcaaac
aacacaccca 300agggcagaac tttgttactt aaacaccatc ctgtttgctt
ctttcctcag gaactgtggc 360tgcaccatct gtcttcatct tcccgccatc
tgatgagcag ttgaaatctg gaactgcctc 420tgttgtgtgc ctgctgaata
acttctatcc cagagaggcc aaagtacagt ggaaggtgga 480taacgccctc
caatcgggta actcccagga gagtgtcaca gagcaggaca gcaaggacag
540cacctacagc ctcagcagca ccctgacgct gagcaaagca gactacgaga
aacacaaagt 600ctacgcctgc gaagtcaccc atcagggcct gagctcgccc
gtcacaaaga gcttcaacag 660gggagagtgt tagagggcgg ccgc 68491215DNAHomo
sapiens 9ggcctcgggg gcctcccagg ctctgggcag gcacaggcta ggtgccccta
acccaggccc 60tgcacacaaa ggggcaggtg ctgggctcag acctgccaag agccatatcc
gggaggaccc 120tgcccctgac ctaagcccac cccaaaggcc aaactctcca
ctccctcagc tcggacacct 180tctctcctcc cagattccag taactcccaa
tcttctctct gcagcttcca ccaagggccc 240atccgtcttc cccctggcgc
cctgctccag gagcacctcc gagagcacag ccgccctggg 300ctgcctggtc
aaggactact tccccgaacc ggtgacggtg tcgtggaact caggcgccct
360gaccagcggc gtgcacacct tcccggctgt cctacagtcc tcaggactct
actccctcag 420cagcgtggtg accgtgccct ccagcagctt gggcacgaag
acctacacct gcaacgtaga 480tcacaagccc agcaacacca aggtggacaa
gagagttgag tccaaatatg gtcccccatg 540cccaccatgc ccagcacctg
agttcctggg gggaccatca gtcttcctgt tccccccaaa 600acccaaggac
actctcatga tctcccggac ccctgaggtc acgtgcgtgg tggtggacgt
660gagccaggaa gaccccgagg tccagttcaa ctggtacgtg gatggcgtgg
aggtgcataa 720tgccaagaca aagccgcggg aggagcagtt caacagcacg
taccgtgtgg tcagcgtcct 780caccgtcctg caccaggact ggctgaacgg
caaggagtac aagtgcaagg tctccaacaa 840aggcctcccg tcctccatcg
agaaaaccat ctccaaagcc aaagggcagc cccgagagcc 900acaggtgtac
accctgcccc catcccagtg cgagatgacc aagaaccagg tcagcctgtc
960ctgcgcggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga
gcaatgggca 1020gccggagaac aactacaaga ccacgcctcc cgtgctggac
tccgacggct ccttcttcct 1080cgtgagcagg ctaaccgtgg acaagagcag
gtggcaggag gggaatgtct tctcatgctc 1140cgtgatgcat gaggctctgc
acaaccacta cacacagaag agcctctccc tgtctctggg 1200taaatgagcg gccgc
12151021DNAArtificialan artificially synthesized primer sequence
10cgcaaatggg cggtaggcgt g 211118DNAArtificialan artificially
synthesized primer sequence 11tagaaggcac agtcgagg
181224DNAArtificialan artificially synthesized primer sequence
12ctctgaatac tttcaacaag ttac 2413116PRTMus musculus 13Met Glu Val
Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Thr1 5 10 15Gln Ser
Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser 20 25 30Gly
Tyr Tyr Trp Thr Trp Ile Arg Gln Phe Pro Gly Asn Asn Leu Glu 35 40
45Trp Ile Gly Tyr Ile Ser Phe Asp Gly Thr Asn Asp Tyr Asn Pro Ser
50 55 60Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Glu Asn Gln
Phe65 70 75 80Phe Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala
Thr Tyr Tyr 85 90 95Cys Ala Arg Gly Pro Pro Cys Thr Tyr Trp Gly Gln
Gly Thr Leu Val 100 105 110Thr Val Ser Ala 115146PRTMus musculus
14Ser Gly Tyr Tyr Trp Thr1 51516PRTMus musculus 15Tyr Ile Ser Phe
Asp Gly Thr Asn Asp Tyr Asn Pro Ser Leu Lys Asn1 5 10 15166PRTMus
musculus 16Gly Pro Pro Cys Thr Tyr1 517120PRTMus musculus 17Met Gln
Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10 15Ala
Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp 20 25
30Asp Tyr Val His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp
35 40 45Ile Gly Arg Ile Asp Pro Ala Asp Gly Lys Thr Lys Tyr Ala Pro
Lys 50 55 60Phe Gln Asp Lys Ala Thr Met Thr Ser Asp Thr Ser Ser Asn
Thr Ala65 70 75 80Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr
Ala Val Tyr Tyr 85 90 95Cys Val Arg Trp Arg Ile Tyr Tyr Gly Leu Met
Asp Tyr Trp Gly Gln 100 105 110Gly Thr Ser Val Thr Val Ser Ser 115
120185PRTMus musculus 18Asp Asp Tyr Val His1 51917PRTMus musculus
19Arg Ile Asp Pro Ala Asp Gly Lys Thr Lys Tyr Ala Pro Lys Phe Gln1
5 10 15Asp2010PRTMus musculus 20Trp Arg Ile Tyr Tyr Gly Leu Met Asp
Tyr1 5 1021123PRTMus musculus 21Met Gln Val Gln Leu Gln Gln Ser Gly
Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr His 20 25 30Phe Val Leu His Trp Val Lys
Gln Asn Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Tyr Ile Ile Pro
Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys 50 55 60Phe Lys Gly Lys Ala
Thr Leu Thr Ser Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Glu
Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala
Arg Gly Asn Arg Tyr Asp Val Gly Ser Tyr Ala Met Asp Tyr 100 105
110Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120225PRTMus
musculus 22His Phe Val Leu His1 52317PRTMus musculus 23Tyr Ile Ile
Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys1 5 10
15Gly2413PRTMus musculus 24Gly Asn Arg Tyr Asp Val Gly Ser Tyr Ala
Met Asp Tyr1 5 1025117PRTMus musculus 25Met Gln Val Gln Leu Gln Gln
Ser Gly Ala Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser
Cys Thr Val Ser Gly Phe Asn Ile Gln Asp 20 25 30Asn Tyr Met His Trp
Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp 35 40 45Ile Gly Arg Ile
Asp Pro Ala Asn Gly Asn Thr Arg Tyr Asp Pro Lys 50 55 60Phe Gln Gly
Lys Ala Thr Ile Thr Ala Asp Ile Ser Ser Asn Thr Thr65 70 75 80Cys
Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90
95Cys Ala Ser Pro Tyr Tyr Pro Leu Gly Cys Trp Gly Gln Gly Thr Leu
100 105 110Val Thr Val Ser Ala 115265PRTMus musculus 26Asp Asn Tyr
Met His1 52717PRTMus musculus 27Arg Ile Asp Pro Ala Asn Gly Asn Thr
Arg Tyr Asp Pro Lys Phe Gln1 5 10 15Gly287PRTMus musculus 28Pro Tyr
Tyr Pro Leu Gly Cys1 529116PRTMus musculus 29Met Gln Val Gln Leu
Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys
Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu 20 25 30Asn Thr Ile
Tyr Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly
Ser Ile Thr Thr Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr 50 55 60Leu
Thr Ile Asp Lys Ser Ser Ser Ser Ala Tyr Met Glu Leu Arg Ser65 70 75
80Leu Thr Ser Glu Glu Ser Ala Val Tyr Tyr Cys Ala Arg Ser Gly Gly
85 90 95Arg Gly Lys Pro Tyr Tyr Phe Asp Ser Trp Gly Gln Gly Thr Thr
Leu 100 105 110Thr Val Ser Ser 115305PRTMus musculus 30Glu Asn Thr
Ile Tyr1 53111PRTMus musculus 31Ser Ile Thr Thr Tyr Asn Gln Lys Phe
Lys Asp1 5 103212PRTMus musculus 32Ser Gly Gly Arg Gly Lys Pro Tyr
Tyr Phe Asp Ser1 5 1033117PRTMus musculus 33Met Gln Val Gln Leu Gln
Gln Ser Gly Ser Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Leu
Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp 20 25 30Asn Tyr Met His
Trp Ile Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp 35 40 45Ile Gly Arg
Ile Asp Pro Gly Asn Gly Asn Ser Arg Tyr Asp Pro Lys 50 55 60Phe Gln
Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala65 70 75
80Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr
85 90 95Cys Ala Ser Pro Tyr Tyr Pro Leu Gly Tyr Trp Gly Gln Gly Thr
Leu 100 105 110Val Thr Val Ser Ala 115345PRTMus musculus 34Asp Asn
Tyr Met His1 53517PRTMus musculus 35Arg Ile Asp Pro Gly Asn Gly Asn
Ser Arg Tyr Asp Pro Lys Phe Gln1 5 10 15Gly367PRTMus musculus 36Pro
Tyr Tyr Pro Leu Gly Tyr1 537114PRTMus musculus 37Met Gln Val Gln
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10 15Ala Ser Val
Lys Leu Ser Cys Thr Val Ser Gly Phe Asn Ile Lys Asp 20 25 30Asp Tyr
Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp 35 40 45Ile
Gly Arg Ile Asp Pro Thr Asn Gly Asn Pro Ala Tyr Ala Pro Lys 50 55
60Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Ile Thr Ala65
70 75 80Tyr Leu Gln Leu Asn Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
Tyr 85 90 95Cys Thr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val 100 105 110Ser Ala385PRTMus musculus 38Asp Asp Tyr Ile His1
53917PRTMus musculus 39Arg Ile Asp Pro Thr Asn Gly Asn Pro Ala Tyr
Ala Pro Lys Phe Gln1 5 10 15Asp404PRTMus musculus 40Ser Phe Ala
Tyr141114PRTMus musculus 41Met Gln Val Gln Leu Gln Gln Ser Gly Ala
Glu Leu Val Arg Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys Thr Ala
Ser Gly Phe Asn Ile Lys Asp 20 25 30Asp Tyr Val His Trp Val Lys Gln
Arg Pro Glu Gln Gly Leu Glu Trp 35 40 45Ile Gly Arg Ile His Pro Ala
Asn Gly Asn Pro Gln Tyr Ala Pro Lys 50 55 60Phe Gln Asp Lys Ala Thr
Ile Ile Ile Gly Thr Ala Ser Asn Thr Thr65 70 75 80Tyr Leu Gln Leu
Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Gly
Pro Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser
Ala425PRTMus musculus 42Asp Asp Tyr Val His1 54317PRTMus musculus
43Arg Ile His Pro Ala Asn Gly Asn Pro Gln Tyr Ala Pro Lys Phe Gln1
5 10 15Asp444PRTMus musculus 44Pro Phe Ala Tyr145116PRTMus musculus
45Met Glu Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser1
5 10 15Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr
Ser 20 25 30Asn Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys
Leu Glu 35 40 45Trp Met Gly Tyr Ile Asn Tyr Asp Gly Ser Asn Asn Tyr
Asn Pro Ser 50 55 60Leu Lys Asn Arg Ile Ser Ile Ser Arg Asp Thr Ser
Lys Asn Gln Phe65 70 75 80Phe Leu Lys Leu Asn Ser Val Thr Thr Glu
Asp Thr Ala Thr Tyr Tyr 85 90 95Cys Ala Arg Gly Gly Ala Phe Thr Tyr
Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val Ser Ala 115466PRTMus
musculus 46Ser Asn Tyr Tyr Trp Asn1 54716PRTMus musculus 47Tyr Ile
Asn Tyr Asp Gly Ser Asn Asn Tyr Asn Pro Ser Leu Lys Asn1 5 10
15486PRTMus musculus 48Gly Gly Ala Phe Thr Tyr1 549114PRTMus
musculus 49Met Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr
Ile Thr Asp 20 25 30Asn Lys Met Asp Trp Val Lys Gln Ser His Gly Lys
Ser Leu Glu Trp 35 40 45Ile Gly Tyr Ile Ser Pro Asn Asn Gly Asp Ile
Gly Tyr Asn Arg Lys 50 55 60Phe Arg Asn Lys Ala Thr Leu Thr Val Asp
Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Glu Leu His Ser Leu Thr
Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg His Arg Ala Tyr
Trp Gly Gln Gly Thr Leu Val Thr Val 100 105 110Ser Ala505PRTMus
musculus 50Asp Asn Lys Met Asp1 55117PRTMus musculus 51Tyr Ile Ser
Pro Asn Asn Gly Asp Ile Gly Tyr Asn Arg Lys Phe Arg1 5 10
15Asn524PRTMus musculus 52His Arg Ala Tyr153121PRTMus musculus
53Met Asp Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly1
5 10 15Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
Thr 20 25 30Tyr Ala Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu
Glu Trp 35 40 45Val Ala Tyr Ile Ser Asn Gly Gly Ala Asn Thr Tyr Tyr
Pro Asp Ser 50 55 60Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Thr Leu65 70 75 80Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu
Asp Thr Ala Leu Tyr Tyr 85 90 95Cys Ala Arg Gly Gly Tyr Arg Tyr Pro
Tyr Ala Met Asp Tyr Trp Gly 100 105 110Gln Gly Thr Ser Val Thr Val
Ser Ser 115 120545PRTMus musculus 54Thr Tyr Ala Met Ser1
55517PRTMus musculus 55Tyr Ile Ser Asn Gly Gly Ala Asn Thr Tyr Tyr
Pro Asp Ser Val Lys1 5 10 15Gly5611PRTMus musculus 56Gly Gly Tyr
Arg Tyr Pro Tyr Ala Met Asp Tyr1 5 1057121PRTMus musculus 57Met Gln
Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10 15Ala
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser 20
25 30Tyr Trp Met His Trp Val Gln Gln Arg Pro Gly Arg Gly Leu Glu
Trp 35 40 45Ile Gly Arg Ile His Pro Ser Asp Ser Glu Ala Arg Tyr Asn
Gln Lys 50 55 60Phe Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ser
Ser Thr Ala65 70 75 80Tyr Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp
Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg Arg Gly Glu Tyr Pro Ser Tyr
Thr Met Asp Tyr Trp Gly 100 105 110Gln Gly Thr Thr Leu Thr Val Ser
Ser 115 120585PRTMus musculus 58Ser Tyr Trp Met His1 55917PRTMus
musculus 59Arg Ile His Pro Ser Asp Ser Glu Ala Arg Tyr Asn Gln Lys
Phe Lys1 5 10 15Ser6011PRTMus musculus 60Arg Gly Glu Tyr Pro Ser
Tyr Thr Met Asp Tyr1 5 1061119PRTMus musculus 61Met Gln Val Gln Leu
Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly1 5 10 15Ala Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser 20 25 30Tyr Trp Met
His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly
Thr Phe Tyr Pro Gly Asn Ser Asp Ser Asn Tyr Asn Gln Lys 50 55 60Phe
Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Thr Ser Thr Ala65 70 75
80Tyr Met Glu Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr
85 90 95Cys Thr Gly Tyr Tyr Gly Asn Tyr Cys Phe Gly Tyr Trp Gly Gln
Gly 100 105 110Thr Leu Val Thr Val Ser Ala 115625PRTMus musculus
62Ser Tyr Trp Met His1 56317PRTMus musculus 63Thr Phe Tyr Pro Gly
Asn Ser Asp Ser Asn Tyr Asn Gln Lys Phe Lys1 5 10 15Gly649PRTMus
musculus 64Tyr Tyr Gly Asn Tyr Cys Phe Gly Tyr1 565117PRTMus
musculus 65Met Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys
Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys Ser Ala Ser Gly Phe Asn
Ile Lys Asp 20 25 30Ser Leu Ile His Trp Val Lys Gln Arg Pro Glu Gln
Gly Leu Glu Trp 35 40 45Ile Gly Trp Ile Asp Pro Glu Asp Gly Arg Thr
Lys Tyr Ala Pro Arg 50 55 60Phe Gln Asp Lys Ala Thr Ile Thr Ala Asp
Thr Ser Ser Asn Thr Ala65 70 75 80Tyr Leu Gln Leu Ser Gly Leu Thr
Ser Glu Asp Thr Ala Ile Tyr Tyr 85 90 95Cys Val Arg Trp Val Tyr Tyr
Phe Asp Tyr Trp Gly Gln Gly Thr Thr 100 105 110Leu Thr Val Ser Ser
115665PRTMus musculus 66Asp Ser Leu Ile His1 56717PRTMus musculus
67Trp Ile Asp Pro Glu Asp Gly Arg Thr Lys Tyr Ala Pro Arg Phe Gln1
5 10 15Asp687PRTMus musculus 68Trp Val Tyr Tyr Phe Asp Tyr1
569123PRTMus musculus 69Met Gln Val Gln Leu Gln Gln Ser Gly Ala Glu
Leu Ala Lys Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Trp Met His Trp Val Lys Gln Arg
Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Glu Ile Asp Ile Ser Asp
Gly Ser Thr Thr Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys Ala Thr Leu
Thr Val Asp Glu Ser Ser Asn Thr Ala65 70 75 80Tyr Met Gln Leu Ser
Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg Gly
Glu Asp Tyr Asp Gly Ser His Asp Ala Met Asp Tyr 100 105 110Trp Gly
Gln Gly Thr Ser Val Thr Val Ser Ser 115 120705PRTMus musculus 70Asp
Tyr Trp Met His1 57117PRTMus musculus 71Glu Ile Asp Ile Ser Asp Gly
Ser Thr Thr Tyr Asn Gln Lys Phe Lys1 5 10 15Gly7213PRTMus musculus
72Gly Glu Asp Tyr Asp Gly Ser His Asp Ala Met Asp Tyr1 5
1073123PRTMus musculus 73Met Gln Val Gln Leu Gln Gln Ser Gly Ala
Glu Leu Val Met Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Trp Met His Trp Val Lys Gln
Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Glu Ile Asp Ile Ser
Asp Ser Ser Thr Thr Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys Ala Thr
Leu Thr Val Asp Glu Ser Ser Asn Thr Ala65 70 75 80Tyr Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Val Arg
Gly Glu Asp Tyr Asp Gly Arg Tyr Asn Val Met Asp Tyr 100 105 110Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120745PRTMus musculus
74Asp Tyr Trp Met His1 57517PRTMus musculus 75Glu Ile Asp Ile Ser
Asp Ser Ser Thr Thr Tyr Asn Gln Lys Phe Lys1 5 10 15Gly7613PRTMus
musculus 76Gly Glu Asp Tyr Asp Gly Arg Tyr Asn Val Met Asp Tyr1 5
1077123PRTMus musculus 77Met Gln Val Gln Leu Gln Gln Pro Gly Gly
Glu Leu Val Met Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Trp Met His Trp Val Arg Gln
Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Glu Ile Asp Ile Ser
Asp Gly His Thr Thr Tyr Asn Gln Glu 50 55 60Phe Lys Gly Lys Ala Thr
Leu Thr Val Asp Glu Ser Ser Ser Thr Ala65 70 75 80Tyr Met Gln Leu
Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg
Gly Glu Asp Tyr Asp Gly Ser Asn Asp Val Met Asp Tyr 100 105 110Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120785PRTMus musculus
78Asp Tyr Trp Met His1 57917PRTMus musculus 79Glu Ile Asp Ile Ser
Asp Gly His Thr Thr Tyr Asn Gln Glu Phe Lys1 5 10 15Gly8013PRTMus
musculus 80Gly Glu Asp Tyr Asp Gly Ser Asn Asp Val Met Asp Tyr1 5
1081123PRTMus musculus 81Met Gln Val Gln Leu Gln Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Trp Met His Trp Val Lys Gln
Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Glu Ile Asp Ile Ser
Asp Ser His Thr Thr Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys Ala Thr
Leu Thr Val Asp Glu Ser Ser Ser Thr Ala65 70 75 80Tyr Met Gln Leu
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Val Arg
Gly Glu Asp Tyr Asp Gly Ser His Asp Val Met Asp Tyr 100 105 110Trp
Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120825PRTMus musculus
82Asp Tyr Trp Met His1 58317PRTMus musculus 83Glu Ile Asp Ile Ser
Asp Ser His Thr Thr Tyr Asn Gln Lys Phe Lys1 5 10 15Gly8413PRTMus
musculus 84Gly Glu Asp Tyr Asp Gly Ser His Asp Val Met Asp Tyr1 5
1085119PRTMus musculus 85Met Gln Val Gln Leu Gln Gln Ser Gly Ala
Glu Leu Ala Lys Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Ser 20 25 30Ser Trp Met His Trp Ile Lys Gln
Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Leu Gly Tyr Ile Asn Pro Ser
Ser Gly Tyr Thr Lys Tyr Asn Arg Lys 50 55 60Phe Arg Asp Lys Ala Thr
Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Gln Leu
Thr Ser Leu Thr Tyr Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg
Gly Gly Asn Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly 100 105 110Thr
Thr Leu Thr Val Ser Ser 115865PRTMus musculus 86Ser Ser Trp Met
His1 58717PRTMus musculus 87Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Lys
Tyr Asn Arg Lys Phe Arg1 5 10 15Asp889PRTMus musculus 88Gly Gly Asn
Gly Tyr Tyr Phe Asp Tyr1 589119PRTMus musculus 89Met Gln Val Gln
Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly1 5 10 15Ala Ser Val
Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr 20 25 30Tyr Trp
Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile
Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Lys Tyr Asn Gln Lys 50 55
60Phe Lys Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala65
70 75 80Tyr Met Gln Leu Ser Ser Leu Thr Asp Glu Asp Ser Ala Val Tyr
Tyr 85 90 95Cys Ala Asn Gly Asn Leu Gly Tyr Phe Phe Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Thr Leu Thr Val Ser Ser 115905PRTMus
musculus 90Thr Tyr Trp Met His1 59117PRTMus musculus 91Tyr Ile Asn
Pro Ser Ser Gly Tyr Thr Lys Tyr Asn Gln Lys Phe Lys1 5 10
15Val929PRTMus musculus 92Gly Asn Leu Gly Tyr Phe Phe Asp Tyr1
593119PRTMus musculus 93Met Glu Val Gln Leu Gln Gln Ser Gly Ala Glu
Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys Thr Ala Ser
Gly Phe Asn Ile Lys Asp 20 25 30Tyr Tyr Met His Trp Ile Lys Gln Arg
Pro Gly Gln Gly Leu Glu Trp 35 40 45Leu Gly Tyr Ile Asn Pro Ser Ser
Gly Tyr Thr Lys Tyr Asn Arg Lys 50 55 60Phe Arg Asp Lys Ala Thr Leu
Thr Ala Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Gln Leu Thr
Ser Leu Thr Tyr Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg Gly
Gly Asn Gly Tyr Tyr Leu Asp Tyr Trp Gly Gln Gly 100 105 110Thr Thr
Leu Thr Val Ser Ser 115945PRTMus musculus 94Asp Tyr Tyr Met His1
59517PRTMus musculus 95Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Lys Tyr
Asn Arg Lys Phe Arg1 5 10 15Asp969PRTMus musculus 96Gly Gly Asn Gly
Tyr Tyr Leu Asp Tyr1 597118PRTMus musculus 97Met Glu Val Gln Leu
Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly1 5 10 15Ala Ser Val Lys
Ile Ser Cys Lys Ala Thr Gly Tyr Thr Leu Ser Asn 20 25 30Asn Trp Ile
Gln Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp 35 40 45Ile Gly
Glu Ile Leu Pro Gly Ser Asp Thr Ile Asn Tyr Asn Glu Lys 50 55 60Phe
Lys Gly Lys Ala Thr Phe Thr Ala Asp Ala Ser Ser Asn Thr Ala65 70 75
80Tyr Met Arg Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
85 90 95Cys Ala Arg Glu Gly Ala Ser Trp Phe Ala Tyr Trp Gly Gln Gly
Thr 100 105 110Leu Val Thr Val Ser Ala 115985PRTMus musculus 98Asn
Asn Trp Ile Gln1 59917PRTMus musculus 99Glu Ile Leu Pro Gly Ser Asp
Thr Ile Asn Tyr Asn Glu Lys Phe Lys1 5 10 15Gly1008PRTMus musculus
100Glu Gly Ala Ser Trp Phe Ala Tyr1 5101118PRTMus musculus 101Met
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Met Lys Pro Gly1 5 10
15Ala Ser Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Ser Ile Ser Asn
20 25 30His Trp Ile Gln Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu
Trp 35 40 45Ile Gly Glu Ile Leu Thr Gly Ser Asp Thr Ile Asn Tyr Asn
Glu Lys 50 55 60Leu Lys Gly Lys Ala Thr Phe Thr Ala Asp Thr Ser Ser
Asn Thr Ala65 70 75 80Tyr Met Gln Leu Arg Ser Leu Thr Ser Glu Asp
Ser Ala Val Tyr Tyr 85 90 95Cys Ala Arg Glu Gly Ser Ser Trp Phe Ala
His Trp Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ala
1151025PRTMus musculus 102Asn His Trp Ile Gln1 510317PRTMus
musculus 103Glu Ile Leu Thr Gly Ser Asp Thr Ile Asn Tyr Asn Glu Lys
Leu Lys1 5 10 15Gly1048PRTMus musculus 104Glu Gly Ser Ser Trp Phe
Ala His1 5105118PRTMus musculus 105Met Gln Val Gln Leu Lys Glu Ser
Gly Ala Glu Leu Val Arg Ser Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys
Thr Ala Ser Gly Phe Asn Ile Lys Asp 20 25 30Tyr Tyr Met His Trp Val
Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp 35 40 45Ile Gly Trp Ser Asp
Pro Glu Asn Gly Asn Thr Ile Tyr Asp Pro Lys 50 55 60Phe Gln Gly Lys
Ala Ser Ile Thr Ala Asp Thr Ser Ser Asn Ile Ala65 70 75 80Tyr Leu
Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Gly Gly Arg Arg Ala Met Asp Tyr Trp Gly Gln Gly Thr 100 105
110Ser Val Thr Val Ser Ser 1151065PRTMus musculus 106Asp Tyr Tyr
Met His1 510717PRTMus musculus 107Trp Ser Asp Pro Glu Asn Gly Asn
Thr Ile Tyr Asp Pro Lys Phe Gln1 5 10 15Gly1088PRTMus musculus
108Gly Gly Arg Arg Ala Met Asp Tyr1 5109119PRTMus musculus 109Met
Glu Val Met Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro Ser1 5 10
15Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr Ser
20 25 30Gly Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu
Glu 35 40 45Trp Met Gly Tyr Ile Ser Tyr Asp Gly Thr Asn Lys Tyr Asn
Pro Ser 50 55 60Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys
Asn Gln Phe65 70 75 80Phe Leu Lys Leu Asn Ser Val Thr Thr Glu Asp
Thr Ala Thr Tyr Tyr 85 90 95Cys Ala Arg Gly Gly Ser Gly His Ala Met
Asp Tyr Trp Gly Gln Gly 100 105 110Thr Ser Val Thr Val Ser Ser
1151106PRTMus musculus 110Ser Gly Tyr Tyr Trp Asn1 511116PRTMus
musculus 111Tyr Ile Ser Tyr Asp Gly Thr Asn Lys Tyr Asn Pro Ser Leu
Lys Asn1 5 10 151129PRTMus musculus 112Gly Gly Ser Gly His Ala Met
Asp Tyr1 5113123PRTMus musculus 113Met Gln Val Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Met Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Asn 20 25 30Tyr Leu Met His Trp Val
Lys Gln Lys Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Phe Ile Ile
Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys 50 55 60Phe Lys Gly Lys
Ala Thr Val Thr Ser Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Gly Asn Arg Tyr Asp Val Gly Tyr Tyr Ala Met Asp Tyr 100 105
110Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 1201145PRTMus
musculus 114Asn Tyr Leu Met His1 511517PRTMus musculus 115Phe Ile
Ile Pro Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys1 5 10
15Gly11613PRTMus musculus 116Gly Asn Arg Tyr Asp Val Gly Tyr Tyr
Ala Met Asp Tyr1 5 10117128PRTMus musculus 117Met Glu Val Lys Leu
Val Glu Ser Gly Gly Gly Ser Val Lys Pro Gly1 5 10 15Gly Ser Leu Lys
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser 20 25 30Asn Ala Met
Ser Trp Val Arg Gln Thr Pro Glu Arg Ser Leu Glu Trp 35 40 45Val Ala
Thr Ile Ser Ser Ala Gly Arg Ser Thr Tyr Tyr Pro Asp Ser 50 55 60Val
Lys Gly Arg Phe Ile Ile Ser Arg Asp Asn Leu Lys Asn Ile Leu65
70
75 80Tyr Leu Gln Met Ser Ser Leu Arg Ser Ala Asp Thr Ala Met Tyr
Tyr 85 90 95Cys Ala Arg His Glu Ala Ser Ile Met Ile Thr Thr Gly Arg
Ile Trp 100 105 110Ala Trp Phe Gly Asn Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ala 115 120 1251185PRTMus musculus 118Ser Asn Ala Met
Ser1 511917PRTMus musculus 119Thr Ile Ser Ser Ala Gly Arg Ser Thr
Tyr Tyr Pro Asp Ser Val Lys1 5 10 15Gly12018PRTMus musculus 120His
Glu Ala Ser Ile Met Ile Thr Thr Gly Arg Ile Trp Ala Trp Phe1 5 10
15Gly Asn121124PRTMus musculus 121Met Asp Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Lys Pro Gly1 5 10 15Gly Ser Leu Lys Leu Ser Cys
Val Ala Ser Gly Phe Thr Phe Arg Arg 20 25 30Tyr Ala Met Ser Trp Val
Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp 35 40 45Val Ala Thr Ile Ser
Ser Gly Gly Ser Tyr Asn Tyr His Pro Asp Ser 50 55 60Val Lys Asp Arg
Leu Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Leu65 70 75 80Tyr Leu
Gln Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr 85 90 95Cys
Val Arg His Val Leu Leu Thr Thr Ile Gly Tyr Tyr Ala Ile Asp 100 105
110Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115
1201225PRTMus musculus 122Arg Tyr Ala Met Ser1 512317PRTMus
musculus 123Thr Ile Ser Ser Gly Gly Ser Tyr Asn Tyr His Pro Asp Ser
Val Lys1 5 10 15Asp12414PRTMus musculus 124His Val Leu Leu Thr Thr
Ile Gly Tyr Tyr Ala Ile Asp Tyr1 5 10125124PRTMus musculus 125Met
Glu Val Gln Leu Gln Gln Ser Gly Gly Val Leu Val Lys Pro Gly1 5 10
15Arg Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg
20 25 30Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
Trp 35 40 45Val Ala Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro
Asp Ser 50 55 60Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
Asn Thr Leu65 70 75 80Tyr Leu Gln Met Ser Ser Leu Arg Ser Glu Asp
Thr Ala Met Tyr Tyr 85 90 95Cys Ala Arg His Val Leu Gln Thr Met Ile
Gly Tyr Tyr Ala Val Asp 100 105 110Tyr Trp Gly Gln Gly Thr Ser Val
Thr Val Ser Ser 115 1201265PRTMus musculus 126Arg Tyr Thr Met Ser1
512717PRTMus musculus 127Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr
Tyr Pro Asp Ser Val Lys1 5 10 15Gly12814PRTMus musculus 128His Val
Leu Gln Thr Met Ile Gly Tyr Tyr Ala Val Asp Tyr1 5 10129124PRTMus
musculus 129Met Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys
Pro Gly1 5 10 15Arg Ser Leu Lys Val Ser Cys Ala Ala Ser Gly Phe Thr
Phe Ser Arg 20 25 30Tyr Thr Met Ser Trp Val Arg Gln Thr Pro Glu Lys
Arg Leu Glu Trp 35 40 45Val Ala Thr Ile Ser Gly Gly Gly Gly Tyr Thr
Tyr Tyr Pro Asp Ser 50 55 60Val Lys Gly Arg Phe Thr Ile Ser Arg Glu
Asn Ala Lys Asn Thr Leu65 70 75 80Tyr Leu Gln Met Ser Ser Leu Arg
Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Val Arg His Val Leu Gln
Thr Thr Ile Gly Tyr Tyr Ala Val Asp 100 105 110Tyr Trp Gly Gln Gly
Thr Ser Val Thr Val Ser Ser 115 1201305PRTMus musculus 130Arg Tyr
Thr Met Ser1 513117PRTMus musculus 131Thr Ile Ser Gly Gly Gly Gly
Tyr Thr Tyr Tyr Pro Asp Ser Val Lys1 5 10 15Gly13214PRTMus musculus
132His Val Leu Gln Thr Thr Ile Gly Tyr Tyr Ala Val Asp Tyr1 5
10133124PRTMus musculus 133Met Glu Val Lys Leu Val Glu Ser Gly Gly
Gly Leu Val Lys Ala Gly1 5 10 15Gly Ser Leu Lys Leu Ser Cys Ala Ala
Ser Gly Phe Thr Phe Ser Arg 20 25 30Tyr Ala Met Ser Trp Val Arg Gln
Thr Pro Glu Lys Arg Leu Glu Trp 35 40 45Val Ala Thr Ile Ser Ser Gly
Gly Arg Tyr Thr Tyr Tyr Pro Asp Ser 50 55 60Val Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asp Ala Gln Asn Thr Leu65 70 75 80Tyr Leu Gln Met
Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr 85 90 95Cys Ala Arg
His Leu Leu Gln Thr Met Ile Gly Tyr Tyr Ala Met Asp 100 105 110Tyr
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 1201345PRTMus
musculus 134Arg Tyr Ala Met Ser1 513517PRTMus musculus 135Thr Ile
Ser Ser Gly Gly Arg Tyr Thr Tyr Tyr Pro Asp Ser Val Lys1 5 10
15Gly13614PRTMus musculus 136His Leu Leu Gln Thr Met Ile Gly Tyr
Tyr Ala Met Asp Tyr1 5 10137120PRTMus musculus 137Met Gln Val Gln
Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30His Asn
Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile
Gly Asp Ile Asn Pro Asn Phe Asp Thr Thr Ile Tyr Asn Gln Lys 50 55
60Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Arg Thr Ala65
70 75 80Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
Tyr 85 90 95Cys Ala Arg Arg Gly Tyr Tyr Arg Phe Asp Leu Asp Tyr Trp
Gly Gln 100 105 110Gly Thr Thr Leu Thr Val Ser Ser 115
1201385PRTMus musculus 138Asp His Asn Met Asp1 513917PRTMus
musculus 139Asp Ile Asn Pro Asn Phe Asp Thr Thr Ile Tyr Asn Gln Lys
Phe Arg1 5 10 15Gly14010PRTMus musculus 140Arg Gly Tyr Tyr Arg Phe
Asp Leu Asp Tyr1 5 10141120PRTMus musculus 141Met Gln Val Gln Leu
Gln Gln Phe Gly Ala Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys
Met Ser Cys Lys Ala Ser Gly Phe Thr Phe Thr Asp 20 25 30Asn Asn Met
Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly
Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ala Tyr Asn Gln Lys 50 55 60Phe
Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75
80Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr
85 90 95Cys Ala Arg Arg Lys Arg Arg Gly Tyr Tyr Phe Asp Tyr Trp Gly
Gln 100 105 110Gly Thr Thr Leu Thr Val Ser Ser 115 1201425PRTMus
musculus 142Asp Asn Asn Met Asp1 514317PRTMus musculus 143Asp Ile
Asn Pro Asn Tyr Asp Ser Thr Ala Tyr Asn Gln Lys Phe Lys1 5 10
15Gly14411PRTMus musculus 144Arg Arg Lys Arg Arg Gly Tyr Tyr Phe
Asp Tyr1 5 10145120PRTMus musculus 145Met Glu Val Gln Leu Gln Gln
Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser
Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30Asn Asn Met Asp Trp
Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Asp Val
Asn Pro Asn Tyr Asp Ser Thr Met Tyr Asn Gln Lys 50 55 60Phe Lys Gly
Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90
95Cys Ala Arg Arg Ile Arg Arg Gly Tyr Ser Phe Asp Tyr Trp Gly Gln
100 105 110Gly Thr Thr Leu Thr Val Ser Ser 115 1201465PRTMus
musculus 146Asp Asn Asn Met Asp1 514717PRTMus musculus 147Asp Val
Asn Pro Asn Tyr Asp Ser Thr Met Tyr Asn Gln Lys Phe Lys1 5 10
15Gly14810PRTMus musculus 148Arg Ile Arg Arg Gly Tyr Ser Phe Asp
Tyr1 5 10149120PRTMus musculus 149Met Glu Val Gln Leu Gln Gln Ser
Gly Ala Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys
Lys Thr Ser Gly Tyr Thr Phe Thr Asp 20 25 30Asn Asn Met Asp Trp Val
Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn
Pro Asn Tyr Asp Ser Thr Ile Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys
Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Arg Ile Tyr Tyr Gly Tyr Ala Leu Asp Tyr Trp Gly Gln 100 105
110Gly Thr Ser Val Thr Val Ser Ser 115 1201505PRTMus musculus
150Asp Asn Asn Met Asp1 515117PRTMus musculus 151Asp Ile Asn Pro
Asn Tyr Asp Ser Thr Ile Tyr Asn Gln Lys Phe Lys1 5 10
15Gly15210PRTMus musculus 152Arg Ile Tyr Tyr Gly Tyr Ala Leu Asp
Tyr1 5 10153120PRTMus musculus 153Met Glu Val Gln Leu Gln Gln Ser
Gly Ala Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30His Asn Met Asp Trp Val
Lys Gln Ser His Gly Lys Asn Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn
Pro Asn Tyr Asp Ser Val Ile Ser Asp Gln Lys 50 55 60Phe Lys Gly Lys
Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Arg Leu Arg Gly Gly Phe Ala Met Asp Tyr Trp Gly Gln 100 105
110Gly Thr Ser Val Thr Val Ser Ser 115 1201545PRTMus musculus
154Asp His Asn Met Asp1 515517PRTMus musculus 155Asp Ile Asn Pro
Asn Tyr Asp Ser Val Ile Ser Asp Gln Lys Phe Lys1 5 10
15Gly15610PRTMus musculus 156Arg Leu Arg Gly Gly Phe Ala Met Asp
Tyr1 5 10157120PRTMus musculus 157Met Gln Val Gln Leu Gln Gln Ser
Gly Thr Val Leu Ala Arg Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys
Lys Thr Ser Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Asn Met Asp Trp Val
Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn
Pro Asn Tyr Asp Ser Thr Ile Tyr Lys Gln Asn 50 55 60Phe Lys Gly Arg
Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Arg Met Arg Arg Gly Tyr Ala Met Asp Tyr Trp Gly Gln 100 105
110Gly Thr Ser Val Thr Val Ser Ser 115 1201585PRTMus musculus
158Asp Tyr Asn Met Asp1 515917PRTMus musculus 159Asp Ile Asn Pro
Asn Tyr Asp Ser Thr Ile Tyr Lys Gln Asn Phe Lys1 5 10
15Gly16010PRTMus musculus 160Arg Met Arg Arg Gly Tyr Ala Met Asp
Tyr1 5 10161120PRTMus musculus 161Met Gln Val Gln Leu Gln Gln Ser
Gly Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30Asn Asn Met Asp Trp Val
Lys Gln Ser His Gly Lys Gly Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn
Thr Lys Ser Gly Gly Ser Ile Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys
Ala Thr Leu Thr Ile Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Arg Arg Ser Tyr Gly Tyr Tyr Phe Asp Tyr Trp Gly Gln 100 105
110Gly Thr Thr Leu Thr Val Ser Ser 115 1201625PRTMus musculus
162Asp Asn Asn Met Asp1 516317PRTMus musculus 163Asp Ile Asn Thr
Lys Ser Gly Gly Ser Ile Tyr Asn Gln Lys Phe Lys1 5 10
15Gly16410PRTMus musculus 164Arg Arg Ser Tyr Gly Tyr Tyr Phe Asp
Tyr1 5 10165120PRTMus musculus 165Met Gln Val Gln Leu Lys Gln Ser
Gly Ala Glu Leu Val Thr Pro Gly1 5 10 15Thr Ser Val Lys Ile Ser Cys
Lys Ala Ser Gly Tyr Thr Phe Thr Asp 20 25 30Asn Asn Met Asp Trp Val
Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn
Pro Asn Tyr Asp Ser Thr Ala Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys
Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Arg Val Arg Arg Gly Tyr His Phe Asp Tyr Trp Gly Gln 100 105
110Gly Thr Thr Leu Thr Val Ser Ser 115 1201665PRTMus musculus
166Asp Asn Asn Met Asp1 516717PRTMus musculus 167Asp Ile Asn Pro
Asn Tyr Asp Ser Thr Ala Tyr Asn Gln Lys Phe Lys1 5 10
15Gly16810PRTMus musculus 168Arg Val Arg Arg Gly Tyr His Phe Asp
Tyr1 5 10169122PRTMus musculus 169Met Glu Val Gln Leu Gln Gln Ser
Arg Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Ile Ser Cys
Lys Thr Ser Gly Tyr Thr Phe Thr Glu 20 25 30Asn Ala Leu Tyr Trp Val
Lys Gln Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Ile Ile Asn
Pro Asn Ser Gly Gly Thr Asn Tyr Asn Gln Lys 50 55 60Phe Lys Asp Lys
Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met
Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr 85 90 95Cys
Ala Arg Ser Gly Gly Arg Gly Gln Pro Tyr Tyr Phe Asp Tyr Trp 100 105
110Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 115 1201705PRTMus
musculus 170Glu Asn Ala Leu Tyr1 517117PRTMus musculus 171Ile Ile
Asn Pro Asn Ser Gly Gly Thr Asn Tyr Asn Gln Lys Phe Lys1 5 10
15Asp17212PRTMus musculus 172Ser Gly Gly Arg Gly Gln Pro Tyr Tyr
Phe Asp Tyr1 5 10173118PRTMus musculus 173Met Gln Val Gln Leu Gln
Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly1 5 10 15Ala Ser Val Lys Leu
Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser 20 25 30Tyr Trp Met Gln
Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile Gly Ala
Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys 50 55 60Phe Lys
Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala65 70 75
80Tyr Met His Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr
85 90 95Cys Ala Arg Asp Gly Tyr Asp Leu Phe Ala Tyr Trp Gly Gln Gly
Thr 100 105 110Leu Val Thr Val Ser Ala 1151745PRTMus musculus
174Ser Tyr Trp Met Gln1 517517PRTMus musculus 175Ala Ile Tyr Pro
Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys1 5 10
15Gly1768PRTMus musculus 176Asp Gly Tyr Asp Leu Phe Ala Tyr1
5177118PRTMus musculus 177Met Glu Val Gln Leu Gln Gln Ser Gly Ala
Glu Leu Ala Arg Pro Gly1 5 10 15Ala Ser Val Lys Leu Ser Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asn 20 25
30Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp
35 40 45Ile Gly Ala Ile Tyr Pro Gly Asp Gly Asp Ile Arg Ile Thr Gln
Lys 50 55 60Phe Arg Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
Thr Ala65 70 75 80Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser
Ala Val Tyr Tyr 85 90 95Cys Ala Arg Asp Gly Tyr Asp Leu Phe Ala Tyr
Trp Gly Gln Gly Thr 100 105 110Leu Val Thr Val Ser Ala
1151785PRTMus musculus 178Asn Tyr Trp Met Gln1 517917PRTMus
musculus 179Ala Ile Tyr Pro Gly Asp Gly Asp Ile Arg Ile Thr Gln Lys
Phe Arg1 5 10 15Gly1808PRTMus musculus 180Asp Gly Tyr Asp Leu Phe
Ala Tyr1 5181117PRTMus musculus 181Met Asp Val Gln Leu Val Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser1 5 10 15Gln Ser Leu Ser Leu Thr Cys
Ser Val Thr Gly Tyr Ser Ile Thr Ser 20 25 30Gly Tyr Tyr Leu Asn Trp
Ile Arg Gln Phe Pro Gly His Lys Leu Glu 35 40 45Trp Met Gly Tyr Ile
Ser Tyr Asp Gly Asn Asn Arg Tyr Asn Pro Ser 50 55 60Leu Lys Asn Arg
Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln Phe65 70 75 80Phe Leu
Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr 85 90 95Cys
Ala Ser Phe Phe Tyr Gly Lys His Asp Trp Gly Gln Gly Thr Thr 100 105
110Leu Thr Val Ser Ser 1151826PRTMus musculus 182Ser Gly Tyr Tyr
Leu Asn1 518316PRTMus musculus 183Tyr Ile Ser Tyr Asp Gly Asn Asn
Arg Tyr Asn Pro Ser Leu Lys Asn1 5 10 151847PRTMus musculus 184Phe
Phe Tyr Gly Lys His Asp1 5185115PRTMus musculus 185Met Glu Val Gln
Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg 20 25 30Ser Trp
Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile
Gly Trp Ile Tyr Pro Gly Asp Gly Ser Thr Lys Tyr Asn Glu Lys 50 55
60Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala65
70 75 80Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
Tyr 85 90 95Cys Ala Arg Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr
Leu Thr 100 105 110Val Ser Ser 1151865PRTMus musculus 186Arg Ser
Trp Met Asn1 518717PRTMus musculus 187Trp Ile Tyr Pro Gly Asp Gly
Ser Thr Lys Tyr Asn Glu Lys Phe Lys1 5 10 15Gly1885PRTMus musculus
188Gly Gly Leu Asp Tyr1 5189119PRTMus musculus 189Met Gln Val Gln
Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10 15Ser Ser Val
Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg 20 25 30Tyr Trp
Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp 35 40 45Ile
Gly Gln Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys 50 55
60Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala65
70 75 80Tyr Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr
Phe 85 90 95Cys Ala Arg Gly Arg Gly Tyr Ser Ala Met Asp Tyr Trp Gly
Gln Gly 100 105 110Thr Ser Val Thr Val Ser Ser 1151905PRTMus
musculus 190Arg Tyr Trp Met Asn1 519117PRTMus musculus 191Gln Ile
Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys1 5 10
15Gly1929PRTMus musculus 192Gly Arg Gly Tyr Ser Ala Met Asp Tyr1
5193120PRTMus musculus 193Met Gln Val Gln Leu Gln Gln Ser Gly Pro
Glu Leu Val Lys Pro Gly1 5 10 15Ala Ser Val Lys Ile Pro Cys Lys Ala
Ser Gly Tyr Thr Phe Thr Asp 20 25 30Tyr Asn Met Asp Trp Val Lys Gln
Ser His Gly Lys Ser Leu Glu Trp 35 40 45Ile Gly Asp Ile Asp Pro Asn
Asn Gly Gly Ala Leu Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys Ala Thr
Leu Thr Val Asp Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Glu Leu
Arg Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg
Arg Pro Val Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110Gly
Thr Ser Val Thr Val Ser Ser 115 1201945PRTMus musculus 194Asp Tyr
Asn Met Asp1 519517PRTMus musculus 195Asp Ile Asp Pro Asn Asn Gly
Gly Ala Leu Tyr Asn Gln Lys Phe Lys1 5 10 15Gly19610PRTMus musculus
196Arg Pro Val Tyr Tyr Tyr Ala Met Asp Tyr1 5 10197120PRTMus
musculus 197Met His Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
Pro Gly1 5 10 15Ala Ser Val Lys Ile Pro Cys Lys Ala Ser Gly Tyr Thr
Phe Thr Asp 20 25 30Asn Asn Met Asp Trp Val Lys Gln Ser His Gly Lys
Ser Leu Glu Trp 35 40 45Ile Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr
Ile Tyr Asn Gln Lys 50 55 60Phe Lys Gly Lys Ala Thr Leu Thr Val Asp
Lys Ser Ser Ser Thr Ala65 70 75 80Tyr Met Glu Leu Arg Ser Leu Thr
Ser Glu Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Arg Gly Tyr Tyr
Gly Arg Thr Phe Asp Tyr Trp Gly Gln 100 105 110Gly Thr Thr Leu Thr
Val Ser Ser 115 1201985PRTMus musculus 198Asp Asn Asn Met Asp1
519917PRTMus musculus 199Asp Ile Asn Pro Asn Asn Gly Gly Thr Ile
Tyr Asn Gln Lys Phe Lys1 5 10 15Gly20010PRTMus musculus 200Arg Gly
Tyr Tyr Gly Arg Thr Phe Asp Tyr1 5 10201117PRTMus musculus 201Met
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly1 5 10
15Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp
20 25 30Asp Tyr Met His Trp Val Asn Gln Arg Pro Glu Gln Gly Leu Glu
Trp 35 40 45Ile Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala
Ser Lys 50 55 60Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser
Asn Thr Ala65 70 75 80Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp
Thr Ala Val Tyr Tyr 85 90 95Cys Thr Tyr Gly Ile Tyr Val Arg Gly Tyr
Trp Gly Gln Gly Thr Thr 100 105 110Leu Thr Val Ser Ser
1152025PRTMus musculus 202Asp Asp Tyr Met His1 520317PRTMus
musculus 203Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Ser Lys
Phe Gln1 5 10 15Gly2047PRTMus musculus 204Gly Ile Tyr Val Arg Gly
Tyr1 5205107PRTMus musculus 205Asp Ile Val Met Thr Gln Ser His Lys
Phe Met Ser Thr Ser Val Gly1 5 10 15Asp Arg Val Ser Ile Thr Cys Lys
Ala Ser Gln Asp Val Gly Thr Ala 20 25 30Val Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45Tyr Trp Ala Ser Thr Arg
His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60Ser Arg Tyr Gly Thr
Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser65 70 75 80Glu Asp Leu
Ala Asp Tyr Leu Cys Gln Gln Tyr Ser Asn Tyr Ile Thr 85 90 95Phe Gly
Gly Gly Thr Lys Leu Glu Leu Lys Arg 100 10520611PRTMus musculus
206Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala1 5 102077PRTMus
musculus 207Trp Ala Ser Thr Arg His Thr1 52088PRTMus musculus
208Gln Gln Tyr Ser Asn Tyr Ile Thr1 5209108PRTMus musculus 209Asp
Ile Val Leu Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly1 5 10
15Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Gly Thr Ala
20 25 30Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu
Ile 35 40 45Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe
Thr Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn
Val Gln Ser65 70 75 80Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr
Asn Ser Tyr Pro Leu 85 90 95Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
Lys Arg 100 10521011PRTMus musculus 210Lys Ala Ser Gln Asn Val Gly
Thr Ala Val Ala1 5 102117PRTMus musculus 211Ser Ala Ser Tyr Arg Tyr
Ser1 52129PRTMus musculus 212Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1
5213107PRTMus musculus 213Asp Ile Val Leu Thr Gln Ser Pro Ala Ile
Met Ser Ala Ser Leu Gly1 5 10 15Glu Lys Val Thr Met Ser Cys Arg Ala
Thr Ser Ser Val Asn Tyr Ile 20 25 30Tyr Trp Tyr Gln Gln Lys Ser Asp
Ala Ser Pro Lys Leu Trp Ile Phe 35 40 45Tyr Thr Ser Asn Leu Ala Pro
Gly Val Pro Pro Arg Phe Ser Gly Ser 50 55 60Gly Ser Gly Asn Ser Tyr
Ser Leu Thr Ile Ser Ser Met Glu Ala Glu65 70 75 80Asp Ala Ala Thr
Tyr Tyr Cys Gln Gln Phe Ser Ser Ser Pro Trp Thr 85 90 95Phe Gly Gly
Gly Thr Lys Leu Glu Ile Lys Arg 100 10521410PRTMus musculus 214Arg
Ala Thr Ser Ser Val Asn Tyr Ile Tyr1 5 102156PRTMus musculus 215Thr
Ser Asn Leu Ala Pro1 52169PRTMus musculus 216Gln Gln Phe Ser Ser
Ser Pro Trp Thr1 5217114PRTMus musculus 217Asp Ile Val Met Thr Gln
Ser Pro Ser Ser Leu Ala Val Ser Val Gly1 5 10 15Glu Lys Val Thr Met
Ser Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser 20 25 30Ser Asn Gln Lys
Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45Ser Pro Lys
Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60Pro Asp
Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr65 70 75
80Ile Ser Ser Val Lys Ala Glu Asp Leu Ala Val Tyr Leu Cys Gln Gln
85 90 95Tyr Tyr Arg Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu
Ile 100 105 110Lys Arg21817PRTMus musculus 218Lys Ser Ser Gln Ser
Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu1 5 10 15Ala2197PRTMus
musculus 219Trp Ala Ser Thr Arg Glu Ser1 52209PRTMus musculus
220Gln Gln Tyr Tyr Arg Phe Pro Tyr Thr1 522118DNAMus
musculusCDS(1)..(18) 221agt ggt tat tac tgg acc 18Ser Gly Tyr Tyr
Trp Thr1 52226PRTMus musculus 222Ser Gly Tyr Tyr Trp Thr1
522348DNAMus musculusCDS(1)..(48) 223tac ata tcc ttc gac ggt acc
aat gac tac aac cca tct ctc aaa aat 48Tyr Ile Ser Phe Asp Gly Thr
Asn Asp Tyr Asn Pro Ser Leu Lys Asn1 5 10 1522416PRTMus musculus
224Tyr Ile Ser Phe Asp Gly Thr Asn Asp Tyr Asn Pro Ser Leu Lys Asn1
5 10 1522518DNAMus musculusCDS(1)..(18) 225ggc ccc ccc tgt act tac
18Gly Pro Pro Cys Thr Tyr1 52266PRTMus musculus 226Gly Pro Pro Cys
Thr Tyr1 522730DNAMus musculusCDS(1)..(30) 227agg gcc acc tca agt
gta aat tac att tac 30Arg Ala Thr Ser Ser Val Asn Tyr Ile Tyr1 5
1022810PRTMus musculus 228Arg Ala Thr Ser Ser Val Asn Tyr Ile Tyr1
5 1022918DNAMus musculusCDS(1)..(18) 229aca tcc aac ctg gct cct
18Thr Ser Asn Leu Ala Pro1 52306PRTMus musculus 230Thr Ser Asn Leu
Ala Pro1 523127DNAMus musculusCDS(1)..(27) 231cag cag ttt tct agt
tcc cca tgg acg 27Gln Gln Phe Ser Ser Ser Pro Trp Thr1 52329PRTMus
musculus 232Gln Gln Phe Ser Ser Ser Pro Trp Thr1 523315DNAMus
musculusCDS(1)..(15) 233cac ttt gtt ttg cac 15His Phe Val Leu His1
52345PRTMus musculus 234His Phe Val Leu His1 523548DNAMus
musculusCDS(1)..(48) 235tat att att cct tac aat gat ggt act aag tac
aat gag aag ttc aaa 48Tyr Ile Ile Pro Tyr Asn Asp Gly Thr Lys Tyr
Asn Glu Lys Phe Lys1 5 10 1523616PRTMus musculus 236Tyr Ile Ile Pro
Tyr Asn Asp Gly Thr Lys Tyr Asn Glu Lys Phe Lys1 5 10 1523739DNAMus
musculusCDS(1)..(39) 237ggg aat agg tac gac gta ggt tcc tat gct atg
gac tac 39Gly Asn Arg Tyr Asp Val Gly Ser Tyr Ala Met Asp Tyr1 5
1023813PRTMus musculus 238Gly Asn Arg Tyr Asp Val Gly Ser Tyr Ala
Met Asp Tyr1 5 1023951DNAMus musculusCDS(1)..(51) 239aag tcc agt
cag agc ctt tta tat agt agc aat caa aag aac tac ttg 48Lys Ser Ser
Gln Ser Leu Leu Tyr Ser Ser Asn Gln Lys Asn Tyr Leu1 5 10 15gcc
51Ala24017PRTMus musculus 240Lys Ser Ser Gln Ser Leu Leu Tyr Ser
Ser Asn Gln Lys Asn Tyr Leu1 5 10 15Ala24121DNAMus
musculusCDS(1)..(21) 241tgg gca tcc act agg gaa tct 21Trp Ala Ser
Thr Arg Glu Ser1 52427PRTMus musculus 242Trp Ala Ser Thr Arg Glu
Ser1 524327DNAMus musculusCDS(1)..(27) 243cag caa tat tat agg ttt
ccg tac acg 27Gln Gln Tyr Tyr Arg Phe Pro Tyr Thr1 52449PRTMus
musculus 244Gln Gln Tyr Tyr Arg Phe Pro Tyr Thr1 524515DNAMus
musculusCDS(1)..(15) 245agc tcc tgg atg cac 15Ser Ser Trp Met His1
52465PRTMus musculus 246Ser Ser Trp Met His1 524751DNAMus
musculusCDS(1)..(51) 247tac att aat cct agc agt ggt tat act aag tac
aat cgg aag ttc agg 48Tyr Ile Asn Pro Ser Ser Gly Tyr Thr Lys Tyr
Asn Arg Lys Phe Arg1 5 10 15gac 51Asp24817PRTMus musculus 248Tyr
Ile Asn Pro Ser Ser Gly Tyr Thr Lys Tyr Asn Arg Lys Phe Arg1 5 10
15Asp24927DNAMus musculusCDS(1)..(27) 249ggg ggt aac ggt tac tac
ttt gac tac 27Gly Gly Asn Gly Tyr Tyr Phe Asp Tyr1 52509PRTMus
musculus 250Gly Gly Asn Gly Tyr Tyr Phe Asp Tyr1 525133DNAMus
musculusCDS(1)..(33) 251aag gcc agt cag gat gtg ggg act gct gta gcc
33Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala1 5 1025211PRTMus
musculus 252Lys Ala Ser Gln Asp Val Gly Thr Ala Val Ala1 5
1025321DNAMus musculusCDS(1)..(21) 253tgg gca tcc acc cgg cac act
21Trp Ala Ser Thr Arg His Thr1 52547PRTMus musculus 254Trp Ala Ser
Thr Arg His Thr1 525524DNAMus musculusCDS(1)..(24) 255cag caa tat
agc aac tat atc acg 24Gln Gln Tyr Ser Asn Tyr Ile Thr1 52568PRTMus
musculus 256Gln Gln Tyr Ser Asn Tyr Ile Thr1 525715DNAMus
musculusCDS(1)..(15) 257gac aac aac atg gac 15Asp Asn Asn Met Asp1
52585PRTMus musculus 258Asp Asn Asn Met Asp1 525951DNAMus
musculusCDS(1)..(51) 259gat att aat act aaa agt ggt ggt tct atc tac
aac cag aag ttc aag 48Asp Ile Asn Thr Lys Ser Gly Gly Ser Ile Tyr
Asn Gln Lys Phe Lys1 5 10 15ggc 51Gly26017PRTMus musculus 260Asp
Ile Asn Thr Lys Ser Gly Gly Ser Ile Tyr Asn Gln Lys Phe Lys1 5 10
15Gly26130DNAMus musculusCDS(1)..(30) 261agg agg agc tac ggc tac
tac ttt gac tac 30Arg Arg Ser Tyr Gly Tyr Tyr Phe Asp Tyr1 5
1026210PRTMus musculus 262Arg Arg Ser Tyr Gly Tyr Tyr Phe Asp Tyr1
5
1026333DNAMus musculusCDS(1)..(33) 263aag gcc agt cag aat gtg ggt
act gct gta gcc 33Lys Ala Ser Gln Asn Val Gly Thr Ala Val Ala1 5
1026411PRTMus musculus 264Lys Ala Ser Gln Asn Val Gly Thr Ala Val
Ala1 5 1026521DNAMus musculusCDS(1)..(21) 265tcg gca tcc tac cgg
tac agt 21Ser Ala Ser Tyr Arg Tyr Ser1 52667PRTMus musculus 266Ser
Ala Ser Tyr Arg Tyr Ser1 526727DNAMus musculusCDS(1)..(27) 267cag
caa tat aac agc tat cct ctc acg 27Gln Gln Tyr Asn Ser Tyr Pro Leu
Thr1 52689PRTMus musculus 268Gln Gln Tyr Asn Ser Tyr Pro Leu Thr1
5
* * * * *
References